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ABSTRACT
Childhood cancer is the second leading cause of death in Australian children, aged
1-14y. As medical advances improve, outcomes for childhood cancer patients also
improve. For children with cancer, treatment occurs at an important period of growth
and development, and this can affect their health as adults. In fact chronic disease
such as obesity and cardiovascular disease are recognised long term problems for
adult survivors of childhood cancer. With the changing landscape in paediatric
oncology, the focus of nutritional therapy for paediatric oncology patients may need
to shift. Decisions on nutritional management during therapy have the potential to
influence nutritional management in the long term. The broad aim of this thesis was
to explore the implications for Nutrition and Dietetics care in managing the needs of
child cancer patients during therapy and following survival. The research was
grounded in clinical practice, using an in depth case study of a specialist paediatric
oncology clinic in Sydney, Australia. A number of separate but related investigations
took place to address specific questions and highlight the way forward for improved
practice.

The first part of the thesis confirmed the assumption of a nutritional problem in the
clinic population. Study 1 aimed to assess the dietary intake and habits of young
survivors of childhood cancer early after treatment completion. Assessment of 3day food diaries found that 54% of young childhood cancer survivors were
consuming above their estimated energy requirements. Fifty, 32% and 44% of
children did not meet requirements for folate, calcium, and iron respectively. When
parents of childhood cancer survivors was questioned about their child’s changing
dietary habits, the majority of parents found their child’s nutritional intake changed
dramatically during the active treatment phase. It appears that some of the dietary
habits established during treatment appeared to carry over once treatment has been
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completed. Parents reported young survivors of childhood cancer had a poor fruit
and vegetable intake; increased consumption of "junk food" and large portion sizes.
These results provided targets for nutritional interventions at the clinic for survivors
of childhood cancer.

The second part of this thesis aimed to examine feeding practices during and
following treatment completion. First, a Cochrane systematic review was undertaken
to assess the effect of nutritional interventions in improving dietary intake to meet
the dietary guidelines, in childhood cancer survivors. Three studies were found that
met the inclusion criteria. One study found an improvement in calcium intake and
calcium supplementation in an intervention in adult survivors of childhood cancer
aimed at osteoporosis prevention. The second study found that a single group
intervention improved the self-reported intake of healthy food, though there was no
improvement in self-reported ‘junk’ food intake.

The review indicated a lack of

effective interventions for preventing or improving the dietary habits of young
childhood cancer survivors.

Because enteral feeding is often introduced in the

treatment phase, study 2 aimed to compare and contrast views among parents,
patients and healthcare workers on the positive and negative aspects of enteral tube
feeding (ETF). There appeared to be common perceptions of the purposes and
impact of ETF among patients, parents and healthcare workers. Both positive (good
nutrition, weight gain and decreased anxiety) and negative (physical appearance,
invasive insertion procedure and comfort) aspects of ETF were discussed. There
were discordant perceptions regarding the timing and type of information provided
on the use of enteral tube feeding, as well as the decision making process used.
This study highlighted the need for standardizing and improving the methods used
for the commencement of ETF on treatment.
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The third part of the thesis considered possible changes in taste and smell that
might create problems with feeding after treatment. First, a literature review was
conducted on taste and smell disorders resulting from cancer and chemotherapy.
The review found self-reported taste and smell alterations were prevalent in
upwards of 86% of cancer patients. In some adult cancer patients, taste and smell
alterations continued well after their cancer treatment had been completed. Taste
and smell alterations in patients with cancer appeared to increase their distress,
reduce appetite and contribute towards a poor nutritional status. There was a lack of
information on the taste and smell function of survivors of childhood cancer. In light
of the results from the review of taste and smell issues in cancer survivors, study 3
aimed to assess smell and taste function in childhood cancer survivors. The study
found that survivors of childhood cancer did have a greater incidence of taste and
smell changes, compared to a control sample from the well population. Twentyseven percent of survivors of childhood cancer had some form of smell dysfunction.
This was considerable higher than the 10% of smell dysfunction reported in the
literature for the general population, using similar methods of assessment. The
incidence of smell dysfunction was 10% of the cancer survivors studied which again
is higher than the one to two percent smell dysfunction reported in the general
population.

In conclusion, as childhood cancer is no longer an acute condition with poor
outcomes and high morbidity and mortality, it should be treated as a chronic
condition. Poor dietary habits are manifesting themselves early after treatment in
paediatric cancer patients. There now needs to be greater awareness of the link
between the nutrition decisions made during the cancer therapy and how they may
be affecting the child’s nutritional intake well after cancer therapy is completed. At
the very least, nutritional interventions to improve the dietary habits of survivors of

xi

childhood cancer need to be initiated soon after treatment completion. Ideally a
focus on long-term good dietary habits may need to occur during cancer therapy.
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1 INTRODUCTION AND AIMS
1.1

Introduction

Nutritional therapy has been a recognised part of the medical management of
hospital patients since the proverbial “skeleton in the hospital closet” of malnutrition
was identified in the 1970s (1). The first published paper assessing the efficacy of
medical nutritional therapy for childhood cancer patients, in the form of parenteral
nutrition (PN), was published in 1977 (2). This study showed an improvement in
weight gain with the introduction of parenteral nutrition in 41 patients. The earliest
review of malnutrition in childhood cancer patients was published in 1979 (3). This
review assessed the incidence, aetiology and consequences of protein-energy
malnutrition and the use of medical nutrition therapy. This was the first published
paper to focus on not just macronutrient deficiencies but micronutrient deficiencies
in this population (3).

Nutritional therapy in paediatric cancer patients tends to focus on weight and growth
based outcomes and the maintenance of normal growth and development is the
primary goal of nutritional interventions (4). Algorithms for initiating nutritional
supplementation are predominantly based on weight changes (5) and the suggested
interventions themselves rely on commercial supplements, enteral tube feeding and
parenteral nutrition (PN) (5). Reviews of nutritional concerns of paediatric cancer
patients report on the use of medical nutritional therapy but rarely discuss
recommendations for food intake (4, 6-9). This may be because many paediatric
cancer patients find eating difficult due to the side effects of intensive chemotherapy
treatment protocols (10, 11). For those who are able to eat, food choices tend to be
limited (11) or they have a preference for “junk food”(12). It also appears that
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parents are not concerned about their child’s overall nutritional intake during their
child’s cancer therapy (13). The goal of both parents and clinicians working in
paediatric oncology has been the prevention of weight loss through the use of a high
energy diet (14).

As medical advances have improved, outcomes for childhood cancer patients have
also improved. For children with cancer, treatment is occurring during an important
time of growth and development and treatment at such an early stage in life has the
potential to affect them when they become adults. Chronic disease such as obesity
and cardiovascular disease are being recognised as long term issues in adult
survivors of childhood cancer (15). Practitioners are beginning to recognise that
adult survivors of childhood cancer may have poor dietary habits (16, 17), which is
likely increasing their risk of chronic health conditions such as the metabolic
syndrome (18).

Interestingly, there is a lack of information regarding the dietary habits of childhood
cancer survivors during and early after treatment completion. This may be because
the focus of nutritional interventions during cancer therapy, have been about protein
and energy and not about overall nutritional intake. Information on the dietary intake
of young cancer survivors will be needed to inform nutritional interventions to help
reduce the risk of chronic diseases in adult survivors of childhood cancer.

This thesis focuses on paediatric patients within a single paediatric unit. This is
important to me as a clinician as it enables me to make changes in clinical practice
specific to the issues with my clinical population. The results from this thesis have
the potential to be extrapolated to other paediatric oncology patients, both in
Australia and overseas.
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1.2

The position of the researcher

I currently work as the senior paediatric dietitian in the Kids Cancer Centre at
Sydney Children’s Hospital, Randwick New South Wales (NSW), Australia. The Kids
Cancer Centre treats children who have both cancer and haematological conditions
and our catchment includes Sydney metropolitan, rural NSW and the territory of
Canberra. We treat between 100-120 new patients each year and have a large
haemapoetic stem cell transplant program. Our transplant unit performs both
autologous and allogenic transplants (cord blood, bone marrow and stem cell
transplants) and the centre receives patients for allogenic transplant from the rural
NSW paediatric oncology unit (John Hunter Hospital in Newcastle) and those from
the Royal Adelaide Hospital in South Australia. Once patients have completed their
treatment they can be followed up by the medical teams in outreach clinics around
NSW and Canberra. Our centre also has a long-term follow-up clinic that reviews
survivors of childhood cancer who are more than five years from treatment
completion. This clinic follows these patients into adulthood.

This thesis was born from a need identified while working with paediatric patients
undergoing their treatment for cancer. Although clinician researchers in the dietetics
field is not common practice (19),

there is an advantage in being a clinician

researcher, as I have the potential to directly improve patient outcomes (20, 21).
The main goal of my position as a clinical dietitian working in paediatric oncology is
the prevention of treatment related malnutrition. The majority of patients are on
active treatment and once their cancer therapy is finished and they no longer require
intensive nutrition support, I did not have the capacity to review these patients long
term. As will be highlighted chapter two, there is now a greater focus on the
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survivorship issues of cancer survivors and I found an increase in the number of
referrals for paediatric patients who were overweight. Many of these patients were
only a few years off their treatment and had not yet started attending the long term
follow-up clinic. Interestingly, there was a dearth of literature regarding the dietary
habits of cancer survivors early off treatment. It has only been since I commenced
work on my thesis that there has been an exponential increase in the number of
publications focusing on the nutritional concerns of young survivors of childhood
cancer.

A number of dietitian students from the University of Wollongong and the University
of NSW contributed to parts of the research included in this PhD. Their involvement
included data collection for the research presented in chapters 3, 4, 6, and 8. The
involvement of the students was approved by the South Eastern Sydney & Illawarra
Health Service, Human Research Ethics Committee-Northern Hospital Network and
they were heavily supervised by me (Appendix 3, 7, and 8).

1.3

Research in a clinical setting

Clinical research is any research involving human subjects who volunteer to take
part in the research (22). It allows the investigator to determine the best methods for
preventing, diagnosing and treating disease (22). Despite the advantages of
undertaking research within the clinical setting, there are inherent issues that make
research in a clinical setting more challenging. Research in a clinical setting focuses
on a specific population, in the case of this thesis, paediatric cancer patients. This
automatically narrows the pool of potential participants, lessening the ability to
achieve adequate statistical power (23).
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Much of the research presented in this thesis is of cancer survivors, many of whom
have completed their therapy. A large part of our population are from rural centres
living an average distance of 240km from the hospital (24). Their ongoing medical
follow-up occurs in outreach clinics throughout the state. This has made face-to-face
recruitment difficult, having to rely on postal recruitment. Recruitment using a mailout approach may have decreased response rates increasing the potential for
recruitment bias (25). The advantage of the use of mail-out recruitment is it is likely
to reduce potential for participants feeling coerced to participate in the study.

1.4

Hypothesis

Much of the research on the nutritional management of childhood cancer patients
has been done in isolation, with the long-term effect of nutritional decisions during
treatment not previously considered. Now that childhood cancer is considered a
chronic disease, a greater focus on how nutritional therapy during cancer treatment
may affect the long-term outcomes of patients is required. The central hypothesis in
this thesis is that the nutritional management decisions made during treatment for
childhood cancer are primarily about the short term goal of promoting an adequate
energy intake to prevent under nutrition. For clinicians to optimise the nutritional
management of childhood cancer patients, issues both during and after treatment
will need to be accounted for.

This thesis is divided into three sections. The sub-hypothesis of each section is:
1) Poor dietary habits are developing during childhood cancer therapy and
these are continuing once treatment has been completed.
2) There are areas of clinical practice that are not accounting for the potential
long-term impact of nutrition decisions on survivors of childhood cancer,
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specifically related to actual feeding practices during and following treatment
completion
3) Taste and smell dysfunction may be implicated in the problem of developing
healthy eating habits in childhood cancer survivors

1.5

Aims

This broad aim of the thesis was to explore the implications for nutrition and dietetics
in managing the needs of child cancer patients during therapy and following survival.

The specific aims of the thesis were:
1. To identify and articulate the problem of childhood nutrition in the cancer
acute care and survival (Section 1)
2. To examine feeding practices following treatment completion both in terms of
dietary intakes and parental views of childhood nutrition (Section 2)
3. To specifically consider the issue of taste and smell as implicated in the
problem of developing healthy eating habits in childhood cancer survivors.
(Section 3)
1.6

Thesis design and methodology

This thesis is based on research in clinical practice and is a single-site case study.
An in-depth analysis from data collected from a specialist paediatric service provides
a useful case study of the problem in situ. The strength of this model is the ability to
translate research findings into practice and to directly influence patient outcomes
(20). Eck et al (1998) recommends that research in clinical practice, also known as
outcomes research, should be routinely integrated into clinical practice (20).
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Traditionally, clinical dietitians’ continually question and assess their practice. They
then search the literature to determine the answers to their questions and
subsequently alter their practice. In the model proposed by Eck et al, (1998) it is the
clinician’s role to design and conduct their own studies to determine the answer if
not available in the literature (20).

As a clinician researcher, I was able to identify the issue of the increasing need for
dietary advice on chronic disease management in survivors of childhood cancer
(figure 1.1). A literature review has allowed me to identify gaps in our knowledge.
This has led me to design studies confirming my hypothesis, assessing clinical
practice and recommending changes.

Figure 1-1 Schema of hierarchy of studies used within the context of research
in practice
This thesis has used a mixed methods approach (Table 1-1) to data collection as a
way of combining both quantitative and qualitative methods (26). The strength of
using a mixed methods approach is that the qualitative and quantitative methods
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can compensate for the limitations inherent with each model (26). A mixed methods
approach also allows the researcher to consider a plethora of viewpoints, and
perspectives of the cohort being studied (27). Mixed methods is particularly useful
for health research because it accounts for the complexity of factors surrounding
health research (28, 29). The thesis also includes both narrative and systematic
reviews used to inform the quantitative and qualitative studies. Sections 1.7-1.9
provide a general background on the research methodology used in this thesis.
Additional background and research methodology are presented and discussed in
the individual chapters.
Table 1-1 Common research methods used in mixed methods research
Common quantitative research
designs

Common qualitative research
methods

Randomized controlled trials
Nonrandomized studies
-Case-control
-Cohort study
-Cross-sectional
-Nonrandomized controlled trial
descriptive studies
-Case series
-Case report
-Incidence or prevalence study without
comparison group

Case study
Ethnography
Grounded theory
Narrative approaches
Phenomenology
Qualitative description

1.7

Quantitative research methods

Quantitative research is the most common method of research used in both medical
and nutritional studies. The National Health and Medical Research Council
(NHMRC) provide a framework for the hierarchy of each quantitative method in
regards to its methodological strength. It allows an assessment of how likely the
research method will be to answer the methodological question and the likelihood of
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bias in the results obtained (30). Chapters 3 and 8 used a cross-sectional study
design without concurrent controls which is level III evidence (30)

Cross-sectional study design involves the assessment of a specific group of
participants at one particular point in time (31). They are used to assess prevalence
and to infer causation (31). It is one of the most common methods used in empirical
research (32). Data gathered from a cross-sectional study can be used to design
larger cohort studies or randomised controlled trials (32). As much of the research
work in this thesis was exploratory, a cross-sectional method allows hypothesis
generation (30). A cross-sectional research design allows for an estimate of the
prevalence of the outcome of interest (33) . In the case of this thesis, a crosssectional study design was used to assess the prevalence of poor dietary habits and
to assess chemosensory function in specific cohorts of survivors of childhood
cancer. There are inherent advantages and disadvantages with this method of
research (Table 1-2) which were reduced with the concurrent use of qualitative data
collection with the study of the dietary intake of cancer survivors in a mixed models
approach (Chapter 4).
Table 1-2 Advantage and disadvantages of using cross-sectional methodology
Advantages

Disadvantages

Inexpensive
Ability to complete over a short time
period
Can assess multiple outcomes and risk
factors
Low risk of ethical issues

Provides only one point in time
High risk of prevalence-incidence bias
Unable to assess causation

Cannot differentiate between cause and
effect
Quick
Inaccurate with rare conditions
Adapted from Levin, 2006 (33) & Mann, 2003(31)
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This thesis employed a number of research methods in the cross-sectional studies.
This included dietary assessment using three-day food diaries, assessment of
Quality

of

Life

(QoL)

and

parental

feeding

behaviours

using

validated

questionnaires, and assessment of chemosensory function using validated methods
of assessment.

1.8

Qualitative research methods

The use of qualitative research in nutrition and dietetic research has been
increasingly recognised as an important research method (34). Qualitative research
investigates the how and why of certain behaviours (34) and is often used for
hypothesis or theory generating (35). Qualitative research is also useful for
assessing the perceptions about an issue from a group participants (35).

Qualitative methodology has been employed in chapters 4 and 6 using a grounded
theory approach. Grounded theory provides the researcher with the ability to derive
their own research questions, rather than using existing theories to structure the
research (35). This thesis used semi-structured interviews to gather the data from
participants. Semi-structured interviews allows an exploration of both opinion and
perceptions of the participants and allows for the interviewee to probe for
clarification of the answer (36) . Analysis of the interviews allowed to derive
concepts and themes from the data to construct new theories(36).

Recruitment of participants in qualitative research differs from that of quantitative
research sampling, with the goal to recruit a representative sample of participants
(35). Maximum variation sampling was chosen in both qualitative studies in this
thesis to ensure that a wide range of diagnosis groups, ages and exposure to types
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of nutrition support were interviewed. Maximum variation sampling ensures that a
balanced perspective of the issue is obtained (35).

1.9

Systematic and narrative review methods

A literature review allows researchers to synthesise existing research to provide a
new perspective and framework on the area of interest (37). If the literature review
is based on emerging topics then the literature review will provide preliminary
conceptualisation of the topic. In contrast, a literature review that synthesises a large
body of existing literature has the potential to reconceptualise previous models (37).
There are three main types of literature reviews include the traditional quantitative
and qualitative systematic reviews as well as narrative reviews (38). Systematic
research reviews are a synthesis of existing literature to inform clinical practice and
may or may not include a meta-analysis (39). A narrative or integrative review allows
the inclusion of a range of methods including experimental and non-experimental
data (39). The narrative review provides a broad perspective on a topic (38) though
are at risk of bias if a systematic method of assessment is not used (39). All types of
literature reviews are retrospective in nature and are at risk of both subjective and
random error (40). See table 1-3 for a comparison between types of systematic
reviews.
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Table 1-3 Comparison of narrative and systematic reviews
Narrative Review

Systematic Review

Question
Search strategy

Broad
Not usually defined

Selection

Not usually defined

Appraisal
Synthesis

Variable
Qualitative summary

Focused clinical question
Well defined and
comprehensive
Well defined and uniformly
applied
Rigorously performed
Quantitative summary
(may include a metaanalysis)
Usually evidence-based

Inferences

Sometimes evidencebased
Adapted from Cook et al, 1997 (40)

Chapter 5 in this thesis uses a quantitative systematic approach to the literature
review, employing the Cochrane Database of Systematic Reviews methodology
(41). A Cochrane review has stringent methodology that the review must follow and
undergoes several layers of peer review prior to publication, thereby reducing its risk
of bias (42). A systematic review was chosen for this section to synthesise the
available data in a relatively new area of study. The systematic review will be used
to inform practice. Contrary to chapter 5, chapter 7 has employed the use of a
narrative systematic review as a way to provide a broad summary of the topic and to
identify potential gaps in the literature. The aim of the narrative review was not to
inform practice.
1.10 Ethical Approval

The studies presented in chapter 3, 4 and 6 underwent both ethical and scientific
review at the South Eastern Sydney and Illawarra Health Service, Human Research
Ethics Committee-Northern Hospital Network prior to commencing. The study
presented in chapter 8 underwent both ethical and scientific review at the Royal
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Alexandra Hospital for Children Ethics Committee. All participants were provided
with written study information and informed consent was obtained prior to data
collection. All participants were free to withdraw from the research studies at any
time.
1.11 Conclusion

Chapter 1 introduced the concepts to be explored in the thesis. It has provided
information on the context of the researcher and the hypothesis and aims driving the
thesis. Chapter 2 will provide a comprehensive overview of the available literature
on the nutritional management of paediatric oncology patients and will further clarify
the need for the research completed in this thesis.
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2 NUTRITIONAL MANAGEMENT IN PAEDIATRIC ONCOLOGY
2.1

Introduction

Childhood cancer is the second leading cause of death in Australian children, aged
between one to fourteen

years (43).

Despite these figures, childhood cancer

survival rates have increased since the 1950s. Eighty-five percent of paediatric
patients who are diagnosed with a malignancy, are likely to survive past five years
(44). With the significant improvement in childhood cancer survival, there is now a
focus on the long term consequences of treating children with chemotherapy and
radiotherapy at such a young age.

In a landmark study published in 2006, 10 000 adult survivors of childhood cancer
were assessed for long term health conditions. Childhood cancer survivors were
three times more likely to have a chronic condition and eight times more likely to
have a severe chronic condition compared to sibling controls (15). The results of this
study has caused a shift in the paradigm of cancer treatment, with childhood cancer
no longer considered an acute disease with high mortality, but a chronic condition
associated with ongoing high morbidity.

The nutritional management of paediatric cancer patients is an important aspect of
their multidisciplinary care plan and medical management. The focus has been on
the prevention of under nutrition (45). Without nutritional therapy, up to 50% of
paediatric oncology patients are likely to become malnourished (46). With this
changing of the landscape of how paediatric oncology is viewed, the focus of the
nutritional therapy of paediatric oncology patients may also need to be altered.
Previously where the prevention or treatment of under nutrition has been the focus
of nutritional therapy, the nutritional management of childhood cancer survivors,
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from infant until adulthood needs to be considered. Childhood cancer survivors may
no longer be at risk of under nutrition, but may be at risk of over nutrition or poor
nutritional intake. Decisions made in regards to their nutritional management during
their therapy, has the potential to influence their nutritional management in the long
term.

This chapter will provide a background on the types of childhood cancers, their
prognosis rates, and treatments, and how these influence the patient’s nutritional
management goals. The literature review will also focus on the types of nutritional
therapy currently available to paediatric oncology patients on treatment and a
discussion on the nutritional management of childhood cancer survivors. This
information will provide a context to the thesis and allow a clear reasoning for the
development of the subsequent chapters and research studies.

2.2
2.2.1

Overview of the medical management and outcomes of paediatric cancer
Types of cancers and prognosis rates

Approximately 580 children are diagnosed with cancer each year in Australia; a rate
of 14 in 100 000 children (43). The prevalence of childhood cancer has remained
stable in Australia in the past 12 years (43). Cure rates for this disease have
increased over the past four decades. The most common form of childhood cancer,
acute lymphoblastic leukaemia (ALL) has a five year survival of 80%, which is up
from 58% during this time (47). Five-year relative survival for all childhood cancers
combined, increased from 72.3% for the years 1983-1994 to 79.5% during 19952004 (44). Despite these improvements in survival, childhood cancer remains the
second most common cause of death among western societies of children between
the ages of 1-14 years (48), with cancer being attributed to 17% of all deaths of
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Australian children aged between one and fourteen years.

Unfortunately other

common childhood cancers such as brain tumours and central nervous system
tumours continue to have high mortality, with five year survival around 50% for some
age groups (44). Table 2-1 outlines the five -year survival rates of common
childhood cancers.
Table 2-1 Common paediatric cancers, their incidence, treatment and five year
survival statistics
Cancer Type

Incidence Treatment

5-year survival

Acute lymphoblastic
leukaemia (ALL)

25%

90% (<15 years)
75% (15-19 years)

Acute myeloid
leukaemia (AML)
Non-Hodgkin’s
lymphoma (NHL)
Hodgkin lymphoma

5%
7%

Chemotherapy
radiotherapy (CNS +ve)
HSCT
Chemotherapy
HSCT
Chemotherapy

6%

68% (<15 years)
57% (15-19 years)
88% (<15 years)
77% (15-19 years)
90-95%

Chemotherapy
radiotherapy
Brain and spinal cord
Surgery +/70%
tumours
radiotherapy +/chemotherapy
Kidney tumours
7%
Surgery +/88% (Wilms’
(Wilms’ and germ cell
radiotherapy +/tumour)
tumours)
chemotherapy
Neuroblastoma
Surgery +/87% (< 1 year)
radiotherapy +/68% (1-4 years)
chemotherapy +/- BMT 52% (5-9 years)
+/- immune therapy
66% (10-14 years)
Ewing’s sarcoma
Surgery +/78% (<15 years)
chemotherapy +/60% (15-19 years)
radiotherapy
Osteosarcoma
5%
Surgery +/76% (<15 years)
chemotherapy +/66% (15-19 years)
radiotherapy
Rhabdomyosarcoma
3.5%
Surgery +/67% (<15 years)
chemotherapy +/51% (15-19 years)
radiotherapy
Adapted from the National Cancer Institute accessed 16/12/2014
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2.2.2

Medical management of paediatric cancer patients

The medical treatment of paediatric oncology patients depends on the type of
cancer, stage of cancer, age of the patient and the patient’s prognosis. For some
solid tumours, surgery is the only treatment modality recommended. For most
paediatric oncology patients’, chemotherapy, radiotherapy and haematopoietic stem
cell transplant (HSCT) are used alone or in combination to treat the cancer.
Combination therapy is used as a way of improving survival rates (49). Surgery
and/or radiotherapy is used to control local disease, while chemotherapy is used to
eradicate the disease (50). The goal of cancer treatment is to maximise the potential
for cure, while reducing the risk of short and long term detrimental side effects (49).

2.2.3

Chemotherapy

Chemotherapy is considered the primary treatment for childhood cancers (44).
Chemotherapy is the umbrella term to describe any drug that is used to treat cancer
(www.cancer.org, accessed on 06/01/2015). Chemotherapy is a systemic treatment
and as such, can be affective on all parts of the body. Chemotherapy is mainly
administered orally or intravenously (49). Other methods of administration include
subcutaneous or intramuscular injection or intrathecally (injection into the lumbar
region of the spine) (49).

Chemotherapy targets actively dividing cancer cells (49), though the point of action
differs for each class of chemotherapy drug (Table 2-2). Chemotherapy cannot
distinguish between cancer cells and non- cancer cells that are rapidly dividing and,
as such, can cause both short term and long term, potentially severe, side effects
(50). The non-cancer cells that are more likely to be affected by the chemotherapy
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agent include hair follicles, blood and bone marrow, gastrointestinal tract and the
reproductive tract (49).
Table 2-2 Common chemotherapy agents and their mode of action
Type
Alkylating agents

How they work
Damage the cancer cell’s DNA
preventing reproduction

Examples
Cyclophosphamide
Busulphan
Thiotepa

Antimetabolics

Interfer with DNA and RNA
growth of the cancer cells

Anthracyclines
Topoisomerase
inhibitors

Interfer with enzymes involved
with DNA replication
Interfere with the cell’s ability
to copy DNA

Mitotic inhibitors

Impair cancer cell reproduction

Corticosteroids

Kill or slow cancer cell growth

6-mecaptopurine
Cytarabine
Fludarabine
Methotrexate
Daunorubicin
Doxorubicin
Etoposide
Topotecan
Irinotecan
Vincristine
Vinblastine
Prednisone
Dexamethasone

Adapted from Pizzo and Poplack, 2011 (50)

Acute side effects such as nausea vomiting and diarrhoea occur during and shortly
after the administration of the chemotherapy (50). Nausea and vomiting is one of the
most common side effects of chemotherapy (51). Nausea and vomiting is classed as
acute (within 24 hours of administration of chemotherapy), chronic (between 24
hours and five days of chemotherapy administration) or anticipatory (conditioned
response before chemotherapy infusion) (51, 52).

Chemotherapy affects the blood and marrow of the patient, causing a short-term
reduction in white blood cells, red blood cells, platelets (thrombocytopenia) and
neutrophils (neutropenia) (51). This usually occurs seven to ten days after the start
of the chemotherapy administration, and places the paediatric cancer patient at
significant risk of infections and fever during this time (51). Patients are also likely to
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experience side effects such as mucositis during this period. Mucositis is an
ulcerative condition of the oral or gastrointestinal tract (51), leading to pain and the
inability to consume and digest oral intake.

Bone marrow recovery occurs

approximately 21 days from the start of the chemotherapy cycle. Many of the acute
side effects, such as nausea, poor appetite and mucositis have reduced by this time.
Once the patient has recovered from one course of chemotherapy they are given
another round of drugs and the cycle starts again. The number of cycles of
chemotherapy varies between chemotherapy regimens.

Long-term side effects of chemotherapy can include secondary cancers, infertility
and damage to the major organs, such as cardiovascular disease. Information on
the long term side effects of chemotherapy and other cancer treatments are covered
in section 2.5.

2.2.4

Radiotherapy

Radiotherapy is a treatment used to cause cancer cell death by the use of ionising
radiation (49). Factors such as the age, body size, tumour type and burden, other
treatment modalities and previous treatment, account for the dosing of radiation
given to a paediatric cancer patient over the treatment period (49). Treatment is
given over a period of one week to six weeks. The aim of radiation therapy is to
target cancer cells only, attempting to minimise damage to healthy cells. This is
done by data from computer tomography and magnetic resonance scans. Although
treatment lasts for a short period of time, the patient is required to stay very still
during the course of the treatment. This can be problematic for young paediatric
cancer patients, requiring daily sedation using general anaesthetics (51, 53).
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Side effects from radiation can depend on the targeted area of the radiation. Similar
to chemotherapy, radiation cannot distinguish between cancer and non-cancer cells
(51). Patients receiving radiation to the area of the gastrointestinal tract may
experience diarrhoea, nausea or vomiting, whereas patients receiving radiation to
the head area may suffer from xerestoma and nausea. Radiation is used for brain
tumour patients as it is more effective than chemotherapy which is unable to cross
the blood brain barrier to be carried systemically into the brain area. Side effects
from radiation to the brain can also include nausea, vomiting and anorexia.
Approximately 50% of radiation patients experience somnolence (extreme
tiredness), though this usually resolves within a few weeks (49). Paediatric cancer
patients who require daily general anaesthetics can also experience additional side
effects such as nausea and vomiting. Patients who require general anaesthetics are
required to fast for a portion of each day of treatment resulting in a reduction in food
intake, leading to weight loss.

Radiation therapy is associated with a neurocognitive dysfunction (54, 55) and
growth retardation in children (53). Growing and developing tissue is more sensitive
to the effects of radiation (50) and the younger the child, the more sensitive their
developing brains are to the effects of the radiation (55). Similar to the use of
chemotherapy, the use of radiation is a balance between providing adequate
treatment for curative intent and reducing potential long term serious side effects for
paediatric cancer patients (54).

2.2.5

Haematopoietic Stem Cell Transplant

Haematopoietic stem cell transplant (HSCT) is used widely to treat children with
hereditary and /or haematological disorders of both malignant and non-malignant
origin (56, 57). Patients are given high dose chemotherapy +/- radiation treatment to
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completely eradicate a patient’s disease (56). The patient is then rescued with their
own source of stem cells (autologous transplant) or a donor’s stem cells (allogenic
transplant) (50). This rescuing of the stem cells allows the patient to receive very
high doses of anti-cancer therapy. Without the stem cell rescue the patient’s own
bone marrow would not recover leading to a very high risk of mortality. Patients with
defective bone marrow, such as those with leukaemia, receive a donor source of
stem cells (50). This is usually provided from a matched sibling, a matching
anonymous donor or banked cord blood (56, 58).

As

the

childhood

cancer

patient

receives

very

high

doses

of

chemotherapy/radiotherapy, they are at risk of morbidity and mortality as a result of
the treatment. Treatment related mortality can be as a high as 20% (59). Recovery
from these acute side effects can take anywhere from two to six weeks. Another
significant morbidity from a HSCT is graft- versus-host disease (GVHD). This occurs
when the donor stem cells (specifically the lymphocytes) consider the host’s (the
patient) body as foreign and starts an immune response against the host (50).
GVHD can affect many body organs such as the skin, GI tract, eyes and liver
resulting in severe rash, diarrhoea and liver disease (50). GVHD is classified as
acute if it occurs within 100 days of the HSCT or chronic if it occurs after 100 days
post HSCT. Chronic GVHD can be diagnosed up to three years after HSCT (60, 61).

Intensive conditioning regimens resulting in anorexia, nausea, vomiting, diarrhoea or
mucositis (62-67) limit voluntary nutritional intake during a HSCT. This increases the
risk of under nutrition (65, 68, 69). Nutrition support is especially important in the
paediatric population as long periods of suboptimal nutrition can also affect growth
velocity (64, 70, 71). The provision of nutrition support has become standard
practice during a paediatric HSCT (68, 69, 72, 73).
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The majority of the paediatric HSCT patients are well nourished at the beginning of
conditioning with a reported incidence of malnutrition between 11-31% (68, 74). For
most patients the goal of nutrition support during a paediatric HSCT is to maintain
their nutritional status (66) and therefore to maintain normal growth patterns (64).
For patients who present to transplant at risk of malnutrition, the goal may actually
be to improve their nutritional status as sub-optimal pre-transplant muscle reserves
are associated with a decreased height velocity post-transplant (71).

2.3

2.3.1

Overview of the nutritional concerns in paediatric oncology

Definition and consequences of malnutrition in children

Nutrition is often seen in terms of a dichotomy; under-nutrition vs. over-nutrition with
the umbrella term of malnutrition being utilised to define both states. The World
Health Organisation (75) defines malnutrition as

“…a pathological state resulting from a relative or absolute deficiency or excess of
one or more essential nutrients….”

Under-nutrition occurs when there is a deficiency of nutrients relating to inadequate
food consumption. Over-nutrition occurs when there is excessive food consumption
leading to excessive calorie intake (75).

Both states can lead to diminished

functioning in different forms (76). The consequences of over-nutrition includes;
obesity and metabolic and endocrine diseases such as heart disease, diabetes and
stroke (77) whereas under-nutrition can lead to diseases such as Marasmus (75) all
of which increases a person’s overall mortality risk. Under-nutrition cannot only
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cause nutrition-related diseases it can have other detrimental consequences on the
body. These include anaemia, fatigue, apathy, extreme weakness, irritability and
neurological deficits which can continue to be an ongoing issue even when nutrition
is re-established (78).

Krehl, 1956 (79) described optimal nutrition as

“…..that which provides all dietary nutrients in respect to kind and amount, and in
proper state of combination or balance so that the organism may always meet the
varied exogenous and endogenous stresses of life, whether in health or disease,
with a minimal demand or strain on the body’s natural homeostatic mechanisms”.

In Krehl’s definition he discusses meeting nutritional needs during disease (79). For
many people certain diseases actually prevent the attainment of optimal nutrition, by
the prevention of the consumption of adequate nutrients thereby leading to
malnutrition. In such cases the nutritional issues are caused by the disease itself
leading a person to be unable to consume or digest adequate nutrients or the
disease state increasing their nutritional requirements. When optimal nutrition is not
achieved in the setting of a disease process this can lead to poorer disease
outcomes, independent of the disease state (80) by increasing morbidity as well as
overall mortality (81). Clinical implications of poor nutrition include impaired immune
function, delayed wound healing, and issues with physical functioning and
decreasing functional status (82) all leading to increased morbidity and possibly
mortality.
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Defining malnutrition in children differs to that of adults due to the needs and
consequences of poor nutrition on a growing child (83). The American Society of
Parenteral and Enteral nutrition defines paediatric malnutrition as (83):

“An imbalance between nutrient requirement and intake, resulting in cumulative
deficits of energy, protein or micronutrients that may negatively affect growth,
development and other relevant outcomes.”

Malnutrition leads to increased morbidity, similar to that of adults, with the additional
risk of growth stunting as a significant consequence of chronic under nutrition. This
leads to a reduction in a child’s weight and height velocity (84). Under nutrition in
children may also cause a reduction in the attainment of appropriate developmental
milestones (83).

2.3.2

Assessment of nutritional status

Assessment of malnutrition, both over and under nutrition remains difficult (83),
especially when comorbidities exist, such as a diagnosis of childhood cancer.
Traditional methods, such as body mass index (BMI), do provide a useful method to
screen patients but do not account for issues with fluid retention (83), tumour weight
(85), changes in body composition and growth failure. Body Mass Index (BMI)
percentile and z scores are used as a way to standardise children across different
age groups (83). A BMI percentile under the 5th indicates under nutrition, while a
BMI percentile over the 85th percentile indicates a degree of over nutrition.
Alternatively, a z score less than -2 indicates under nutrition and a z-score over +2
indicates over weight (86).
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Percentage of ideal body weight (percentage expected weight for height) is also
used as a method to define a child’s nutritional status (87) . A child’s ideal weight is
calculated using standardised growth charts, assuming their ideal weight
corresponds with the weight percentile. A calculation of current weight/ideal weight x
100 is used to define their percentage of ideal body weight. The Waterlow factors
are a method for classifying protein-energy malnutrition in children (87, 88). A
percentage of ideal body weight greater than 110% indicates over nutrition and a
percentage of ideal body weight below 90% indicates under nutrition (87).

It is important to note that a patient can remain within a healthy weight range as
measured by BMI z-scores or the Waterlow factors, but still be considered
malnourished. Significant reductions in body weight over a short period of time can
also be a marker of malnutrition. A five percent loss of body weight over a period of
one month or from pre-illness weight can also be an indicator of malnutrition (89). It
is also important to consider that markers which rely on weight measurements alone
to indicate a patient’s nutritional status, do not take into consideration body
composition (90), tumour burden (85) or fluid status (89). Using these markers of
nutritional status alone could misdiagnose up to 40% of childhood cancer patients
who are malnourished (90) as excess fluid or tumour burden could mask a loss of
fat or skeletal muscle (7). Childhood cancer patients are likely to have a higher fat
mass and a lower fat free mass compared with their peers, despite assessment of
weight for height within reference ranges (91). Arm anthropometry (triceps skinfold
(TSF); mid-arm circumference (MAC)) has been shown to be a reliable method for
assessment of fat mass (92) but not fat-free mass (90) in paediatric cancer patients.

Other methods of nutrition assessment such as biochemical markers and physical
examination can be used to provide information on a childhood cancer patient’s
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nutritional status. The physical examination of a patient’s lower ribs, orbital fat pads,
triceps skin fold, deltoids and quadriceps by a trained clinician provides a subjective
assessment of fat and muscle stores (4, 93). The presence of ascites or oedema
should be noted as these may influence anthropometric measures (93). Information
on nutrition impact symptoms such as nausea, vomiting, taste and smell changes
and anorexia can provide information on the likelihood of a poor oral intake and
provide targets for dietary education and interventions.

The biochemical marker albumin which is a visceral protein had initially been used
as a marker of nutritional status. The biochemical marker is an acute-phase reactant
and its production by the liver is influenced by acute and chronic illness. Albumin is
not considered a good marker of nutritional status in paediatric oncology patients
(93). Other visceral proteins such as pre-albumin and retinol-binding protein have
shorter half-lives (4) and may be a better indicator of recent protein stores (93). The
cost of these tests can be prohibitive (93) leaving clinicians to rely on anthropometric
measures and physical examination to provide an assessment of nutritional status.

2.3.3

Prevalence of malnutrition

Childhood cancer patients with solid malignancies, and patients with advanced
cancer are at risk of under nutrition (94) before treatment has commenced.
Prevalence may be as high as 25% of all patients diagnosed (94). The prevalence of
under-nutrition for childhood cancer patients during treatment has been suggested
to be anywhere

between six to 50% of patients (6), while the incidence of

malnutrition amongst children with metastatic disease approaching the upper end of
this range and may be as high as 40% (14). Much of the literature on prevalence
rates of malnutrition in paediatric oncology were assessed in the 1980s and 1990s
using weight based assessments such as BMI z-scores. Treatment regimens and
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protocols have changed since then, though there remains very little literature on the
prevalence rates of malnutrition based on modern day protocols. There also remains
no uniform definition of malnutrition (46) to enable comparison between prevalence
studies. A recent systematic review of the literature suggests a prevalence of under
nutrition for leukaemia patients of between 0-10%, 20-50% for neuroblastoma and
0-30% for other malignancies (46). These figures took into account studies that not
only used weight as a measure of under nutrition, but studies that used other
measures of under nutrition such as body composition and dietary intake.

Recent studies have looked at the change in body composition of childhood cancer
patients over the course of cancer therapy based on measurements of weight/BMI
changes. The majority of these studies focused on patients with ALL, finding
increasing BMI z-scores over the course of treatment (95, 96). A recent study
assessed body composition changes over the course of intensive paediatric cancer
patient’s treatment. Patients with haematological disease and solid tumours did
have a reduction in BMI and fat free mass (FFM) during the initial phase of their
treatment. BMI z-scores and fat mass (FM) appeared to increase over the course of
the treatment, relating to the use of intensive nutrition support, mainly tube feedings
(97).

2.3.4

Aetiology of malnutrition

The primary aetiology of weight loss is the inability of childhood cancer patients to
consume adequate nutrients to meet their requirements (98). The reason for this is
multi-factorial, relating to both affects from the disease itself and the treatment of the
disease.
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2.3.5

Inflammation & cachexia

Cachexia is a term to describe a state of depletion (99) seen in cancer patients
(100), characterised by anorexia and weight loss (100). There is a distinct difference
between weight loss and patients in a cachectic state.

Weight loss, due to

insufficient intake, is predominantly characterised by a reduction in fat mass and can
be reversed with an improvement in nutritional intake or adequate nutritional
support. In contrast, the weight loss seen in patients with cachexia predominantly
involves a reduction in skeletal muscle mass (101) with or without a loss in fat mass
(102, 103). These changes are related to an inflammatory response mediated by
pro-inflammatory cytokines (100) resulting in a difficulty in reversing malnutrition
using traditional methods of nutritional support (101, 104) leading to

functional

impairment (103).

2.3.6

Altered substrate metabolism

Fat, protein and carbohydrate metabolism appears altered in childhood cancer
patients (6, 98) causing a loss FFM as well as FM resulting in weight loss and
under nutrition (Table 2-3) (105).
Table 2-3 Altered substrate metabolism and the consequences

Substrate
Protein

Fat

Carbohydrate

Alteration in metabolism
Increase muscle catabolism
Decreased muscle synthesis
Increased protein turnover
Increased free fatty acid
turnover
Increased lipid breakdown
Decreased lipogenesis
Increased gluconeogenesis
Increased use of cori cycle
Abnormal insulin response

Outcome
Skeletal muscle atrophy
Hypoalbuminemia
Marked wasting of body fat
Raised plasma lipid

Decreased glucose
intolerance
Higher energy cost to
metabolise glucose
Adapted from Picton (98), Tisdale (101), Ladas (4), Bauer (7) & Andrassy (6)
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2.3.7

Altered energy metabolism

The body’s usual response to starvation is to conserve energy by decreasing energy
expenditure (6). In adult patients with cancer, energy expenditure has been shown
to increase, though this appears to be cancer specific and more likely in patients
with certain solid tumours (106). Measuring energy expenditure in children has
proven difficult and the studies assessing energy expenditure in young cancer
patients have been limited (7, 46, 98). A recent systematic review of the literature
found contradictory results regarding energy expenditure in childhood cancer
patients (46). There is some suggestion that childhood cancer patients with solid
tumours had higher energy expenditures at diagnosis (98). This may be related to
the tumour burden.

2.3.8

Cancer and treatment related side-affects

Factors such as lethargy, pallor and nausea as a result of the disease process can
lead to anorexia and weight loss prior to diagnosis (46). These symptoms are often
used for a differential diagnosis (94).

Poor oral intake is a common among

paediatric oncology patients once treatment has commenced. As discussed in
section 2.2.3, cancer therapy such as chemotherapy targets rapidly dividing cells (7)
resulting in symptoms such as nausea and vomiting (10) and mucositis (107). These
symptoms lead to prolonged periods of anorexia (108). In a meta-analysis of
symptoms experienced by paediatric oncology patients, the prevalence of anorexia
was 40% (107). Taste and smell changes have also been implicated as a factor in
reducing or changing food intake in paediatric cancer patients (109).

Fatigue is commonly described in paediatric cancer patients (10, 107). Fatigue is
associated with an increase in sleep as an energy conservation technique, (107)
indirectly reducing a patient’s food intake. Another consequence of fatigue is a
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reduction in physical activity, leading to a reduction in FFM (110), contributing to a
patient’s risk of under nutrition.

2.3.9

Consequences and outcomes of malnutrition in paediatric oncology

Under nutrition in the paediatric hospital setting has been shown to be associated
with an increased length of hospital stay as well as a reduced QoL (111). Specific
consequences of under nutrition for paediatric oncology patients include a reduced
treatment tolerance and increased treatment side-effects, potentially leading to
poorer outcomes (6, 14). Recent literature suggests that under nutrition in paediatric
patients is associated with increased infections and increased mortality (112-114),
and this is likely independent of disease severity (115). Malnutrition in children
reduces the absorption of chemotherapy (116) and may be one explanation of
poorer outcomes in underweight patients (114). Other suggested mechanisms
include an increased susceptibility to infections from hormonal changes (117).

Acute and chronic under nutrition can also have detrimental effects on a developing
child as childhood is a significant time of growth and development. Acute under
nutrition (less than three months in duration) can cause lean body mass depletion
(83). Chronic under nutrition (greater than three month’s duration) can cause growth
stunting (84) and cognitive/developmental delay (83). For childhood cancer patients,
whereby cancer therapy can take between up to two years to complete, their risk of
extended periods of poor nutrition, in the absence of nutritional support can
potentially lead to long term issues with growth and development.

Much of the focus on the literature regarding the consequences of poor nutritional
status has focused on the detrimental effects of under nutrition in the paediatric
oncology population. New research is showing that being overweight, especially at
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diagnosis, may also be associated with morbidity and mortality in cancer therapy
(114, 118). It has also been suggested that overweight patients undergoing a HSTC
have poorer prognosis than their normal weight peers (119) and higher treatment
related mortality (120). A recent study of over 400 survivors of childhood

cancer found that obesity at diagnosis was an independent predictor of
relapse in child above the age of 10 years (118). This did not appear to be a
linear relationship as patients who were underweight at diagnosis also have a
poorer event-free survival than their normal weight peers (114, 118).

Mechanisms for the association between over nutrition and a poor prognosis remain
unknown. It has been suggested that obesity alters drug deposition decreasing the
effectiveness of the chemotherapy treatment (119), but the reasoning may be more
complex. Growth factors and lymphokines which are produced by adipose

tissue may change the effectiveness of anti-cancer therapy (118).

2.4

2.4.1

Nutritional management in paediatric oncology during therapy

Recommendations for the timing of nutritional interventions

Nutritional therapy has been established as an integral part of paediatric cancer
therapy to ensure normal growth and development (4, 8). The three primary
methods for preventing or reversing under-nutrition include oral nutrition support
(ONS), enteral nutrition (EN) and parenteral nutrition (PN). Ideally the prevention of
malnutrition should be the goal of any nutritional intervention (4, 121), yet there
remain no standardised criteria for initiation of nutrition support (7, 122). Table 2-4
indicates criteria suggested for nutritional implementation. Algorithms, providing
criteria for nutritional interventions, have been shown to improve the consistency of
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the nutritional management of paediatric oncology patients (5, 123), yet they are not
routinely used.
Table 2-4 Recommended criteria for initiation of nutrition support

Anthropometric measure

>5% loss of body weight
<90% of ideal body weight
<5th BMI percentile
<5th TSF percentile
A decrease in weight down two percentiles

Biochemistry

Serum albumin #3.2 g/dL (in the absence of recent acute metabolic stress within the
last 14 days).

Clinical measures

Anticipated gut dysfunction of > 5 days

Dietary intake

<70% of their estimated requirements for oral intake
Adapted from Rickard et al, 1986 (8)

Certain diagnosis groups and the subsequent treatment protocols used, places
patients at a higher risk of nutritional depletion. (Table 2-5)
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Table 2-5 Paediatric oncology diagnosis and their nutritional risk

High nutritional risk disease

Advanced diseases during initial treatment
Stage III & IV neuroblastoma
Pelvic rhabdomyosarcoma
Ewing’s sarcoma’
Some non-Hodgkin’s lymphoma
High risk leukemia (AML*, VHRALL**, Phi+ ALL***)
Medulloblastoma
Multiple relapse leukemia
HSCT

Low nutritional risk disease

Standard risk ALL$
Non metastatic solid tumours
Advanced diseases in remission during maintenance treatment
Wilm’s tumour
Adapted from Rickard et al, 1986 (8); Bowman et al, 1998 (5); Bauer et al, 2011 (7)*
AML: Acute myeloid leukaemia; VHRLL: Very high risk acute lymphoblastic
leukaemia; Phi+ ALL: Philadelphia positive acute lymphoblastic leukaemia; $ ALL:
Acute lymphoblastic leukaemia

2.4.2

Oral nutrition support

Oral nutrition support involves the manipulation of the oral intake to provide the
patient with additional nutrients by consuming nutrient-dense foods (14). The use of
specialty drinks and supplements containing a concentrated source of nutrients that
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can act as a meal replacement can also be used (14). Oral nutrition support also
involves counselling on strategies for increasing oral intake when suffering the sideeffects of cancer treatment. The literature suggest that oral nutrition support be
initiated if patients have lost as little as five percent of their body weight (6, 124).

Oral nutrition support is typically the preferred first step for preventing malnutrition in
children (4) as it is the least invasive method of nutritional supplementation (125)
and is therefore preferred by the patient group, However success with the use of this
form of nutritional supplementation for high risk paediatric oncology patients is
generally poor (14), and more aggressive nutritional interventions are indicated.

Success with ONS requires the childhood cancer patient to have the ability to ingest
food in a sufficient enough quantity that by adding additional energy to the food
already consumed, their overall energy intake will be sufficient enough to meet their
requirements (12). Oral supplements are also generally not tolerated in this patient
group. Earlier published work by our centre suggests that fresh milk based
supplements are preferred to other high energy supplements recommended for this
patient group (ref). Side effects associated with cancer therapy such as mucositis,
nausea (126), taste changes, pain and food aversions (127) preclude patients from
being able to consume or tolerate adequate oral intake (14) and may also appear to
change patients food preferences. These food preferences do not appear to be
standardised across all patients but vary from patient to patient (126). For many
childhood cancer patients, consuming an adequate oral intake is impossible (126).

Another factor to consider when choosing ONS as a method of nutritional
supplementation is the longer term consequences of pushing food via the oral route
when children are undergoing cancer therapy. Food aversions are a common in
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both children (126) and adult cancer patients (128). Food aversions can occur when
food is consumed while having negative experience (129). Food aversions are also
associated with a higher level of parental pressure to eat (130). Recent work at our
centre on the feeding practices that parents used during their child’s cancer
treatment revealed negative feeding practices. These included pressuring their child
to eat, offering nutrient poor food rewards and non-food rewards (131). Many
childhood cancer patients are at an age where long term feeding patterns and habits
are being established. Food aversions to certain foods may continue well after the
child has completed their treatment for cancer and influence their long term food
preferences.

2.4.3

Enteral nutrition support

For patients who cannot maintain an adequate nutritional status via the oral route,
use of EN is recommended (4). EN is the provision of nutrition in a liquid form, via a
tube into the gastrointestinal (GI) tract, usually the stomach, duodenum or jejunum
(47). This can be done using a silastic feeding tube which is inserted via the nose
and fed through the oesophagus to the stomach or duodenum. A gastrostomy can
also be used to provide EN. This method uses a tube inserted directly into the
stomach, or jejunum, either surgically or endoscopically. Childhood cancer patients
who receive tube feeding use formulated liquid supplements that get infused with a
pump into the tube. The patient can also be given the feeds during the day via a
pump or with the use of gravity.

EN has been shown to be effective in promoting weight gain in paediatric oncology
patients, (132-134) especially when used prophylactically (135, 136). Similar to
ONS, absorption of nutrients continues through the gastrointestinal tract. Enteral
nutrition is associated with a reduced risk of bacterial translocation and maintenance
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of the integrity of the GI tract when compared with use of PN alone. (137). The use
of tube feeding also allows easier administration of medications and fluids (6).

Many patients also consider the tube a visible sign they are sick and therefore there
is concern regarding altered body image (137). Gastrostomy feeding has been
recommended for use when patients are likely to require long-term feeding during
their cancer treatment (138). The use of a gastrostomy for paediatric cancer patients
has been shown to be safe (136). A gastrostomy can also be hidden under the
patient’s clothes which is seen as an advantage for patients (137).

2.4.4

Parenteral nutrition support

Parenteral nutrition is an alternate form of nutritional intervention that can be used to
prevent or reverse malnutrition in the paediatric oncology setting when this cannot
be achieved using the oral or enteral route (7, 139). PN involves the intravenous
administration of a solution containing a balanced mix of essential and non-essential
amino acids, glucose, fatty acids, electrolytes and micronutrients (47). Ideally PN
infusion should be via the central line to meet the nutrient needs of childhood cancer
patients (4). Most children undergoing chemotherapy have a central line inserted for
chemotherapy, making infusion of PN accessible (140).

PN has been used widely in the paediatric oncology setting (122), especially those
undergoing a HSCT (67, 69, 141). High dose chemotherapy regimens may result in
gastrointestinal complications such as mucositis, enteritis and typhlitis preventing
nutrition being tolerated via the enteral route (50). PN is associated with a higher
risk of infective complications (139) bacterial translocation (137) hyperglycaemia
and hepatic stenosis (142). It is not recommended that PN be administered at
home, resulting in longer hospital stays for patients requiring PN.
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Issues and concerns with the implementation of enteral and parenteral nutrition
A survey of nutritional practices in North American paediatric oncology centers,
found no standardised method of nutritional supplementation to prevent or reverse
under-nutrition in paediatric oncology patients (143). A recent Cochrane review
comparing EN with PN in the paediatric oncology setting concluded that there is
inadequate evidence to allow recommendations for the best form of nutrition
support. (144). The review concluded that PN may improve nutritional status in wellnourished paediatric patients compared with EN (144) but these findings are not
replicated with malnourished patients. Due to a high risk of infective complications
(139) associated with using PN, the literature suggests that the use of EN should be
considered before using PN for nutrition support (5, 135, 137). In reality, these
recommendations are not always being implemented in a clinical setting (143).

Reasons for the choice of PN being chosen over EN appear multifactorial. A recent
study of paediatric oncology patients, and their parents, suggests that the perceived
discomfort of EN influences patient/parent decision to allow EN to be used (145).
There is also suggestion that EN is more likely to be initiated in younger patients (<
6 years) (135). The healthcare team’s recommendations influence the initiation of
EN (145). In non-oncology settings, such as paediatric patients with developmental
delay, it appears that timing of the initiation of EN may also be influenced by the
views and support of the medical teams (146, 147). Literature also suggests that
parents use EN as a threat to get their child to eat (131), thereby potentially
exacerbating the negative views of EN with the childhood cancer patients.
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2.5

Nutritional management in paediatric oncology after therapy completion

The majority of the literature focuses on the management (both medical and
nutritional) of childhood cancer patients during the active phase of their treatment. In
the last 10 years, there is a shift in focus, and the long term consequences of giving
cancer therapy to children at a young age have been studied. In a landmark paper
published in 2006, the health status of 10 000 long term survivors of childhood
cancer was compared with sibling controls. This study showed that childhood cancer
survivors have a relative risk of developing a chronic condition of 3.3 and a relative
risk of a severe or life-threatening condition of 8.2 when compared with their siblings
(15). Female sex and older age at diagnosis are independent risk factors for
developing chronic conditions (148). These chronic health conditions include (but
are not limited to) secondary cancers, endocrine disorders, renal dysfunction and
severe musculoskeletal problems. However, it may be many years before patients’
display these conditions which tend to worsen over time (149).

Specific chronic health conditions of long-term survivors that have the potential to be
managed by lifestyle factors include osteoporosis, metabolic syndrome, endocrine
disorders and cardiovascular disease (150). Adult survivors of childhood cancer
have a greater chance of being diagnosed with the metabolic syndrome than healthy
controls(151). There prevalence of the metabolic syndrome in childhood cancer
survivors may be as high as 30% (18). Yet many adult survivors of childhood cancer
do not meet guidelines for fruit and vegetable intake, consume excessive fat and
have an inadequate calcium intake (17, 152). Adult, survivors of childhood cancer,
diagnosed with metabolic syndrome, are 2.2 more likely to have poor diets than
those without the metabolic syndrome (18). This is independent of disease type and
treatment. Long-term survivors report barriers to consuming a healthy diet that
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include taste preferences for higher fat foods and the lack of availability of healthier
foods (153). They may also be unaware of their risk of chronic disease (150),
lessening the motivation to change their lifestyle. As childhood cancer survivors are
already at a higher risk of long-term metabolic complications as a result of their
cancer therapy, poor nutritional intake may be exacerbating this risk.

2.6

Role of the dietitian in paediatric oncology

The role of the dietitian in the clinical management of paediatric oncology patients
has focused on the prevention and treatment of under nutrition during cancer
therapy. The goals of nutritional interventions have focused on ensuring adequate
energy and protein to prevent or reverse under nutrition, potentially at the detriment
of good nutrition principles. The dietitian must also balance the recommendations
from the literature regarding the initiation and type of nutrition support recommended
with the realities’ of working with sick children and their parents.

For many parents, the more aggressive forms of nutrition support, such as enteral
nutrition, are seen as a last resort and as such parents are tending to force their
child to consume meals or using the more invasive forms of nutritional
supplementation as a threat to encourage eating. In turn, clinicians are encouraging
paediatric oncology patients to “consume whatever they liked,” as a way of
preventing the child from losing weight. The reality of intensive cancer therapy is
that most patients with a high nutritional risk diagnosis are unable to maintain their
nutritional status using food and supplements alone.

Paediatric oncology used to be considered an acute disease with poor short-term
outcomes. For patients who were “cured” there was no focus on the long term
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morbidity associated with a cancer diagnosis at such a young age. Since cure rates
have increased, there has been a shift of thinking to realising that cancer is now a
chronic disease. The goal of treatment is to provide cure without causing long term
harm. It appears that nutritional recommendations have been slower to shift the
paradigm. Childhood cancer survivors are at a greater risk of lifestyle diseases such
as diabetes, obesity, osteoporosis and metabolic syndrome. The literature also
shows that adult survivors of childhood cancer are not consuming diets that would
help to reduce the risk of these diseases, yet there remains a dearth of literature
regarding the dietary intake and habits of younger cancer survivors.

2.7

Contribution of this thesis

The literature review in this chapter provided a context for the placement of this
thesis. The concepts of malnutrition in childhood cancer and the goals of nutritional
therapy were introduced. The recent focus by clinician working in paediatric
oncology on the impact that cancer therapy has on the lives of childhood cancer
survivors and the concept that clinicians need to maximise cure while minimising
harm was introduced. This thesis aims to explore the impact that cancer therapy
has on the dietary intake of childhood cancer survivors. Contrary to the focus of
previous work on the nutritional management of childhood cancer patients in which
protein and energy has been the primary outcome, this thesis will explore childhood
cancer patients’ nutritional intake based on their diet as a whole.

The studies in this thesis were designed using a cumulative approach, with each
new study being informed by the results of other studies. The first phase of work in
this thesis focuses on determining the dietary intake and habits of childhood cancer
survivors early off treatment. The second phase of the thesis then explores
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nutritional interventions both on and off treatment. The thesis assesses the
nutritional interventions that may be available for young cancer survivors and
specifically determines the reasons for the inadequate use of enteral tube feeding as
a method of nutritional intervention. The third phase of the thesis explores factors
that may responsible for the poorer dietary habits of older cancer survivors,
specifically taste and smell changes.
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3 DIETARY INTAKE AFTER TREATMENT FOR CHILD CANCER SURVIVORS1
Chapter 2 provided the background to the medical and nutritional management of
childhood cancer patients. The majority of research has focused on the nutritional
management of cancer patients during their cancer therapy. With the improvement
in survival rates, and an increasing number of adult survivors of childhood cancer,
childhood cancer therapy can no longer be considered an acute disease. There is
evidence for poor dietary intake in adult survivors of childhood cancer but there is a
dearth of information regarding the dietary intake of young cancer patients early
after treatment completion. Part 1 of this thesis will examine the hypothesis that
there is significant nutrition related problems in childhood cancer survivors. This
chapter will report on the findings of a study assessing the dietary intake of young
cancer survivors early after treatment completion. This study has been published in
Pediatric Blood and Cancer.
3.1

Introduction

Childhood cancer survivors have a relative risk of developing a chronic condition of
3.3 when compared with their siblings (15). These conditions include, but are not

1
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RC & LT contributed to the manuscript.
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Health and Behavioural Medicine ASM & the ANZCHOG Long-term Follow-up Symposium.
The abstracts included in the following publications:
Cohen J, Goodenough B, Cohn RJ. Parental attitudes to their child’s nutrition at completion
of cancer treatment. Pediatric Blood and Cancer. 2009; 53 (5); 853
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limited to, endocrine disorders, metabolic disorders, cardiovascular disease and
pulmonary disease (154, 155). Specific conditions such as obesity, type II diabetes
and osteoporosis have the potential to be managed by lifestyle interventions (156).
Even though behaviours such as consuming a healthy diet and/or maintaining
adequate physical activity could prevent or lessen the impact of some of these
chronic diseases (157) health-protecting behaviour prevalence is similar to the
general population (150, 158, 159). Many adult survivors of childhood cancer
consume high fat diets, do not meet guidelines for fruit and vegetable intake, and
have an inadequate calcium intake (16, 17), though their overall energy intake does
not appear excessive (153). Long-term survivors report barriers to consuming a
healthy diet that include taste preferences for higher fat foods and the lack of
availability of healthier foods (153).

The treatment completion period of the cancer trajectory has been described as a
teachable moment (152). Young patients who have recently completed treatment
may be the more appropriate target group in whom to intervene and develop
preventative strategies. This is especially the case as younger age at diagnosis has
been documented as a risk factor for these chronic conditions, especially obesity
(160). There is limited information about the dietary intake of childhood cancer
survivors (CCS) who have recently completed their treatment and almost no data
examining how this may influence lifelong dietary practices and long-term metabolic
and endocrine outcomes (161). A small number of studies have assessed the
dietary intake of childhood cancer patients during treatment with varied findings
(162-164), though this is unlikely to be generalisible to patients who have completed
treatment.
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For dietary intervention plans to be effective in a young population, parental
involvement is important (150). It is known that parents of children not affected by
cancer strongly influence their child’s eating patterns, playing a pivotal role in the
development of their child’s food preferences and energy intake, (165) and playing a
role in long-term feeding practices (166).

Evidence suggests that parents who

restrict their child’s dietary intake when they are young may place their child at risk
of obesity when they are older as they may not develop the skills necessary to
regulate their own intake (167, 168). This is more likely to occur in parents who are
highly invested in their child’s health (169). Only one study has specifically
examined parental influences on child cancer patients’ health behaviours, reporting
that many parents lessen their control over their child’s eating (and their other
lifestyle behaviours) during their child’s cancer therapy (13). What is unknown is
what parenting styles are used at completion of their child’s cancer therapy and
whether these have the potential to place their child at risk of nutritional issues in the
future.

The aim of this study was to assess the weight status, dietary intake and associated
parent feeding practices of a cohort of childhood cancer survivors less than 13 years
of age and less than 5 years after treatment completion.

3.2

3.2.1

Methods

Study participants

The participants were parents and/or carers of CCS who were: a) less than 5 years
post treatment for any type of cancer; b) under 13 years of age; and c) attending the
Centre Kids Cancer Centre (KCC) at Sydney Children’s Hospital, Australia for follow
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up.

Eligible participants were identified using KCC records and posted a study

invitation, a participant information sheet and an opt-in card. Participants were
excluded if they had insufficient English language skills to complete the
questionnaire. Participants were recruited between the June 2009 and June 2010.
The study protocol was approved by the South Eastern Sydney & Illawarra Health
Service, Human Research Ethics Committee-Northern Hospital Network. Written
informed consent was received.

3.2.2

Demographics

CCS-related demographic data including gender, age, cancer diagnosis, and dates
of diagnosis and completion of treatment were compiled from medical records.
Historical data on anthropometric measures at diagnosis was also collected. CCS
weight and height were used to calculate BMI, using the formula: weight in
kilograms divided by height in meters squared. To allow for comparisons across age
groups, BMI percentiles were calculated using Epi Info™ (Version 3.5.1, 2008;
Centres for Disease Control and Prevention, USA). A BMI percentile of <5th
percentile was classified as underweight, those between the 5th-84th percentile were
classified as a healthy weight, those between 85-94th percentile were classified
overweight and >95th percentile were classed as obese (170).

3.2.3

Child Feeding Questionnaire (CFQ)

The 31-item CFQ (Appendix 4) was used to assess participant beliefs, attitudes and
practices about their child’s feeding (171). Mean CFQ item scores were calculated
for each of the seven subscales which fall under 2 categories (Table 3-1) Risk
factors and concerns; 2) Control in child feeding, attitudes and practices (171).
Response options are scored on a 5-point likert scale (1=’disagree’ to 5=’agree’).
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Scores in each of the seven subscales were averaged. Higher mean scores in each
subscale indicated higher levels of parental concern and control over child feeding.
The CFQ has been validated for use in parents of children aged two up to the end of
primary school age (171).

Table 3-1 Child Feeding Questionnaire (CFQ) sub-scales and operational
definitions
Sub-scale

Operational Definition

Example

Perceived feeding
responsibility

Extent in which parents
takes responsibility for
feeding the child

“How often are you
responsible for deciding
what your child’s portion
sizes are?”

Perceived parent
overweight

Parent’s perception of
their own weight at
various stages
Parent’s perceptions of
their child’s weight at
various stages

“ Perception of weight
during adolescence”

Concerns about child
overweight

How concerned the
parents are that their child
is overweight

Restriction

Parent’s attempts to
control their child’s eating
by restricting access to
foods.
Parents’ attempts to
control their child’s eating
by encouraging the
amount and type of food
The extent to which a
parent reports keeping
track of their child’s
consumption of energy
dense foods”

“How concerned are you
about your child having to
diet to maintain a
desirable weight?”
“ I intentionally keep some
foods out of my child’s
reach”

Perceived child
overweight

Pressure to eat

Monitoring
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“Perception of their child’s
weight when they were a
toddler”

“If my child says “I’m not
hungry”, I try and get her
to eat anyway”
“How much do you keep
track of the high fat foods”

3.2.4

Dietary intake

A three-day food diary was used to assess CCS nutrient intake (parent report).
Participants were given written instructions on how to complete the food diary and
were asked to complete this over two weekdays and one weekend day. Although
this method can lead to high respondent burden and is subject to bias (including
selection of the sample, reporting bias and issues associated with measurement of
the diet) (172), this prospective method of a three-day food record was utilized as it
has been shown to be appropriate for measuring individual, short term nutrient
intake (172). Information on multi-vitamin use was not collected as dietary intake
from food sources was the focus of this study.

3.2.5

Data analysis

The three-day food records were analyzed using the Foodworks nutrient analysis
software program (version 5, 2007; Xyris Software, Brisbane, Australia). For foods
and beverages not represented in the Foodworks database, nutrient content was
obtained from nutrition panels. From these dietary data, the CCS mean daily energy
intakes were calculated and expressed as a percentage of their estimated energy
requirement (%EER). EER is the mean energy intake predicted to maintain energy
balance including the needs related to tissue deposition (173). The age-appropriate
Schofield equation was used to calculate basil metabolic rate (174) and a physical
activity level of 1.5 (sedentary) was used to calculate EER. Use of a physical activity
level of 1.5 was based on research of the physical activity levels from previous
studies of childhood cancer survivors (164, 175). The CCS mean daily nutrient
intake was calculated and expressed as a percent of their age-appropriate
estimated average requirement (EAR) (173) to allow comparisons across age
groups. EAR is used for group assessment of the prevalence of inadequate intake of
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nutrients in a particular life stage and gender (173). For certain nutrients, EARs have
not been established and therefore these nutrients were excluded in this analysis.

Remaining data were analyzed using the statistical software package SPSS (version
17.0, 2009; SPSS Inc, Chicago, IL, USA). Descriptive statistics were calculated for
demographic and anthropometric, dietary intake and CFQ data. A p-value of <0.05
was considered statistically significant.

Paired t-tests were used to compare differences between BMI percentiles at each
assessment time-point. Likewise, paired t-tests were used to determine whether
there was a significant difference between the three factors in the attitudes and
practices category of the CFQ and the 4 factors in the risk factors and concerns subscale. As the data were normally distributed, Pearson’s correlation coefficients were
used to assess correlations between the subject’s %EER, BMI percentiles, CFQ
factors, gender, age and time since completion of treatment. A backwards linear
regression model was used to determine the degree of the relationship between
each of the CFQ subscales and the patient’s BMI percentile. Time since treatment
completion was included as a covariate.

3.3

3.3.1

Results

Patient demographics

A total of 139 participants were invited to participate in the study and 50 volunteered
to take part, yielding a response rate of 36%. Reasons for refusal to participate
could not be determined. The CCS mean age at diagnosis (SD) was 3.47 (2.41)
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years and the mean age at the time of their parent’s study participation was 7.12
(2.59) years. See Table 3-2 for further demographic details.
Table 3-2 Demographic and medical characteristics of child cancer survivors
Characteristic
Sex (male:female)
Cancer diagnosis, %
ALL
ALL - relapsed
AML
Neuroblastoma
Wilms Tumour
Rhabdomyosarcoma
Lymphoma
Medulloblastoma
Other
Age at cancer diagnosis, years
Mean (SD)
Range
Age at assessment, years
Mean (SD)
Range
Time since treatment completed, years
Mean (SD)
Range

3.3.2

N (%)
60:40
25 (50)
2 (4)
2 (4)
5 (10)
6 (12)
2 (4)
2 (4)
2 (4)
4 (8)
3.47 (2.41)
0.7-8.8
7.12 (2.59)
3.1-12.3
2.29 (1.56)
1.0-4.8

Dietary intake

Results from the three-day food diaries revealed that 54% of the CCS was
consuming more than 110% of their %EER, while 50, 32 and 44% of children did not
meet their requirements for folate, calcium and iron respectively (Table 3-3). Only
6% percent of the CCS was consuming less than 75% of their %EER. There was no
significant difference in %EER between those treated for Acute Lymphoblastic
Leukemia (ALL) and other diagnoses (110% vs. 121% respectively, t= -1.164
p=0.26).
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Table 3-3 Mean nutrient intake
Mean (SD)
Range
(%)
(%)

Percent not
meeting
requirements

Normative
data*.

Percent of estimated energy requirement (EER)
115.6 (34.0)

59-235

54% (>110%
EER)

Protein

359.5 (158.5)

124-955

0%

0%

Thiamin

267.0 (177.3)

75-1180

2%

0%

Riboflavin

307.9 (150.5)

74-834

2%

0%

Niacin
Equivalents
Vitamin C

392.3 (167.9)

158-1068

0%

0%

314.8 (202.2)

72-917

4%

2%

Folate

119.7 (85.0)

43-630

50%

2%

Vitamin A

203.9 (106.7)

73-549

8%

2.3%

Magnesium

214.2 (142.9)

62-860

4%

2%

Calcium

126.5 (56.6)

39-323

32%

31.5%

Phosphorus

226.1 (91.4)

56-504

4%

4%

Iron

111.1 (49.8)

49-370

44%

1%

Zinc

232.4 (112.9)

75-780

2%

0%

Nutrient intake

* Australian National Children’s Nutrition and Physical Activity Survey- Main
Findings. In: Department of Health and Ageing, editor. Australian Government;
2007. Based on ages 2-13 years.

Table 3-4 presents the distributions of mean BMI percentiles as measured at
diagnosis (T1), end of treatment (T2) and at the time of parent’s study participation
(T3). Data for BMI percentiles of CCS under the age of two cannot be calculated
and were therefore not included in the analysis. Historical anthropometric data was
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not available for four CCS (T3). Paired t-tests showed a statistically significant
increase in BMI percentiles from T1 to T3 (56.29 vs. 67.17 t= -2.758, p=0.01).

Table 3-4 Mean body mass index (BMI) percentiles for subjects over the age
of 2 years
n
Mean (SD)
Range
p-value
Diagnosis (T1)
30
56.3 (29.4)
0.14-99.3
0.06 (T1-T2)
End treatment (T2)
37
65.4 (31.0)
0.1-97
0.28 (T2-T3)
Time of study (T3)
46
67.1 (24.9)
0.75-99.9
0.10 (T1-T3)*
* Value is significant at p<0.05

The majority of children were within the healthy weight range at the three
assessment points with 10% of children overweight and 10% obese at T3 (Figure 31). There was no difference in BMI percentiles between those treated for ALL and
those treatment for another diagnosis (65.88 vs. 67.10; t=-0.167, p=0.87).

Figure 3-1 Percentage of children in each weight category over three
assessment time points
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3.3.3

Child feeding practices

From the risk factors and concerns subscale of the CFQ, parents appeared to have
had a high perceived responsibility in regards to their child’s intake and were the
least concerned about their child’s risk of being overweight (t=8.249, p=0.001)
(Table 3-5). In the control of child feeding, attitudes and practices subscales parents
had significantly higher scores for monitoring their child’s intake (t=-6.621, p=0.001)
and using a restrictive form of parenting (t= 3.822, p=0.001) compared with
pressuring their children to eat.
Table 3-5 Mean scores for the 7 subscales of the child feeding questionnaire
Categories

Sub-scales

Mean ±SD*

Range

Risk factors and
concerns

Perceived responsibility
4.18 ± 0.48
3-5
Perceived parent weight
3.10 ± 0.40
2-4
Perceived child weight
2.91 ± 0.41
2-4.3
Concerns about child
2.52 ± 1.28
1-5
weight
Control in child feeding,
Restriction
3.43 ± 0.80
1.5-4.75
attitudes and practices
Pressure to eat
2.77 ± 0.99
1-5
Monitoring
3.99 ± 0.71
2-5
* Possible values: 1=low levels of concern or control; 5=high levels of concern

The full additive regression model with 8 independent variables (CFQ sub-scales
and time since end of treatment) explained 38.4% of the variance in BMI z-scores
(F= 2.803; p= 0.016). The final model with only 3 variables (parental perception that
their child was overweight, parental concern about their child being overweight and
time since treatment completion) explained 36% of the variance in BMI z-scores (F=
7.672, p=0.001), a loss of only 2%.
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3.4

Discussion

Assessment of the dietary intake of childhood cancer survivors is essential to allow
the development of appropriate nutritional interventions. Yet there is a paucity of
literature in this area, especially relating to young childhood cancer survivors. This
study assessed childhood cancer survivor’s dietary intake less than five years from
completion of treatment to determine overall nutritional adequacy, as well as to
describe parental attitudes and beliefs about their child’s feeding practice.

Obesity is associated with CCS both less than 18 years of age (176) and adult
survivors of childhood cancer, especially those treated for ALL and with cranial
irradiation (177, 178). The present study found that 10% of the CCS was overweight
and 10% were obese at the time of the study using BMI percentiles as a marker of
obesity. It has been suggested that BMI is not an accurate marker of abdominal
obesity, (156), (179) potentially underestimating obesity rates in this cohort.
However there was a statistically significant increase in BMI percentiles from the
start of treatment (T1) to the time of assessment (T3). Although this has the
potential of being more a reflection of the catabolic state associated with diagnosis
resulting in lower BMI percentiles, recent literature suggests that malnutrition rates
at diagnosis in this population may only be around 9% (180) .

This study found that a large proportion of the CCS (54%) were consuming above
their estimated energy requirement. This finding is important because energy
imbalances as small as 1-2%, sustained over a period of time, are likely to promote
weight gain in this population (181). This may, in part, explain the increasing BMI
percentiles of our cohort, though this will need to be confirmed with future studies.
This is clinically important as it provides a potential target for dietary intervention
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programs, namely to decrease energy intake in this population, which may go some
way towards preventing obesity and associated endocrine and metabolic
complications in young childhood cancer survivors (16). Additionally, obesity
prevention in these patients is more likely to be successful than treatment of obesity
in long term survivors (182, 183).

It is

noted that the energy intake of this cohort of paediatric cancer survivors

appears similar to that of the general Australian population (184). Although it was
not assessed in this study, it may be that paediatric cancer survivors need to
consume less than their peers to prevent long-term weight gain due to the fact that
childhood cancer survivors may

have lower total energy expenditure than the

general population (caused by reduced physical activity levels rather than reduced
resting energy expenditure) (164, 185). Issues such as motivation, fear and pain
(186, 187) have been reported as reasons for adult cancer patients having
sedentary lifestyles and lower physical fitness levels (188) both during and after
cancer treatment (189). Targets for energy intake for CCS may therefore need to be
set at lower ranges or an increase in physical activity will need to be encouraged so
as to prevent long-term weight gain.

Our findings regarding micronutrient intake indicate that inadequate calcium intake
may be an important concern soon after the treatment period (with 32% of our
population not meeting daily requirements). Inadequate calcium intake also appears
to be a concern for older CCS, with the literature reporting up to 68% of CCS were
not meeting guidelines for calcium intake(16). Although this trend is similar to the
general Australian population this is more concerning for survivors of childhood
cancer, particularly those treated for ALL, as they are at higher risk of osteopenia
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(190). Altered bone metabolism during treatment may interfere with the attainment
of peak bone mass, predisposing survivors of childhood cancer to premature onset
and complications related to osteopenia and osteoporosis (191). While treatment
greatly affects bone mineral density (BMD), BMD is multi-factorial and lifestyle
factors including nutritional status, adequate calcium intake (particularly dairy
calcium) and weight-bearing exercise are important modifiable factors in the
prevention of osteoporosis (190, 192). Survivors of childhood cancer must ensure
they have a positive calcium balance to build bone and attain peak bone mass to
prevent these problems (190).

The finding that 50% of the CCS failed to meet their folate EAR is also of concern,
as current epidemiological research suggests a link between decreased folic acid
intake and increased homocysteine levels (193). Increased homocysteine levels are
associated with endothelial dysfunction, decreased nitric oxide bioavailability,
decreased vasodilatation and increased low-density lipoprotein deposition in arterial
walls, resulting in atherosclerosis and ultimately increased risk for cardiovascular
disease (193). Good food sources of folate include green leafy vegetables and citrus
fruit (194).

Studies of adult cancer survivors have found inadequate vegetable

intake (17) which has the potential to lead to inadequate folate intake. These habits
may be manifesting early in the off treatment period, leading to inadequate folate
intake, however this needs to be confirmed in future studies. It also appears that an
inadequate folate intake is unique to the childhood cancer population compared with
children unaffected by cancer (Table III).

Although studies assessing parental influences, (including beliefs, attitudes and
practices), on child’s eating patterns and weight status could not be found for the
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paediatric oncology population, research in children not affected by cancer has
demonstrated that parent feeding methods are linked to child weight status (171).
Parent child feeding behaviours of monitoring, pressure and restriction are highly
correlated with an increased energy intake and BMI in children (167) . This study
failed to find any relationship between CCS BMI percentiles and %EER between all
7-domains of the CFQ. It is possible this was due to a floor effect, given that only
20% percent of children were classified as overweight/obese. The parents in this
study were more likely to endorse behaviours such as monitoring and restrictive
style of parenting and felt responsible for their child’s intake which has the potential
to lead to increasing weight and risk of obesity over time. These results provide
possible targets for interventions in the future.

3.4.1

Limitations

This single centre study was limited by a low response rate, which increased the
chance of bias and reduces generalisability to the broader paediatric oncology
survivor population. The high participant burden associated with completing 3-day
food diaries (172) may have reduced participation rates. Recruitment via a letter
invitation instead of face-to-face recruitment may also be a factor in the poor
response rate. The lower representation of overweight children may also have
introduced bias into the study whereby only parents of CCS within a healthy weight
were willing to participate in this study out of concern for being judged for their child
feeding practices. It is also important to note that using BMI percentiles may not be
a sensitive marker of obesity in this population, as the measure may not reflect
changes in body fat (179). Waist circumference may be more predictive of
cardiovascular risk in the CCS (156). Another limitation of this study was the lack of
a control group. Although it is recommended that future studies utilise a control
group, these studies need to be consider that the control children may also not be
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meeting the dietary guidelines. It is recommended that future studies compare the
dietary intake of childhood cancer patients with both control groups and ageappropriate dietary guidelines.
3.4.2

Conclusion

This study has provided preliminary data regarding the dietary intake of childhood
cancer survivors less than 13 years of age, within five years of completing cancer
therapy. It provides potential targets for nutritional interventions that may be
implemented to prevent some of the deleterious long-term effects associated with
cancer therapy. It appears that a large proportion of the CCS are consuming more
than their recommended energy requirements, and if this continues, their intake may
place this group at increased risk of obesity and other associated endocrine and
metabolic disorders. Large proportions are also consuming inadequate calcium,
folate and iron, which could increase the risk of late-effects associated with cancer
therapy. Parents used both monitoring and restriction to regulate their child’s intake,
which may also contribute to poor dietary habits by decreasing their child’s selfregulation of intake. This is especially of concern considering they do not appear to
be concerned about their child’s risk of being overweight. It is imperative that
interventions are established soon after treatment completion, targeting parents to
enable us to improve the long-term dietary habits of this population.

3.4.3

Implications

The findings from this chapter provide a quantitative assessment of the nutritional
intake of a cohort of child cancer survivors. This study is the first to provide evidence
that the poor dietary intake seen in adult survivors of childhood cancer is
manifesting itself recently off treatment. Although we hypothesised that the poor
nutrient intake seen in this population may be related to an inadequate fruit and
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vegetable intake or an intake of high energy foods, this cannot be confirmed with the
results from this current study alone. The next chapter will provide further insight into
the dietary habits of the cancer survivors.
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4 EXPLORING THE VIEWS OF PARENTS REGARDING THE DIETARY HABITS
OF THEIR YOUNG CANCER-SURVIVING CHILDREN2
Chapter 3 provided information on the nutrient intake of young survivors of
childhood cancer early after their cancer therapy has finished. This chapter will
provide further insight into the dietary habits of the childhood cancer survivors and
how these habits have change over their cancer trajectory. It will provide clinicians
with the information on the dietary habits that could be targeted when developing
appropriate nutritional interventions. The findings of this chapter have been
published in Supportive Care in Cancer.
4.1

Introduction

Poor dietary intake during childhood cancer treatment is well documented.
Treatment side-effects such as nausea, vomiting, diarrhoea, mucositis and anorexia
2

This chapter has been published in the following peer reviewed journal:
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Cohen J, Wakefield C.E, Fleming CAK, Cohn RJ. A qualitative study of parent attitudes to
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Oncology. 2010; 6(3): 205.
Cohen J, Wakefield, CE, Fleming CAK, Cohn RJ. Consequences of treatment on food
preferences and dietary habits of childhood cancer survivors. Pediatric Blood and Cancer.
2011; 57(5); 827
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lead to poor oral intake and, in some cases, malnutrition (14, 195, 196) Childhood
cancer patients’ dietary habits appear to be altered during cancer treatment.
Preferences for sweeter or sour tasting foods and significant challenges with food
refusal of previously tolerated foods have been reported. (127)

Child feeding behaviours can be strongly influenced by positive and negative
associations when young. (197) Dietary habits that are established when a child is
young are also more likely to continue into their adult life. (198-201) Adult survivors
of childhood cancer also have a poor dietary intake, with an inadequate intake of
fruit and vegetables, consumption of high fat diets and an inadequate calcium
intake. (17, 153) These dietary habits are manifesting themselves early after the
treatment period, with child cancer survivors (CCS) recently off treatment displaying
an excessive energy intake and an inadequate calcium and folate intake. (202) The
concern is that the dietary habits and food preferences that are established during
childhood cancer therapy are persisting once treatment has been completed.

There remains a dearth of literature regarding the dietary habits of CCS at treatment
completion. The determination of parental views about their child’s nutritional habits
is important, as parents can influence child dietary behaviours.(200)

Dietary

interventions for younger children will also need to be parent focused. The more
concerned a parent is about their child’s intake the more likely they may take steps
to intervene. (203) The study aimed to compare parental views of CCSs’ current
dietary habits with their habits prior to their cancer diagnosis, during their treatment,
and with those of children in the general population. In doing so, this study aimed to
contribute to the evidence-base regarding the dietary habits and patterns of young
child cancer patients.
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4.2

4.2.1

Methods

Study participants

Participants were parents and/or carers of CCS who were: a) less than 5 years post
treatment for any type of cancer; b) not attending a long-term follow-up clinic; c)
under 13 years of age; and d) attending the Kids Cancer Centre (KCC) at Sydney
Children’s Hospital, Australia for follow up. Eligible participants were identified using
KCC records and were posted a study invitation, a participant information sheet and
an opt-in card. Participants initially participated in a study assessing their child’s
dietary intake after cancer treatment using a questionnaire and three-day food
diaries. (202) Participants who participated in this study were able to indicate
whether they would participate in the follow-up qualitative study. All participants of
the dietary intake study agreed to participate in this follow-up qualitative study
(n=51). A cohort of parents/carers of child cancer survivors who had participated in
the dietary intake study (202)

were selected to participate in semi-structured

telephone interviews. Participants were purposefully sampled to build on the insights
gained thus far. Maximum variation sampling was implemented to allow a range of
diagnosis groups and ages of parents of childhood cancer patients to be
interviewed. Incentives for participation were not used in the dietary intake study or
the qualitative study.

4.2.2

Controls

Control participants were recruited via advertising in the hospital and through
community organisations. Control participants were well children who were not
patients of the hospital and were age-matched. Parents of multiple children were
asked to focus on the dietary habits of one child only. Parents of age and sex
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matched children without cancer or another disease that could affect their dietary
intake or required food restrictions were interviewed regarding their child’s current
intake. Excluded diseases included, but were not limited to,: food allergies or
intolerance, diabetes, coeliac disease, crohn’s and ulcerative colitis, cystic fibrosis,
renal failure, metabolic conditions and failure to thrive. Children were also excluded
from the control arm of the study if they required supplemental nutrition via a
nasogastric tube or gastrostomy. The parent/carer who was interviewed for both the
cancer and control groups was the main carer responsible for food purchasing and
meal preparation. The study protocol was approved by the South Eastern Sydney
and Illawarra Health Service, Human Research Ethics Committee-Northern Hospital
Network. Informed, written consent was obtained from each participant.

4.2.3

Procedure

Interviews for both the CCS and the control group were conducted via the
telephone. This method of interviewing was chosen to ensure participation by a
geographically diverse group, specifically those living in rural and remote regions, to
reduce the bias associated with studying a group in the same geographic region.
Telephone interviews have been shown to be as effective in eliciting reliable
information as face-to-face interviews (25). Telephone interviews may also have
some advantage due to the anonymity that telephone interviews provide, favouring a
more in-depth response (25).

The interview schedule was prepared by a multidisciplinary team (dietitian,
psychologist and oncologist) and used a semi-structured approach. The interviews
further explored previous insights gained from our previous study regarding their
dietary intake.(202) The interviews for the parents of the young child cancer
survivors were separated into their current intake, intake during treatment and intake
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prior to the cancer diagnosis. The interviews focused on determining parental views
regarding their child’s eating habits, food volumes, food types and weight at each
stage of their cancer journey. There was also a focus on self-reported parent
feeding practices. The parents of controls were asked similar questions; however
the focus was on their current intake (Table 4-1). As prescribed by Miles and
Huberman (204), results from early interviews were used to suggest additional lines
of questioning in subsequent interviews and all interviews were conducted by one
researcher. Interviews were conducted until thematic saturation was reached.
Thematic saturation was determined when there was a continual repetition of
themes and when no new themes were mentioned in subsequent interviews. In
accordance with gold-standard guidelines (204), participant’s responses were
recorded and transcribed verbatim.
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Table: 4-1 Questions used during the telephone interview to parents of young
child cancer survivors and healthy controls
Young child cancer survivors

Healthy controls

Nutrition prior to treatment
Could you tell me how you viewed
your child’s eating habits before they
were diagnosed?
Compared to other children their age
how did you feel about the amount
your child ate?
Did you use any strategies to help
your child to eat?
How did you feel about their weight
compared to other children before
they got sick?
Nutrition during treatment
How did you feel about your child’s
eating during their cancer therapy?
How did you feel about the types of
foods you child was eating?
Did your child need any other forms of
nutrition?
Did you use any strategies to get your
child to eat?
How did you feel about your child’s
weight during treatment?
Current nutrition
How do you view your child’s intake
and diet?
How do you view your child’s portion
sizes?
What are your thoughts about the
types of foods your child eats?
Do you use any strategies to help
your child to eat?
How do you feel about your child’s
weight?

Current nutrition
How do you view your child’s intake
and diet?
How do you view your child’s portion
sizes?
What are your thoughts about the
types of foods your child eats?
Do you use any strategies to help
your child to eat?
How do you feel about your child’s
weight?
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4.2.4

Qualitative data analysis

Transcripts were coded line-by-line and analysis was facilitated by the qualitative
data analysis software NVivo, 2008, Version 8 (QSR International, Victoria,
Australia) which allows the researcher to store, code and retrieve raw data as well
as to collate secondary information such as researcher observations/ideas. To
ensure accuracy with regards to the coding and analysis and to meet goldstandards(205), a multi-level consensus coding methodology was used. (206, 207)
Fifteen percent of interviews from the CCS (n=3) and the control group (n=3) were
coded independently by two investigators, who met to review the coding and
address any disagreements (204). The final coding was analyzed and emerging
themes were categorized and enumerated (204).

All coding was done by an Accredited Practising Dietitian. Any mention of individual
foods by the participants were classified into food groups based on the Australian
Guide to Healthy Eating (208). Accredited Practising Dietitians, are skilled in food
composition, to be able to conduct this categorisation. Terminology used by parents
such as “junk food” and “unhealthy foods” were coded separately and counts were
done on the number of times these words were mentioned. “Junk foods” and
“unhealthy foods” were classified as such, if they were energy dense, nutrient poor
foods that were providing a large number of calories for relatively few nutrients.

4.3

4.3.1

Results

Demographics

Eighteen parents/carers of CCS and 18 controls participated in the semi-structured
interviews. The CCS represented a range of ages and diagnosis groups (Table 4-2).
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There was no significant difference between the CCS and control group in regards
to age or gender. The control group all resided within metropolitan Sydney. Fiftyfive percent (n=10) of the parents worked full time and 39% worked part time (n=7).
One parent was a full time career.

Table 4-2 Demographic characteristics of parents, young child cancer
survivors and healthy controls
Young child cancer
patients
(n=18)

Healthy control
(n=18)

Child demographic
Sex (M:F)
11:9
11:7
Age (SD) years
8.50 (2.71)
8.5 (2.90)
Diagnosis (number)
ALL a
8
Neuroblastoma
3
Wilm’s Tumour
3
Rhabdomyosarcoma 1
Lymphoma
2
Brain Tumour
1
Age at diagnosis (yrs
3.47 (2.41)
(SD))
Time since treatment
2.29 (1.56)
completion (yrs(SD))
Nutrition intervention
during treatment
(number)
6
Nutrition education
5
Enteral nutrition
2
Oral supplements
2
PN b
Parent demographics
Sex (M:F)
0:18
1:17
Area of residence
8:10
18:0
(urban:rural)
Employment
7:8:3
(full:part:unemployed)
a
ALL-acute lymphoblastic leukaemia; bPN=total parenteral nutrition
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4.3.2

Remembered dietary habits prior to diagnosis of CCS

The majority of the parents described their child as a “healthy eater” prior to their
cancer diagnosis (Table 4-3). Most parents appeared satisfied with the amount of
food their child was consuming. Four parents described their child as consuming
inadequate volumes of food and one parent considered their child to be consuming
an excessive volume of food. Parents did not appear to be experiencing concerns
about their child’s weight prior to their diagnosis. A small number of parents believed
their child was underweight and two considered their child to be overweight. Parents
appeared to use a variety of strategies to encourage their child to eat, though none
of the parents recalled providing “unhealthy” foods as an alternative to their normal
foods as a way of ensuring that their child had an adequate intake.
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Table 4-3 Summary of themes from parents of young child cancer survivors of
their child’s remembered dietary habits prior to their cancer diagnosis
Number of
Quote
respondents
( n=18)
Dietary habits
Healthy eater

16

“….was a very healthy little eater, you
know fruits, vegetables - look [he]
love[d] his lollies and chocolates like
any other kid but …just pretty normal
eating…” (male;12 yrs; Wilms’)”
“Yeah, she was a good eater….I can’t
really remember exactly what she was
like but there was no problems with
what she ate and she ate very healthy
foods” (female; 5yrs, ALL a)

Volumes of food
Adequate

13

“I wasn’t worried about the amount
either. I didn’t have to watch it. It was
fine” (male; 10yrs, ALL)

Weight perception
Healthy weight range

13

“(Her weight ) you know like a chubbed
up baby, a good weight, healthy”
(female; 5yrs, ALL)

Parent feeding practices
Restricting foods

5

“I do everything in moderation….I don’t,
I never stock junk food at home”
(female; 8yrs, ALL)

Pressuring to eat

5

Bribery

Positive encouragement

“our strategy was, if you don’t eat your
vegies, you don’t get dessert, it’s that
simple” (male, 11yrs, Lymphoma)

3

“It always used to be if you eat all of
your dinner you get yoghurt for dessert.
It was never bribe him with lollies or
anything like that” (male; 10yrs,
lymphoma)

3
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Monitoring

2

“(I) always tell them that like for
example she didn’t like carrot and I said
“carrot has good colour, so if you eat
carrot it gives you good colour for your
skin” (female; 8yrs, ALL)
“ I mean sometimes he’d have to pull
back on the chips” (male; 13yrs, ALL)

a

ALL: Acute Lymphoblastic Leukaemia

4.3.3

Remembered dietary habits during treatment of CCS

Parents reported a significant change in CCSs’ eating habits while their children
were receiving their anti-cancer treatment (Table 4-4). The main themes that
emerged from the parent report regarding their child’s eating habits during their
cancer therapy included: 1) A decreased preference for fruits and vegetables; 2) An
increase in preferences for carbohydrate-based foods such as bread, pasta or
savoury biscuits; 3) An increased desire for foods they considered “junk food”. It
also appeared that savoury foods were chosen by the CCS in preference for sweet
foods. Parents also considered the foods eaten by CCS during treatment to be
“unhealthy”.

Parents’ views regarding the volume of foods appeared to be evenly split. Half of the
parents were concerned that their child was not eating adequate volumes of food
while the majority of the remaining parents described their child as overeating at
certain phases of treatment.

Parental concern about their child’s weight also appeared to change when their child
was on treatment. A larger number of parents were concerned that their child was
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underweight or overweight. Parent feeding practices also changed on treatment.
Parents appeared to allow CCS to eat “whatever they liked” during treatment and
several pushed their child to eat. None of the parents interviewed restricted their
child’s food intake or type of foods eating during treatment.

Table 4-4 Summary of themes from parents of young child cancer survivors
of their child’s remembered dietary habits during their child’s cancer
treatment.
Number of
Quote
respondents
( n=18)
Dietary habits
Decreased fruit and
vegetable intake

13

“She was not interested in fruit, vegies,
anything like that which…. it was
certainly something I noticed because
my toddler had always been a really
good fruit and vegie eater…” (female;6
years; neuroblastoma).

Increased preference for
carbohydrate-based
foods

11

“you know he would eat lots of crackers
probably more than anything … maybe
that was like the salt content” (4)

Increased desire for “junk
foods”

18

Increased preference for
savoury foods

18

“….definitely with the treatment of
chemo, more carbs, more sugar, more
salt.” (female; 11 yrs; ALL a).
“As long as it was savoury and it was
crap, she would eat it…” (female;8yrs;
Wilms’).

Volumes of food
Excess

8

Inadequate

9

“…[the patient] was put on to steroids. I
couldn’t feed him enough. He just
wanted to eat anything and
everything… He would have a full meal;
he would eat more than me and then
say, “Can I have a pie now please?”
(male; 13yrs;ALL).
“I would say lack of eating, (the patient)
couldn’t really stomach food” (male;
12yrs; Wilm’s)

Weight perception
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Underweight

11

Overweight

3

“my husband was taking him down to
the shower, and just looking at him from
behind it was like, oh my God, he had
no bum, no legs, there was nothing
(male; 13yrs, ALL)
“She ate a lot. Puffed up obviously with
the steroids and gained a bit of weight”
(female; 11yrs, ALL)

Parent feeding practices
Encourage any types of
18
foods

“We didn’t care as long as he ate. It
didn’t matter if he wanted a cupcake for
breakfast … and we would go and get
him McDonalds, he wanted garlic bread
one time when he woke up from an
anaesthetic so we went and got him
garlic bread” (male;10 yrs; lymphoma).

18
No food restrictions

“I mean as a mum it goes against
everything that I would normally do for
my child. As I say, I was pretty pedantic
about what they ate and how I prepared
their food and then all of a sudden I’m
begging this child to eat absolutely
anything just to be able to get
something into him….” (male; 11
yrs;Lymphoma).

5
Forcing their child to eat

“I did not reward him but I actually
begged him (to eat)”(male; 8yrs,
neuroblastoma)
a

ALL: Acute Lymphoblsatic Leukemia

4.3.4

Current dietary habits of CCS and controls

4.3.4.1 Young child cancer patients
When parents were questioned about their observations on CCSs’ nutritional habits
after treatment compared with prior to the cancer diagnosis, three main themes
emerged (Table 4-5): 1) Decreased fruit and vegetable intake; 2) Increased
consumption of “junk food”; 3) Increased portion sizes. However, not every parent
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interviewed reported concerns about their child’s excessive dietary intake, with
some reporting that they were concerned that their child did not consume adequate
portions of food.
There appeared to be a shift toward increased parental concern about their child’s
weight, with parents reporting their child was gaining too much weight after
treatment had been completed. The strategies parents used to encourage CCS to
eat appeared to change once the cancer treatment had been completed. Many
parents started restricting their child’s food intake and two parents continued to
provide their child with unhealthy foods to ensure adequate intake. Parents also
tended to use a larger variety of methods to encourage their child to eat than they
did during cancer treatment.

4.3.4.2 Controls
A small number of parents of healthy children considered their child to be a fussy
eater. The majority of parents believed that their child ate a sufficient amount of
foods, while only a small number of parents expressed concerns that their child
consumed excessive volumes of food. A smaller number of parents of healthy
children compared with parents of CCS did report that their child did not consume
adequate vegetables, though even these children appeared to eat some vegetables
or salads. The majority of parents of healthy children considered their child to be a
healthy weight for their age and height.

The feeding practices of parents of healthy children appeared to differ to those of
CCS after treatment. A smaller number of parents of healthy children felt the need
to restrict food. The most common parenting practices used in this group to
encourage their children to eat was providing education to their children on healthy
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eating. None of the parents of the control children felt the need to provide
“unhealthy” food as a way of ensuring that their child “ate something”.
Table 4-5 Summary of themes from parents of young child cancer survivors
compared with parents of healthy children regarding their child’s current
dietary habits.

Dietary habits
Inadequate
fruit and
vegetable
intake

Young child cancer patients

Healthy controls

Number of
respondent
s ( n=18)

Quote

Number of
respondent
s
(
n=18)

Quote

16

“….[he] won’t eat
vegetables and fruit
since coming off
treatment
…”(male;4 yrs;
neuroblastoma).

6

“he is fussy
with his
vegetables...th
e main vegies
he eats is
carrots, bok
choy and
broccoli...”
(male;6yrs).

18
High intake of
“junk foods”

Volume of food
Excessive
11

Inadequate

13
“she'd eat more junk
food now if I allowed
it, whereas before
she would eat
carrots and apples
over lollies.”
(female; 8
yrs;Wilms’).

“there are days
when she overeats,
like she might go to
someone’s house
and they say, ‘God
she eats a lot’.”
(female;4yrs;ALL a).

5

“[he} loves
lollies; loves
chips; loves
cake and all
that sort of
stuff but we
don’t not let
him have it”
(male; 11yrs)
2

“I think he eats
more than
other kids his
age” (male;
11yrs)

2
“Only eats salty carb
foods so [her]
mother has her on
multi vitamins... she
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“She goes
through
phases. Some

still doesn’t put on
any weight.”
(female;4
yrs;Wilm’s).
Weight perception
Underweight
3

Overweight

“…she’s quite tiny,
she’s quite thin…I
always look at her
and think she’s
small” (female; 5yrs,
ALL)

7

days she
barely eats at
all” (female;
4yrs)
0

2

“ …I think he’s
too heavy and
it’s all around
his tummy”
(male; 11yrs)

6

“I think that
one of the
secrets is that
you can't have
too much junk
in the house,
because if it is
in there, if
you're not in
the kitchen,
then they are
easily sneaking
it you know...”
(male;10 yrs)

”we’ve spent half his
life, most of his life,
concerned with him
not putting weight
on and not eating
and now we have
gone the other way
and he is actually a
bit overweight for
his age and size”
(male;9 yrs;
rhabdomyosarcoma
).
Parent feeding practices
Food
14
restriction

6

I am probably quite
strict because a lot
of parents would
think that that’s too
controlling but I
think I see the
difference after
treatment and it’s in
order to help her
(female; 11 yrs;
ALL)

5

‘If you eat it then I’ll
let you watch TV.’
(male; 8yrs;
neuroblastoma)

5

Bribery

Pressuring
their child to
eat

“you know we sit
there and make her
eat one piece ….
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4
“We’ve bribed
him; we’ve
paid him;
we’ve hidden
them

5
Food as
reward

5

Concealing
vegetables

4

Positive
encouragemen
t

that’s about the only
way I can get her to
do that (eat)”
(female; 5yrs,
Wilms’)

“.. (we) try and bribe
her so if she eats
that she can have
something else”
(female; 5yrs,
Wilms’)

“…with spaghetti
bolognaise I’ll put a
lot of vegies in the
bolognaise sauce …
I’ll grate the zucchini
and the carrot in
there” (male; 5yrs,
ALL)

“..I acknowledge
that I’m losing a
degree of control,
I’m trying to educate
him about healthy
foods … and
making healthy
choices himself”
(male; 10yrs, ALL)

[vegetables]”
(male; 11 yrs)
1

2

7

“He doesn’t eat
a great deal of
fruit during the
day, … at
home I have to
cut it up and
put it in front of
him and tell
him to eat it to
get fruit into
him.” (male; 13
yrs)
“Before he can
have dessert
… he has got
to eat his
dinner” (male;
10yrs)

“Because she
doesn’t try a lot
of other
vegetables … I
put about six to
seven
vegetables in a
very, very
powerful food
process, and I
cook it in the
mince and she
won’t see it
and she’ll eat
it.” (female;
4yrs)
“We talk about
what's good for
you and what's
not good for
you and what's
going to help
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you grow and
be strong and
have energy.”
(female; 4yrs)
a

ALL: Acute Lymphoblsatic Leukaemia

4.4

Discussion

This study revealed a parent-reported change in CCS dietary habits across the
cancer journey. CCS may not return to their pre-diagnosis dietary habits once their
treatment is completed, instead developing new eating habits. The three main
themes that emerged from parental report of their CCS’s current eating habits were;
1) Decreased fruit and vegetable intake; 2) Increased consumption of “junk food”; 3)
Increased portion sizes. The majority of parents appeared less concerned with their
child’s weight, dietary intake or dietary habits prior to the cancer diagnosis, but
developed concerns about excess weight gain and poor eating habits after
treatment completion. These results were in contrast to the control group, in which
the majority of parents viewed their child to be a healthy weight, consuming
reasonable volumes of food. Although one-third of control parents reported that they
were not satisfied with their child’s vegetable consumption, this proportion was lower
than the number of parents of CCS who were concerned about their child’s
inadequate intake of vegetables.

Reasons for this change in CCS dietary habits and intake are likely multi-factorial.
Previous studies of cancer patients (both child and adult) suggest a role of learned
food aversions influencing dietary habits (127, 209-211). Cancer patients experience
significant side-effects such as nausea, vomiting, mucositis and diarrhoea (195,
196) that can lead to anorexia, weight loss and malnutrition (14, 195, 196). There is
an emphasis on preventing treatment-related weight loss during cancer therapy,
especially in children, to maintain adequate growth and development (105, 122).
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Parents of CCS reported changing their parenting styles regarding food during their
child’s cancer treatment and allowed their child to eat “whatever they wanted”. One
third of parents also reported pushing their child to eat as a way of preventing weight
loss. It may be that this emphasis on food and eating during the intensive cancer
treatment may be a contributing factor to learned food aversions and a subsequent
change in their dietary habits long term.

Many parents appeared to allow and encourage the intake of “unhealthy” foods
during their child’s treatment and reported that their child continues to consume
these foods once treatment has been completed. Healthcare workers may also
encourage parents to allow their child “eat whatever they want” during treatment, as
a way of preventing weight loss. Dietary habits, food preferences and oral skills are
established at a young age and these habits, once established, are likely to be
carried into adulthood (198-201). Young children also have an innate preference for
energy dense foods and constant exposure to these types of foods at a young age
can increase the desire for these foods through associative learning (200). Although
parental reports indicated eating habits did improve after treatment, there was a
consistent parental theme regarding their child’s strong, and ongoing, preference for
“Junk food” and larger portions of these foods. As these patients are being treated at
such an important time in the establishment of long term eating habits, not only the
cancer therapy, but the foods they are exposed to during this time, may strongly
influence their dietary habits at treatment completion.

Repeated exposure to certain foods during childhood is also needed for long-term
acceptance of foods. (198) Parental reports of the dietary habits of their children
suggest a significant reduction in the preference for vegetables and other “healthy”
foods. The majority of parents in this study allowed the consumption of unhealthy
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foods during the cancer treatment as a way of getting their child to eat. If CCS has a
reduced exposure to other (healthier) foods during their cancer treatment, this may
influence their acceptance of these foods once treatment had been completed.

4.4.1

Limitations and conclusions

Although the study numbers were small, this qualitative study provides insight into
parent-reported change in dietary habits of child cancer patients across the cancer
journey. It appears that child cancer survivors may not re-establish pre-cancer
dietary habits, once their cancer treatment has been completed. Limitations of this
study include the control group not being matched for socio-economic status and the
reliance on parent memory and recall. This study does provide insight that the
dietary habits of CCS may differ from that of the age-matched, non-oncology
population.

This study provides evidence that future studies, to longitudinally

explore childhood cancer patients’ dietary habits and food intake during and after
cancer treatment are justified.

This study suggests that not attending to the

development of health dietary habits during cancer therapy may have adverse longterm effects. This may be more so for some diagnostic groups, such as ALL, for
whom weight loss is not as common. Information about healthy dietary habits may
need to be provided during cancer therapy, in particular during maintenance phase
therapies, rather than waiting until treatment completion or long term follow-up.
Information on the predictors, such as diagnosis, treatment type and use of nutrition
support on the dietary habits of child cancer patients and survivors, is also needed
to allow the development of appropriate dietary interventions. Future research may
need to assess the influence of medical treatments on the dietary habits of children
with other chronic diseases.
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4.4.2

Implications

This chapter provides evidence that the dietary habits of childhood cancer survivors
are changing throughout the cancer journey. This chapter also shows that young
childhood cancer survivors are not returning to the dietary habits that they had prior
to their cancer diagnosis. Part 2 of the thesis will be exploring the hypothesis
regarding the areas of concern for clinical practice, specifically related to actual
feeding practices during and following treatment completion. In light of the evidence
from both this thesis and the literature, regarding the poor dietary habits of survivors
of childhood, it is important to determine whether nutritional interventions have been
able to improve their nutritional intake. The next chapter is a systematic review of
the literature, assessing the availability and efficacy of nutritional interventions in
cancer survivors.
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5 SYSTEMATIC REVIEW OF NUTITIONAL INTERVENTION IN CHILDHOOD
CANCER SURVIVORS3
Chapters 3 and 4 provided evidence that young cancer patients have a poor dietary
intake and habits early after their cancer therapy is complete. The literature review
(chapter 2) also revealed that the predominant studies on the nutritional
management of childhood cancer patients focuses on the prevention of under
nutrition. This chapter is a systematic review of the literature assessing the number
and effectiveness of nutritional interventions for survivors of childhood cancer. This
chapter has been accepted for publication as a Cochrane Review in the Cochrane
Collaboration of Systematic Reviews.

3

This protocol for this systematic review has been published in the following peer review

journal:
Cohen J, Wakefield CE, Bartle J, Cohn RJ. Nutritional interventions in childhood cancer
survivors. Cochrane Database of Systematic Reviews (Protocol). 2012.
This chapter has been peer reviewed and accepted for publication in the following peer
review journal:
Cohen J, Wakefield CE, Cohn RJ. Nutritional interventions in childhood cancer survivors.
Cochrane Database of Systematic Reviews
JC designed the systematic review, undertook the screening of abstracts, data collection,
and assessment of bias, data analysis and synthesis and developed the manuscript; CW
designed the review, undertook the screening of the abstracts and the assessment of bias
and contributed to manuscript preparation; RC designed the review and contributed to
manuscript preparation.
The key findings have been peer reviewed and presented as a poster at The 45th Congress
of the International Society of Pediatric Oncology with the abstract being included in the
following publications:
Cohen J, Wakefield CE, Cohn RJ. A systematic review of interventions for childhood cancer
survivors. Pediatric Blood and Cancer. 2013; 60(S3); 163
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Background
5.1.1

Description of the condition

In the last thirty years, detection and treatment methods for childhood cancer have
improved to such an extent that up to 80% of paediatric patients now survive their
cancer (48, 212). This has resulted in a growing number of child cancer survivors
and an increased clinical and research interest in the survivorship issues as a
consequence of treatment, in particular treatment-related morbidity and quality of life
(212). Childhood cancer survivors have a relative risk of developing a chronic
condition of 3.3 and a relative risk of a severe or life-threatening condition of 8.2
when compared with their siblings (15). Female sex and older age at diagnosis are
independent risk factors for developing chronic conditions (148). These chronic
health conditions include (but are not limited to) secondary cancers, endocrine
disorders, renal dysfunction and severe musculoskeletal problems (15, 154, 155,
213). However, it may be many years before patient’s display these conditions
which tend to worsen over time (15).

There is now much focus in the literature on the importance of long-term monitoring
of these patients (160, 214, 215) and increasing recognition of the need for both
secondary and tertiary interventions that may lessen the burden of these chronic
conditions (15, 216, 217). It may be possible to reduce the incidence of these
chronic conditions with focused prevention strategies (15, 150) aiming for quality of
life similar to peers (218). Specific chronic health conditions of long-term survivors
that have the potential to be managed by lifestyle factors include osteoporosis,
metabolic syndrome, endocrine disorders and cardiovascular disease (150). An
individual's risk of these conditions varies depending on factors such as disease and
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treatment type, age and sex. For example, survivors of acute lymphoblastic
leukemia (ALL) who were treated with radiotherapy are at a greater risk of obesity,
whereas those who received treatment for brain tumours are at risk of inadequate
growth hormone (160). Those who received chemotherapy agents such as
anthracycline are at risk of cardiovascular disease (219).

5.1.2

Description of the intervention

Despite the fact that health-promoting behaviour, such as consuming a healthy diet
or maintaining adequate physical activity, could lessen the impact of these chronic
issues (157), the prevalence of health-protecting behaviour in adults who have
survived childhood cancer is similar to that of the general population (150, 158).
There is a strong association in the general population between inadequate physical
activity combined with a diet high in saturated fat and sugar and low in fruit and
vegetable intake, and symptoms associated with the metabolic syndrome (220).
This is of concern since many adult survivors of childhood cancer do not meet
guidelines for fruit and vegetable intake, consume excessive fat and have an
inadequate calcium intake (16, 17). These poor eating habits appear to be
manifesting themselves early after treatment completion. Long-term survivors report
barriers to consuming a healthy diet that include taste preferences for higher fat
foods and the lack of availability of healthier foods (153). They may also be unaware
of their risk of chronic disease (150), lessening the motivation to change their
lifestyle. As childhood cancer survivors are already at a higher risk of long-term
metabolic complications as a result of their cancer therapy, poor nutritional intake
may be exacerbating this risk.
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Interventions may need to be age-specific and differ between the older and younger
childhood cancer survivor cohorts. Interventions may also need to target specific
conditions and high risk groups or may target the general paediatric population. For
example, childhood cancer survivors treated for ALL using cranial irradiation are at a
higher risk for obesity and subsequently metabolic syndrome (221) and, therefore,
they could be targeted with specific nutritional interventions to reduce obesity rates.
In contrast, patients treated with anthracycline are at risk of cardiovascular sequelae
(221) and, therefore, interventions may target not only weight reduction but also aim
to reduce cardiovascular risk (222). Strategies to manage these chronic conditions
may involve prevention interventions for younger cancer survivors or treatment
interventions for older cancer survivors. Due to these variations in risk, a “one-size
fits all” approach may not be indicated.

5.1.3

How the intervention might work

There is clear evidence that lifestyle changes, including improved diet and physical
activity, are effective in the prevention or reduction of metabolic and cardiovascular
risk factors in the general adult population (223). A range of nutritional interventions
have been reported to be effective in preventing or reducing risk factors associated
with the metabolic syndrome. These include: low glycaemic index/high protein diets,
increased fruit, vegetable and fibre intake, reduced salt diets and a Mediterraneanstyle diet (224, 225). A recent Cochrane review assessing nutritional interventions
for reducing or preventing cardiovascular risk found that interventions were more
likely to be effective in participants who were told of their higher risk of disease
(225).
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In the general paediatric population, little research has focused on the prevention of
metabolic syndrome. Rather, there is a focus on prevention and treatment of
childhood obesity. The literature suggests that family-targeted behavioural lifestyle
interventions using a combination of nutrition, physical activity and behavioural
components are effective for bringing about change in overweight children (226).
There does not appear to be research focusing on the efficacy of specific types of
nutritional interventions. As the mechanisms for the increased incidence of these
chronic diseases may be different in the general population to the oncology
population, the results and recommendations from these studies may not be able to
be extrapolated to childhood cancer survivors. Interventions focusing on older and
adult survivors of childhood cancer may not be appropriate for the younger
survivors.

5.1.4

Why is it important to do this review?

As this is a new area of study, there are minimal data in the literature with regard to
the most effective nutritional interventions available to reduce the incidence of
chronic disease after childhood cancer, despite the ongoing focus on long-term
follow-up of these patients. The purpose of this Cochrane review was to assess the
literature regarding nutritional interventions developed for childhood cancer
survivors, to facilitate the production of best-evidence management guidelines.

5.1.5

Objectives

To assess the efficacy of a range of interventions designed to improve the dietary
intake of children who have completed treatment for cancer, as compared to a
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control group of childhood cancer patients off treatment who did not receive the
intervention.

5.2

5.2.1

Criteria for considering studies for this review

Types of studies

All randomized controlled trials were included in this review. There was no limit to
length of the intervention, type of intervention and length of follow-up.

5.2.2

Types of participants

Studies that involved childhood cancer survivors of any age, who were diagnosed
with any type of cancer type when less than 18 years of age were eligible for the
review. Participating childhood cancer survivors had completed their treatment with
curative intent prior to the intervention. Studies including parents and/or carers of
this participant group were also included if the parents/caregivers were involved in
the intervention or reported on the participant outcomes. Treatment included
chemotherapy and/or radiotherapy. Studies which included participants with a comorbidity that may have affected eating such as autism (227), developmental delay
(228) and Down’s syndrome (229) were excluded.
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5.2.3

Types of interventions

5.2.3.1 Strategies

Interventions that included educational and counselling strategies, health promotion
or behavioural interventions with either individual or family-based interventions were
included in this review.

5.2.3.2 Topics

Nutritional interventions involving cancer survivors with or without their family
members were captured. Physical activity interventions for cancer survivors (230)
and nutritional interventions for childhood cancer patients receiving active treatment
(231) were excluded as these have been targeted by an alternate Cochrane
reviews.

5.2.3.3 Settings

There was no restriction on the settings for the interventions. Settings may have
included community, home-based or hospital-based interventions.

5.2.3.4 Delivery

All methods of delivery of the intervention were eligible, including face-to-face,
telephone and online interventions. There were no restrictions regarding the
interventionist. That is, eligible interventions were those that were delivered by
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specialist and non-specialist medical and allied health professionals, as well as by
other non-health professionals.

5.2.3.5 Types of comparison

We included studies which compared nutrition interventions to a non-intervention
control group that received usual care or another intervention.

5.2.4

Types of outcome measures

We included studies that reported one or more of the following primary outcomes
listed below. These outcomes needed to be assessed at baseline and at a minimum
of one follow-up time point.

5.2.4.1 Primary outcomes

A change in nutritional intake which was measured by one or more of the following:

1. Weighed food diaries;
2. Self-reported food diaries;
3. Single or multiple 24 hour recalls;
4. Food frequency questionnaires.

The nutrients may include but are not limited to:

1. Energy;
2. Protein;
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3. Fat;
4. Carbohydrate;
5. Calcium;
6. Iron;
7. Folate;
8. Vitamin(s);
9. Mineral(s).

5.2.4.2 Secondary outcomes

1. Metabolic risk factors, i.e. glucose and insulin metabolism;
2. Cardiovascular risk factors, i.e. resting blood pressure, blood lipids, and
cholesterol;
3. Measures of weight and body fat distribution, i.e. body mass index (BMI),
Dual-energy X-ray Absorptiometry (DEXA) and weight/height percentiles;
4. Behavioural change, i.e. changes in nutritional intake;
5. Changes in knowledge regarding disease risk and nutritional intake;
6. Participant views of the intervention;
7. Measures of health-status and quality of life;
8. Measures of harm associated with the process or outcomes of
the intervention;
9. Cost effectiveness of the intervention;
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5.2.5

Search methods for identification of studies

5.2.5.1 Electronic searches

We searched the following electronic databases: the Cochrane Central Register of
Controlled

Trials

(CENTRAL)

(The

Cochrane

Library,

Issue

3,

2013),

MEDLINE/PubMed (from 1945 to April 6th, 2013) and EMBASE/Ovid (from 1980 to
April 6th, 2013). The search strategies for the different electronic databases (using a
combination of controlled vocabulary and text words) are shown in the appendices
(Appendix 2, Appendix 3, Appendix 4).

5.2.6

Searching other resources

We located information about trials not registered in CENTRAL, MEDLINE/PubMED,
EMBASE/OVID, either published or unpublished, by searching the reference lists of
relevant articles and review articles. We hand searched the conference proceedings
of the International Society for Paediatric Oncology (SIOP) (from 2008 to 2012) and
The International Conference on Long-Term Complications of Treatment of Children
and Adolescents for Cancer (2008-2012). We scanned the ISRCTN register and the
register of the National Institute of Health (NIH) (http://www.controlled-trials.com) for
ongoing trials at the first half of 2013. We did not impose language restrictions on
the search.
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5.2.7

Data collection and analysis

5.2.7.1 Selection of studies

Two review authors (JC, CW), worked independently, screening all the titles and
abstracts resulting from the searches and excluded articles that were clearly
irrelevant. Full text copies of all relevant articles were retrieved. Using the defined
eligibility criteria, the two review authors determined their eligibility for inclusion. We
resolved any disagreement between review authors on classification of an article
between the review authors. Third party arbitration was not necessary. There was a
need for clarification of detail of one trial. One of the review authors (JC) contacted
the study authors from Rai 2008 (232), to obtain clarification for a complete
assessment of the trial’s relevance for the review. The reasons for exclusion of any
study considered for review are summarised in Table 5-1.

Table 5-1 Characteristics of excluded studies
Excluded study
Hudson 1999 (233)
Hudson 2002 (234)

Mays 2012 (235)
Moyer-Mileur 2009 (236)
Nathan 2009 (150)

Reason for exclusion
This study described the study protocol
and participant baseline data only.
The nutrition component of this study
was described in another publication
which has been included for assessment
in this review.
This was a validation study and did not
include an intervention.
The study included participants on
maintenance therapy
This study contains a review of the
literature and only reported on a smoking
cessation intervention in childhood
cancer survivors.
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5.2.7.2 Data extraction and management

Two review authors (JC and CW) independently extracted data, using a
standardised form, from each article. For each trial, the following data was
extracted:

1. Characteristics of the studies including the study sponsors and the authors’
affiliations, study design, risk of bias items, duration of study, loss to followup and compliance;
2. Characteristics of study population including country where participants
enrolled, inclusion and exclusion criteria, number randomised in each arm,
information on the control group, demographic characteristics, type of
cancer, age at diagnosis, cancer treatment, time since diagnosis, time
beyond active treatment;
3. Characteristics of the intervention including type of nutritional intervention,
details of the intervention, frequency, duration, intensity, number of sessions,
intervention format (i.e. individual or group, professionally led or not, homeor facility-based), description of control intervention, adherence and
contaminations as well as co-interventions (i.e. physical activity, medication
use);
4. Characteristics of the outcomes as stated previously.

We entered and combined the trial data using Review Manager 5.2. One review
author entered the data into RevMan 5.2 (JC), and another review author worked
independently to verify the data entry (CW). We resolved any disagreement
between review authors on classification of an article between the review authors.
Third party arbitration was not necessary.
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5.2.7.3 Assessment of risk of bias in included studies

Two independent reviewers (JC, CW) assessed the validity of each study using the
risk of bias items. We reported the following criteria for each trial: adequate
sequence generation and allocation concealment (selection bias), masking or
blinding of personnel, participants and outcome assessors (performance or
detection bias), incorporate incomplete data (attrition bias) and selective outcome
reporting (reporting bias). Baseline imbalance (gender, ethnicity, diagnosis, age and
health behaviour or nutritional intake) and differential diagnostic activity were also
assessed as other potential sources of bias.

We assessed and graded each trial’s risk of bias parameter as “adequate”,
“inadequate”, or “unclear”. Trials with one or more unclear or inadequate risk of bias
components were be considered to have a high risk of bias. We resolved any
disagreement between review authors on classification of an article between the
review authors. Third party arbitration was not necessary.

The Grades of Recommendation, Assessment, Development and Evaluation
(GRADE) system was used to rate the overall quality of evidence for each outcome
by two independent reviewers (237, 238). The GRADE approach defines the quality
of a body of evidence as “High”, “Moderate”, “Low” or “Very Low” (239). Factors that
may have resulted in a decrease in the quality of evidence included: 1) risk of bias;
2) inconsistency; 3) indirectness; 4) imprecision; and 5) publication bias.
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5.2.7.4 Measures of treatment effect

For continuous outcomes, the mean difference between groups was assessed. For
dichotomous outcomes, a relative risk was assessed.

5.2.7.5 Unit of analysis issues

We aimed to include cluster-randomised, cross-over and repeated measures trials in
this analysis, though none of the eligible studies used these methodologies.

5.2.7.6 Dealing with missing data

It was necessary to contact the authors of the Rai 2008 study (232), to gather further
detail on the nutrition intervention.

Intention-to-treat analysis was performed for all studies.

5.2.7.7 Assessment of heterogeneity

As none of the data was able to be pooled due to the different outcome measures
and interventions between the trials, assessment of heterogeneity using the I2
analysis was unable to be performed.

93

5.2.7.8 Assessment of reporting biases

We had planned to assess reporting bias by constructing funnel plots. As there were
less than 10 studies included in this review, the power of the tests was too low to
distinguish chance from real asymmetry (239) so this was not able to be completed.

5.2.8

Data synthesis

The data of the included studies were entered into Review Manager 5.3 software.
Data analysis was performed according to the Cochrane Handbook for Systematic
Reviews of Interventions (239). As the data was not able to be combined in a metaanalysis, we provided a narrative summary of the trial findings according to the
review objectives. For data that was provided as medians and ranges, the mean
difference was converted to mean and SD based on the methodology of Hozo 2005
(240).

5.2.9

Subgroup analysis and investigation of heterogeneity

We had planned to perform subgroup analysis based on the following categories: 1)
age at intervention (< 13 years; 13 to 18 years; > 18 years); 2) forms of intervention
(face-to-face; phone etc.); 3) duration of intervention; 4) childhood cancer type; and
5) type of treatment received. Due to insufficient trials, this was unable to occur. Due
to lack of data in the included studies subgroup analyses were not possible
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5.2.10 Sensitivity analysis

As pooling of the results was not possible, we were unable to use sensitivity
analyses to explore the impact of the inclusion of studies with a high risk of bias and
studies with an unclear risk of bias.

5.3

5.3.1

Results

Results of the search

A total of 3607 studies were identified from running the search through three
electronic databases CENTRAL, MEDLINE/PubMED, EMBASE/OVID. An additional
study was identified from searching the ongoing trial registries. No studies were
identified upon screening reference lists of relevant articles and reviews. No studies
were identified from the conference proceedings from The International Pediatric
Oncology Society and The International Conference on Long-Term Complications of
Treatment of Children and Adolescents for cancer. Initial screening of the title and
abstracts of each study allowed the exclusion of 3599 publications. We obtained the
full text articles of nine studies, of which three met the inclusion criteria. Five studies
did not meet the inclusion criteria and one of the studies was classified as ongoing
(Figure 5-1).
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Figure 5-1 Study flow diagram
5.3.2

Included studies

Three studies were included in this review. All three studies were RCTs. For further
details on the studies see Table 5-2
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Table 5-2 Characteristics of included studies
Mays 2011

Rai 2008

Design: Parallel RCT

Design: Parallel RCT

Setting: Two site, Pediatric oncology
units, USA

Setting: Single site, paediatric
oncology unit, USA

Number

Number

Number

Intervention: n=131 (4 lost to followup)

Intervention:38

Intervention: n=141 (45 dropouts)

Control: 37

Control: n=134 (49 dropouts)

No information on attrition was
available.

Age at study entry

Cox 2005

Methods

Design: Parallel RCT
Setting: Single-site paediatric
oncology unit, USA

Participants

Control: n=135 (1 lost to follow-up)
Age at study entry
Group:12-18 years

Age at study entry

Intervention (mean ± SD): 15.09 ±
1.90 years

Group:11-21 years

Control (mean ± SD): 14.96 ± 1.97
years

Intervention (mean; range): 16.6
(9.4 35.3) years
Control (mean; range): 17.2 (9.4
33.5) years

Intervention (mean ± SD): 14.2 ± 2.0
years

Sex

Control (mean ± SD): 14.2 ± 2.8 years

Intervention: 78 males: 63 females

Sex

Control: 78 males: 56 females

Sex
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Intervention: 57 males: 74 females

Intervention: 17 males: 21 females

Diagnosis

Control: 61 males: 74 females

Control: 19 males: 18 females

ALL

Diagnosis

Diagnosis

Treatment

Leukaemia/Lymphoma

Intervention: 21 Leukaemia: 17 others

Radiation

Intervention: 73

Control: 18 Leukaemia: 19 others

Intervention:53

Control: 72

Treatment

Control:34

Solid Tumour:

Information not available

Chemotherapy

Intervention: 58

Age at diagnosis

Intervention: 141

Control: 63

Information not available

Control:134

Treatment

Time since treatment completion

Age at diagnosis

Information not available

Information not available

Intervention (mean; range): 4.7
(0.7; 17.4) years

Age at diagnosis

Inclusion criteria

Information not available
Time since diagnosis
Intervention (mean ± SD): 15.09(1.90)
years

1. Previously treated for any form
of oncologic malignancy
2. One or more years off treatment
3. One or more years cancer-free
4. Able to comprehend and speak
English
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Control (mean: range): 4.6 (1.0;
16.39) years
Time since treatment completion
Intervention (mean ; range): 7.1
(5.0 18.2) years

Control (mean ± SD): 10.31 (2.94)
Inclusion criteria
1. 12-18 years
2. In remission 2+ years from
completion of therapy
3. Adequate cognitive functioning
4. English as a primary language
Exclusion criteria

Exclusion criteria
1. Suffering from renal
insufficiency or end stage renal
disease
2. Currently taking a thiazide
diuretic
3. Suffering from a pervasive
developmental or other major
psychiatric disorder precluding
valid informed consent

1. Not U.S. residents
2. English not their primary
language

Control (mean ; range): 7.2 (4.6
19.1) years
Inclusion criteria
1. Treated on St Judes
Children's Research
Hospitals total XI, XII or XIII
treatment protocol
2. At least five years from
completion of cancer
therapy
3. In first remission
Exclusion criteria
1. Active disease
2. Pregnant or lactating
females
3. Inability to chew or swallow
pills
4. Currently consuming more
than 800mg of
supplemental calcium or
800IU of Vitamin D
5. Anaemia

Interventions

Intervention

Intervention

Intervention

The intervention consisted of standard

The intervention consisted of a single

This study was a 24 month nutrition
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care plus a single multi-behavioural
intervention provided by a clinical
physician or nurse practitioner during
a routine visit to the long-term followup clinic. The multi-behavioural
intervention consisted of:
1. Discussion of after therapy
clinical summary
2. Health behaviour training of
health goal
3. Health goal commitment to
practice

half-day, group workshop in addition to
standard care. The workshop was given
by a registered dietitian. The workshop
included an interactive behavioural
session and focused on risk reducing
health promotion behaviours. The
workshop had a focus on bone health.
Co-interventions:
None
Contraindications:

Telephone reinforcement of the
education was provided at 3 and 6
months after their initial clinic visit

None

Co-interventions:

The control group received standard
care and were offered the intervention
at the conclusion of the study.

Other health behavior practices were
targeted during the intervention.
These included; smoking cessation,
sun protection and exercise.

and supplementation intervention.
The intervention group received
nutrition education sessions every
6 months. At baseline and 12
months these were given face-toface by a registered dietitian, and
at 6 months and 18 months these
were given in the form of mailed
information. The education
included information such as:

Control group

1. Number of serves of dairy
products
2. Serve sizes of dairy foods
3. Healthy diet
The intervention group was also be
given 24 months of calcium and
vitamin D supplementation which
were taken daily
Co-interventions:
None

Contraindications:

Contraindications:

None

None
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Control Group

Control group

Standard care consists of:

The control group received
education sessions identical to the
intervention group. They also
received placebo tablets instead of
calcium and vitamin D
supplements.

1. Breast or testicular selfexamination
2. Targeted late-effects screening
3. Clinical assessment
4. Late effects risk counselling

Outcomes

The outcomes were measured at
baseline and 12 months postintervention for both the intervention
and control groups.

The outcomes were measured at
baseline and 1month post-intervention
for both the intervention and control
groups. These outcomes were:

Outcome measure: Behavioural
change

Outcome measure: Change in
nutritional intake:

1) Frequency of nutrition as a health
protective behaviour

1) Dietary calcium intake measured
with 24-h recall

2) Frequency of junk food
consumption as a health risk
behaviour

Outcome measure: Behavior change:

The outcomes were measured at
baseline, 12 months, 24 months
and 36 months post-intervention for
both the intervention and control
groups.
Outcome measure: Body
composition
1) Bone mineral density

1) milk consumption frequency
2) Use of calcium supplementation

Notes

Study Sponsors

Study Sponsors

Oncology Nursing Society Foundation

Study Sponsors
National Institutes of Health; Grant
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(2003-2005)

American Cancer Society

number: P30 CA-21765

American Lebanese Syrian
Associated Charities (ALSAC)

Lance Armstrong Foundation

Centre of Excellence grant from the
State of Tennessee

National Cancer Institute (CA091831)
Le Bonheur Foundation (Memphis
TN)
American Lebanese Syrian
Associated Charities (ALSAC)
NIH; Grant numbers: R21
HD059292; GM 92666 Grant
sponsor
Gabrielle’s Angel Foundation
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5.3.3

Participants

A total of 616 participants from the three studies were included in the analysis. One
of the studies included participants who had been treated for ALL (232). Cox 2005
and Mays 2011 included participants with all forms of paediatric cancer (212, 241).
The number of participants in each study varied. The smallest study included a total
of 38 participants in the intervention and 37 in the control group (241). It was unclear
whether any participants were lost to follow-up. Cox 2005 study included a total of
266 participants (131 in the intervention and 135 in the control group) (212). Four
and one participants respectively were lost to follow-up. The largest study included a
total of 275 participants (141 in the intervention and 134 in the control group) (232).
Ninety-four participants (45 in the intervention and 49 in the control group) did not
complete the study.

The ages of the participants varied among the three studies. Two studies recruited
adolescent childhood cancer survivors [ages 11-21 years (241) and 12-18 years
(212)]. The third study included childhood cancer survivors of all ages up to 18 years
(232). None of the included studies had participants older than 21 years at study
entry.

5.3.4

Intervention

The timing of the interventions after the childhood cancer therapy varied among the
studies. Cox 2005 and Mays 2012 included participants within two years of
diagnosis (212, 241) and Rai 2008 included participants who were more than five
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years since therapy completion (232). The intervention and timing also varied
among the three studies included in this analysis. Two of the studies included
interventions that consisted of an initial, single, face-to-face health education
session focusing on health behaviour change (212, 241). One of these studies
focused on general health behaviours such as reducing junk food intake(212). The
individual education session was provided by a clinician or nurse practitioner during
a routine visit to the hospital. These participants were giving education
reinforcement, via the telephone, at three and six months after the intervention. The
other intervention focused on bone health, calcium and dairy intake and the final
assessment was done one month after the intervention (241). The education
session was provided in a group setting by a registered Dietitian.

The final study (Rai 2008) (232) had a 36 month follow-up, with the focus of the
intervention being on bone health. The intervention consisted of calcium and vitamin
D supplementation. Nutrition education was provided at baseline and every 6
months for 24 months. At baseline and 12 months post baseline, the education was
given face-to-face by a registered dietitian. At 6 months and 18 months the nutrition
education was in the form of mailed information. For further information on these
studies, see Table 5-2.

The study of Cox 2005 also included a co-intervention of changing the health
behaviour practices of smoking cessation, sun protection and exercise (212). This
study did not have any contraindications. The studies of Mays 2011 and Rai 2008
(232) did not include any co-interventions or contraindications (232, 241).
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5.3.5

Control

Of the three studies included in this review, the control groups of two of those
studies received standard care (212, 241). The standard care between these groups
did vary. The standard care of the control group for the study of Cox 2005 included
late-effects screening and education on their risk factors which was provided during
routine clinic visits (212). The standard care of the control group for Mays 2011 was
no education on nutrition related risk factors (241). The control group of the final
study received an identical nutrition education component as the intervention group
in combination with placebo tablets (232).

5.3.6

Outcomes

The primary outcomes of the studies in this review were dietary/nutrient intake. The
secondary outcomes measured by the included studies were body composition
(BMD) and health behaviours. The control group measurements were assessed at
the same time points as the intervention groups for all three of the studies. The time
points for the outcome measures, differed between the studies. The study of Mays
2011

measured

their

outcomes

(milk

consumption

frequency,

calcium

supplementation, dietary calcium intake) at baseline and one-month post
intervention (241). The study of Cox 2005 measured their outcomes (frequency of
nutrition as a health protective behaviour; frequency of junk food consumption as a
health risk behaviour) at baseline and 12 months post-intervention (212). The final
study of Rai 2008 measured their outcomes (bone mineral density) at baseline, 12
months, 24 months and 36 months post intervention (232).

105

The other secondary outcomes were not addressed in any of the three included
studies. These secondary outcomes were: metabolic risk factors, cardiovascular risk
factors, changes in knowledge, participant views of the intervention, health status
and QoL, measures of harm or cost effectiveness of the intervention. All three
studies had different methodology and different outcomes being measured and for
this reason the data was unable to be pooled.

5.3.7

Excluded studies

The full text publications of five studies were analysed but were subsequently
excluded. Three of the studies (Hudson 1999; Hudson 2002; Mays 2012) described
the study protocol and provided results from other components of the study. The
study data relating to the aims for this review were reported in other articles which
were included in this review (212, 241). The fourth study (Nathan 2009) contained a
review of the literature and the results of a smoking cessation intervention and was
subsequently excluded from the review. The final study (Moyer-Mileur 2009)
included participants on maintenance therapy and had not completed their cancer
therapy. For information on the excluded studies see Table 5-1.
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5.3.8

Risk of bias in included studies

See Table 5-3 and Figure 5-2 and Figure 5-3 for detailed information on the risk of bias assessment.

Table 5-3 Risk of bias in included studies
Mays 2011

Cox 2005

Random sequence
generation
(selection bias)

Allocation
concealment
(selection bias)

Risk
Low risk

Unclear
risk

Reason for judgement
Quote: "The randomisation
was stratified by gender and
age because of the clinical
impression that risk
perception could carry by
gender or age".

Risk
Unclear
risk

Comment: Although
randomisation was
performed using the
procedure as set out by
Zelen 1974,(242) it was
unclear which actual
randomisation technique

Unclear
risk
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Rai 2008

Reason for judgement
Comment: The paper
states that the
participants were
randomly allocated but
no further information
on the methodology
was provided.

Risk
Low risk

Comment: The
participants were
stratified when
randomised into sex,
race, age and BMD zscore.
Low risk

Comment: There was
no information
provided on participant
attrition.

Reason for judgement

Quote: "Only the St
Jude pharmacy had
access to the
randomisation system,
which is maintained by
the Department of
Biostatistics at St Jude".

was used.

Incomplete
outcome data
(attrition bias)

Selective reporting
(reporting bias)

Unclear
risk

High risk

Comment: The study
reported that five
participants (four in the
intervention group and one
in the control group) were
lost to follow-up. There was
no discussion on how this
data was handled. We were
unable to assess how this
would influence the outcome
or whether this would have a
clinically relevant effect.

Unclear
risk

Comment: This study
presented a secondary
analysis of data. This
analysis was not in the
original publication of the
results.

Low risk

Unclear
risk
Comment: There were
a large number of
dropouts in both the
intervention (n=45) and
control groups (n=49). It
is unclear how this data
was treated.

Comment: This study
reported data at
baseline and follow-up
on all outcomes cited
in the protocol or
methodology section

Comment:
Minimal baseline
imbalance: At
baseline, there was no
significant difference
between the
intervention and the
control group for
demographic and
other reported
characteristics.
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High risk

Comment: This study
did not publish all
outcomes that were
reported on the clinical
trials registry

No differential
diagnostic activity: All
assessments were
performed at baseline
and follow-up for both
the intervention and
the control group.
Other bias

Low risk

Comment:

Low risk

Minimal baseline imbalance:
At baseline, there was no
significant difference
between the intervention
and the control group for
demographic and other
reported characteristics.

High risk

Comment: This study does
not discuss whether
participants or personnel
were blinded. Due to the
nature of the study and the

Minimal baseline
imbalance: At baseline,
there was no significant
difference between the
intervention and the
control group for
demographic and other
reported characteristics.

Comments: This study
does not discuss
whether participants or
personnel were
blinded. Due to the
nature of the study
and the form of the
intervention, it would
be impossible for the
participants and
personnel to be
blinded.

No differential diagnostic
activity: All assessments
were performed at baseline
and follow-up for both the
intervention and the control
group.

Blinding of
participants and
personnel
(performance bias)

Low risk

High risk
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Quote: "All telephone
interviews were
administered by a
trained research
assistant who was

No differential
diagnostic activity: All
assessments were
performed at baseline
and follow-up for both
the intervention and the
control group.
Low risk

Comment: Both the
participants and the
research personnel
were blinded.

form of the intervention, it
would be impossible for the
participants and personnel
to be blinded.

Blinding of outcome
assessment
(detection bias)

High risk

Comment: The outcome is
subjective (a self-reported
outcome) and the
participants are not blinded.

masked to the trial
condition".

Low risk
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Comment: The paper
states that the
participants were
randomly allocated but
no further information
on the methodology
was provided.

Low risk
Comment: Both the
participants and the
research personnel
were blinded.

Figure 5-2 Risk of bias summary: review authors' judgements about each risk
of bias item for each included study

Figure 5-3 Risk of bias graph: review authors' judgements about each risk of
bias item presented as percentages across all included studies
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5.3.9

Allocation (selection bias)

Two of the studies (Cox 2005; Rai 2008) described an adequate random sequence
generation and were assessed as low risk (212, 232). In the study by Rai 2008, the
randomisation was completed by the pharmacy after participants had been stratified
into sex, race, age and BMD (232). The study of Cox 2005 used a randomisation
procedure that was stratified by gender and age (212). The final study was
assessed as “unclear” in the use of random sequence generation (241). Mays 2011
reported that the participants were randomised, but no further information was
provided on the procedure (241). Two of the studies were assessed as having an
unclear allocation concealment as there was no mention of the procedures used in
the study methodologies (212, 241). The study of Cox 2005 referred to the
methodology used by another author, though the methods used were still not clear
(212). The study of Rai 2008 used a well described randomisation procedure and
was assessed as having a low risk of allocation concealment (232).

5.3.10 Performance bias
Due to the nature of the interventions, blinding of the personnel or the participants
was impossible with two of the three studies (Cox 2005; Mays 2011) assessed as
having a high risk of performance bias (212, 241). In the final study (Rai 2008), the
participants and the personnel were blinded to the intervention as participants were
given a vitamin supplement or a placebo (232). This study was assessed at having a
low risk of performance bias.
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5.3.11 Detection Bias
Although personnel cannot be blinded when delivering nutrition interventions such
as these, it is possible for detection bias to be minimized by blinding the outcome
assessment. One study (Cox 2005) did not provide any information regarding
blinding of the outcome assessment but the outcome was subjective (a self-reported
outcome) and therefore the blinding of the outcome assessment was assessed as
high risk (212). In the remaining two studies (Cox 2005; Rai 2008), detection bias
was assessed as low risk because the assessors were blinded to the study groups
(212, 232).

5.3.12 Incomplete outcome data (attrition bias)
Two of the three studies reported drop-outs during the study (Cox 2005; Rai 2008)
(212, 232). No further information was provided on how the missing data was
handled and the studies were assessed as having an unclear risk of attrition bias.
Although the fourth study had a short follow-up time of one month and was less
likely to have drop-outs, no information was provided on study attrition. This study
was assessed as having an unclear risk.

5.3.13 Selective reporting (reporting bias)
The study of Mays, 2011 was the only study to be assessed as having a low risk of
reporting bias (241). This study reported data at baseline and follow-up on all
outcomes cited in the protocol or methodology section. Cox 2005 presented the
results of a secondary analysis, not mentioned in the original protocol. Hudson 2002
and Rai 2008 did not publish all outcomes that were reported on the clinical trials

113

registry (232, 234). These two studies were assessed to be at high risk of reporting
bias.

5.3.14 Other potential sources of bias
All studies were assessed for baseline imbalances and differential diagnostic activity
as other potential sources of bias. In regards to baseline imbalances, there was no
significant difference between the baseline data between the intervention and the
control group for all studies (212, 232, 241). All three studies were assessed at
being low risk.

All three studies were classified as a low risk of differential diagnostic activity
because the studies performed the same assessments in the intervention and the
control group at all time-points (212, 232, 241).

5.3.15 Effects of interventions

The three studies included in this review focused on different outcomes. We were
unable to pool the data and the findings reported were from individual studies only.

5.3.16 Change in nutritional intake
Calcium intake was the only nutrient that was assessed across any of the studies
(241). Use of a single, group-based behaviour change intervention showed no
statistically significant difference in the calcium intake (as measured by a 24-hour
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recall) between the intervention (n= 38) and control group (n=37) at the one month
follow-up (MD 111.60; 95% CI -258.97 to 482.17; P value = 0.56) (Figure 5-4) (241).
As analysed by Mays 2011, after regression analysis, adjusting for baseline calcium
intake and changes in knowledge and self- efficacy, there was a significantly greater
calcium intake for the intervention as compared with the control group at the one
month follow-up (Beta coefficient= 4.92; 95% CI 0.33 to 9.52; P value = 0.04) (241).

Figure 5-4 Forest plot of change in nutritional intake (calcium)

5.3.17 Body Composition
Body composition was used as an outcome measure in one study (Rai 2008) (232).
The data was provided as medians and ranges. This data was converted to mean
and SD based on the methodology of Hozo 2005 (240). There was no statistically
significant difference in bone mineral density (measured with a DEXA scan) at the
36 month follow-up (MD -0.05; 95% CI -0.26 to 0.16; P value = 0.64) (Rai 2008)
(Figure

5-5)

between

those

who

received

the

calcium

and

vitamin

D

supplementation in conjunction with nutrition education (n=141) and those
participants who received nutrition education alone (n=134) (232). There was no
statistically significant difference in bone mineral density between the intervention
and the control group at the 12 month (median difference -0.17: P value 0.99) and
24 month follow up (median difference -0.04: P value 0.54).
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Figure 5-5 Forest plot of change in body composition (bone mineral density)

5.3.18 Behavioural Change
The behaviour change outcome was assessed in two studies. In the first study,
health behaviour change was measured using single questions on a four-point Likert
scale (212). The participants were asked how often they practiced health practicing
behaviours and rated this from 1=never to 4=always. A single, face-to-face, multicomponent health behaviour change intervention with two telephone follow-ups
brought about no statistically significant difference in the use of nutrition as a health
protective behaviour (n=131) compared with those who received standard care (n=
135) (MD -0.05; 95% CI -0.24 to 0.14; P value = 0.60) (Figure 5-6) (212).

Figure 5-6 Forest plot of behaviour change (nutrition)

The same intervention brought about a statistically significant reduction in selfreported junk food intake (measured on a four-point likert scale: 1= never to 4=
always) in the intervention (n=131) compared with the control group (n= 135) (MD 0.17; 95% CI 0.33 to -0.01; P value= 0.04) (Figure 5-7).
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Figure 5-7 Forest plot of behaviour change (junk food)

A single, face-to-face, group health behaviour session focusing on bone health
brought about a statistically significant increase in the intervention group’s selfreported milk consumption (measured in number of days) (MD 0.43; 95% CI 0.07 to
0.79; P value = 0.02) (Figure 5-8) as compared with those who received standard
care (241).

Figure 5-8 Forest plot of behaviour change (milk consumption)

The intervention was also effective in increasing the participants days on calcium
supplementation (MD 11.42; 95% CI 7.11 to 15.73; P value <0.00001) (Figure 5.9)
(241).

Figure 5-9 Forest plot of behaviour change (days on calcium supplementation)

There was a statistically significant increase in calcium supplementation in the group
that received the education sessions compared with those who received standard
care (RR 3.35; 95% CI 1.86 to 6.04; P value < 0.0001) (Figure 5-10). A total of 31
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participants took some form of calcium supplementation after the intervention and
nine participants took some form of calcium supplementation in the standard care
group.

Figure 5-10 Forest plot of behaviour change (any calcium supplementation)

5.4

5.4.1

Discussion

Summary of main results

Childhood cancer survivors are at higher risk of health conditions such as
osteoporosis, metabolic syndrome, endocrine disorders and cardiovascular disease
than their peers (150). Targeted nutritional interventions may prevent (216, 217) or
reduce (15, 150) the incidence of these chronic diseases. This systematic review
included three studies (212, 232, 241) that have studied the efficacy of a nutritional
intervention, in a randomised manner, in childhood cancer survivors. These studies
utilised differing methodologies, and as a consequence, pooling of the results did
not occur.

The interventions that appeared to bring about a significant positive change were
those that focused on health behaviour change. A single, group health behaviour
education session significantly increased self-reported milk intake (MD 0.43; 95% CI
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0.07 to 0.79; P value = 0.02), use of calcium supplementation (RR 3.35; 95% CI
1.86 to 6.04; P value < 0.0001) and the number of days on calcium supplementation
(MD 11.42; 95% CI 7.11 to 15.73; P value <0.00001) as compared with standard
care (241). The intervention did not improve calcium intake (MD 111.60; 95% CI 258.97 to 482.17; P value = 0.56), though a regression analysis, adjusting for
baseline calcium intake and changes in knowledge and self- efficacy, found a
significantly greater calcium intake for the intervention as compared with the control
group at the one month follow-up (Beta coefficient= 4.92; 95% CI 0.33 to 9.52; P
value = 0.04).This study had a short follow-up time of one month and the effect of
the intervention long term was not assessed.

A face-to-face, multi-component health behaviour session with two telephone followups with education reinforcement, over a 12 month period, reduced self-reported
junk food intake (MD -0.17; 95% CI -0.33 to -0.01; P value= 0.04) but did not
improve childhood cancer survivors’ use of nutrition as a health-protecting behaviour
(MD -0.05; 95% CI -0.24 to 0.14; P value = 0.60) (Cox 2005) as compared with
standard care.

The study of Rai 2008 was the only study to assess the efficacy of nutritional
supplementation on childhood cancer survivors’ body composition. This study was a
randomised, double-blind RCT of calcium and vitamin D supplementation versus
placebo. Both the intervention and control group received nutrition education by a
registered Dietitian. There was no statistically significant difference on bone mineral
density as measured by DEXA between the intervention and the control group at the
36 month follow-up (MD -0.05; 95% CI -0.26 to 0.16; P value = 0.64). There was
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also no statistically significant difference in bone mineral density between the
intervention and the control group at the 12 month (median difference -0.17: P value
0.99) and 24 month follow up (median difference -0.04: P value 0.54).

5.4.2

Overall completeness and applicability of evidence

This review does not provide evidence that the nutritional interventions used in
these studies improved dietary intake or body composition in childhood cancer
survivors. The study of Mays 2011, was the only included study that assessed the
primary outcome of a change in nutritional intake (241). Mays 2011 found no
statistically significant improvement in calcium intake with a single, group, education
session (241). A regression analysis, adjusting for baseline calcium intake and
changes in knowledge and self- efficacy, found a significantly greater calcium intake
for the intervention as compared with the control group at the one month follow-up
(241). The study had a short follow-up time of one month and long-term compliance
with the nutritional changes were not assessed. There was a modest, positive effect
for health behaviour change interventions on improving self-reported health
behaviours such as junk food consumption (212), and milk intake (241). Although no
statistically significant differences were found for many of the outcomes this could
be the result of low power in the studies. It should be noted that no evidence of
effect is not the same as evidence of no effect.

The following outcomes were not assessed in any of the included studies: metabolic
and cardiovascular markers, changes in knowledge, and participant views of the
intervention, health status and QoL, measures of harm or the cost effectiveness of
the intervention.
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The two studies that did show a positive change in health behaviours may not be
applicable in all settings. The intervention required an initial face-to-face information
session. This type of intervention may not be possible for survivors of childhood
cancer who come from geographically diverse regions who may not travel to the
primary care centre for long-term follow-up. An efficacy of interventions utilising
computer and other technologies may need to be assessed.

Many of this systematic review’s predetermined outcomes (e.g. metabolic risk
factors, cardiovascular risk factors, changes in knowledge, and measures of harm)
were not assessed in the included studies. Only one of the studies assessed the
primary outcome of dietary intake. Although two of the interventions found a
significant positive change in health behaviours, there is no evidence to suggest that
this translates to the prevention of risk factors such as cardiovascular disease,
metabolic syndrome or obesity. Future interventions should consider assessing
outcomes such as body composition and blood lipids in combination with dietary
intake and changes in health behaviours.

All three of the captured studies were from paediatric oncology units in the USA.
The findings therefore may not be generalisable to childhood cancer survivors from
other countries, especially low income countries.

5.4.3

Quality of the evidence

By applying the GRADE criteria (237, 238), the quality of findings varied between
moderate (bone mineral density) and low (all other outcomes). All outcomes were

121

downgraded one level for imprecision. Due to a lack of blinding of participants,
personnel and outcome assessors, the quality of evidence for the outcomes “.selfreported nutrition) and “junk food” was further downgraded. Due to lack of details
regarding the randomisation procedure and lack of blinding of participants and
personnel, the outcomes “calcium intake”, “milk consumption” and “calcium
consumption” were downgraded to low quality. The study of Cox 2005 had a high
risk of reporting bias (results were from a secondary analysis) and performance bias
(inadequate blinding of the personnel) (212). The study of Cox 2005 had an unclear
selection bias, attrition bias and detection bias and results from this study therefore
need to be interpreted with caution (212).

The study of Rai 2008 was the only study to be assessed as having a low risk of
performance bias as both the participants and personnel were blinded (232); Mays
2011 had a high risk of performance bias (241). Although it is difficult to blind
participants to the intervention due to the nature of many nutritional trials, two
studies blinded the assessors (232, 241). Adequate allocation concealment would
be possible for all nutritional intervention trials, though the study of Rai 2008 was the
only study to be assessed as a low risk of selection bias (232); Mays 2011 had an
unclear risk (241). The studies of Mays 2011 and Rai 2008 had a low risk of
reporting bias (232, 241). All three studies were assessed as unclear in their attrition
bias. All three studies were assessed as having a low risk of other bias (212, 232,
241). The studies had minimal baseline imbalance and no differential diagnostic
activity.
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5.4.4

Potential biases in the review process

The search strategies for the electronic databases (CENTRAl, MEDLINE/PubMED,
EMBASE/OVID) were developed in collaboration with the Cochrane Childhood
Cancer Group. Additional searching was done of clinical trials databases, reference
lists and proceedings from conferences. Although it is always possible to miss
studies, an earlier published review did not identify any different additional
interventions prior to 2010 (217).

5.4.5

Agreements and disagreements with other studies or reviews

Only one other review paper was identified in the literature systematically reviewing
diet (and exercise) in childhood cancer survivors (217). This review included studies
that focused on diet in childhood cancer survivors, though the majority of these were
observational studies and unable to be included in the current review. They
identified one nutritional intervention in childhood cancer survivors which was also
included in our review (212) but did not identify any other type of interventional
studies. Stolley 2010 concluded that the literature on the dietary intake of childhood
cancer survivors is methodologically weak (217). There were very limited
intervention studies and use of control groups in the observational studies was rare.
Stolley 2010, highlights the minimal use of validated methods of dietary assessment
(217). Since the paper by Stolley 2010 was published, there are an increased
number of intervention trials (three) which were included in this review though the
use of validated dietary methods remains poor (217).
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5.5

5.5.1

Authors' conclusions

Implications for practice

Due to the heterogeneity of the studies included in this review, the authors are
unable to draw conclusions regarding the effectiveness of nutritional interventions
for childhood cancer survivors. Although there is weak evidence for the
improvement in health-behaviours using health behaviour change interventions,
there remains no evidence as to whether this translates into an improvement in
dietary intake. It is important to note that ‘no evidence of effect’ is not the same as
‘evidence of no effect’. Many outcomes were not assessed in the included studies.
There remains no evidence that there is a subsequent reduction in the risk of
cardiovascular and metabolic disorders in childhood cancer survivors from the
interventions.

5.5.2
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5.5.3

Implications

This review highlights the need for further intervention trials to be implemented in
survivors of childhood cancer. Chapters 2 and 3 found that poor dietary habits are
manifesting early after treatment completion. Nutritional interventions are more likely
to be effective if they are implemented early after treatment completion. The use of a
randomised design with a blinding of personnel to the outcome measures is possible
with this type of nutritional intervention and is recommended in future studies. It is
also suggested that future studies utilise validated measures of dietary intake.
Objective measures of body composition, cardiovascular and metabolic risk should
also be included as outcome measures in these studies. The next chapter will focus
on the nutritional management of paediatric cancer patients during cancer therapy.
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6 ENTERAL NUTRITION IN PAEDIATRIC ONCOLOGY: A MULTIPERSPECTIVE
STUDY4
Chapters 3 and chapter 4 provided evidence that poor dietary intake seen in adult
survivors of childhood cancer, is manifesting itself early after treatment completion.
It also appears that these dietary habits are occurring during the treatment. Section
2.4.2. of the literature review discussed recent work at our center regarding the
feeding practices used by parents to encourage a child to eat during cancer therapy.
These practices were predominantly negative. The literature review also indicated
that the threat of tube feeding was also used as a method of coercion to eat.
Negative feeding practices during cancer therapy may be contributing to the long
term poor dietary habits seen in survivors of childhood cancer. This chapter focuses
on the views of parents, patients and healthcare workers surrounding the use of
tube feeding as a method of nutritional supplementation.

4
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6.1

Introduction

Nutritional therapy is an important part of the management of childhood cancer
patients to ensure adequate growth and development (4). Oral intake can be
reduced due to the presence of oral mucositis, nausea and vomiting (14, 51) or taste
and smell changes (243). Child cancer patients’ nutritional status may also be
compromised due to intestinal malabsorption (14) and inflammation (46). Without
nutritional therapy, the prevalence of under-nutrition during treatment for childhood
cancer may be as high as 50% of patients in developed countries (46). Maintenance
of a good nutritional status during cancer therapy can also improve a childhood
cancer patient’s tolerance to chemotherapy, reduce their risk of infection and
improve quality of life (8, 244). Enteral tube feeding (ETF) is an important part of
nutritional therapy in paediatric cancer patients. It is used when oral nutritional
therapy is no longer effective (4).

Evidence shows that ETF promotes weight gain

in paediatric oncology patients (133, 134, 245, 246), especially when used
prophylactically (135). Despite the evidence for its effectiveness as a method of
nutritional intervention, the criteria for the use of ETF for paediatric oncology
patients are inconsistent (122).

The prevention of hospital malnutrition has become a focus in the clinical setting
(247). Prompt nutritional interventions are considered a key to prevention (248). To
achieve

appropriate

and

timely

nutritional

interventions,

multidisciplinary

collaboration is considered paramount (248). Although the healthcare team’s
recommendations influence the initiation of ETF in the paediatric setting,
recommendations for the utilization of ETF can differ between healthcare
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practitioners (122), leading to inconsistencies in ETF initiation. A cohesive team
management of nutritional therapy will likely enhance appropriate utilisation of ETF.

Patient centered decision making is also important when initiating ETF (249).
Parents and patients have a strong influence over the initiation of nutrition support,
with many refusing the use of ETF for their children. A recent study of paediatric
oncology patients, and their parents, suggested that the perceived discomfort of
ETF influences patient/parent decisions to allow ETF to be initiated (145). Parents
also use the threat of the use of ETF as a way to coerce their child to eat (131).
There is also suggestion that ETF is more likely to be initiated in younger patients (<
6 years) (135), than in older patients.

To ensure that the appropriate initiation of ETF is optimized, collating the views of
paediatric oncology clinicians, parents and patients on ETF in a paediatric oncology
setting would be beneficial. This would enable the development of psychoeducational interventions for families and staff. The aim of this study was therefore
to compare and contrast views among parents, patients and healthcare workers on
the positive and negative aspects of ETF, the ways in which information was
provided on ETF; and, how the decision making process was conducted for the
initiation of ETF.
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6.2

6.2.1

Methods

Study participants

Two groups of participants were recruited at the Kids Cancer Centre (KCC), Sydney
Children’s Hospital, Australia, for this study: 1) Paediatric cancer patients <18 years
of age, who were currently on treatment or who had undergone treatment at the
KCC in the previous three years; and 2) Healthcare professionals. There is no
literature determining the minimum age in which a child can participate in qualitative
research (250). For our study, for participants under the age of 12 years, the parents
were interviewed. The healthcare professionals included medical, nursing and allied
health staff. Potential participants were mailed a study invitation letter, a participant
information sheet and an opt-in card. Participants were also invited, in person,
through the outpatient clinic of the KCC. Participants were excluded if they were
unable to speak English. This study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involving human
subjects/patients were approved by the South Eastern Sydney and Illawarra Health
Service, Human Research Ethics Committee-Northern Hospital Network. Informed,
written consent was obtained from each participant.

6.2.2

Procedure

Interviews were conducted via the telephone by a research assistant. She was not
associated with, or known by, the participants and had extensive training and
experience with semi-structured interviews. Telephone interviews were offered as
many participants lived in rural or remote areas (24), and did not attend hospital on
a regular basis. Telephone interviews are considered to be as effective as face-to-
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face interviews for eliciting reliable qualitative data (25). All interviews were
recorded.

Semi-structured interviews were used to elicit information from the participants
(Table 6-1). After an extensive literature review, the initial core discussion guide was
developed. The interview focused on: 1) Attitude and impact of ETF; 2) Information
and support regarding ETF; and 3) Clinical management of ETF. The discussion
points were based on themes elicited in previous research on attitudes towards
enteral feeding in a general pediatric setting (146, 251). Once the initial discussion
guide had been developed, a multidisciplinary team (dietitian, psychologist and
oncologist) who have extensive experience in conducting qualitative research and
understood many of the challenges faced by families in this situation reviewed the
discussion guide. Results from the early interviews were also used to determine
additional lines of questioning for subsequent interviews (204).

The health

professional discussion guide was based on the same domains as the parent/patient
discussion guide. There was also a focus on the criteria they used to initiate EN.
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Table 6-1 Discussion guide for semi-structured interviews for
parents/patients and healthcare workers
Parents/Patients
Views prior to use of enteral tube feeding
 What information were you given about enteral tube feeding at the beginning
of your/your child’s treatment?
 Who gave this information to you?
 What did you think about the use of enteral tube feeding at the beginning of
your/your child’s treatment?
Views during and after use of enteral nutrition
 Can you describe whether there were any positives of you/your child receiving
enteral tube feeding?
 Can you describe any negatives of you/your child receiving enteral tube
feeding?
 Did your feelings about enteral tube feeding change after you/your child
received it?
 Did you/your child experience any complications with receiving enteral tube
feeding? If so, what?
 Could you tell me how you felt when you/your child received the nasogastric
tube or gastrostomy?
 Do you think enteral tube feeding affected your life in any way? For example,
your social life, your family relationships, how you/your child coped with your
cancer treatment.
 Did you have any issues or concerns with the enteral feeding process?
 Do you have any advice or recommendations about enteral tube feeding for
other patients/parents?
 How about for doctors or other healthcare workers?
Healthcare workers









What are the first two things that come to mind when you think about enteral
tube feeding in the pediatric oncology setting?
What are the positive aspects of enteral tube feeding?
What are the negative aspects of enteral tube feeding?
What are your thoughts about how enteral tube feeding is managed on the
ward?
What criteria do you use to decide whether or not you should initiate enteral
tube feeding?
What materials and resources do you use to make this decision?
How do you think enteral tube feeding impacts on the patients and their
families?
Can you comment on how you would approach a family about initiating enteral
tube feeding in their child?
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6.2.3

Can you comment on the support given to health professionals to initiate
enteral tube feeding in oncology patients?
Do you have any other advice or recommendations regarding the use of
enteral tube feeding in the paediatric oncology setting?

Data analysis

All participant responses were transcribed verbatim by an independent, trained
transcriber. This methodology was performed in accordance with gold-standard
guidelines (204). Transcripts were coded line-by-line, and analysis was facilitated by
the qualitative data analysis software NVivo, 2008, Version 8 (QSR International,
Victoria, Australia). To ensure accuracy with regards to the coding and analysis,
fifteen percent of the interviews were coded independently by two investigators, and
their coding was compared for consistency (204, 205). The final coding was
analyzed and key themes were categorized and enumerated (204).

6.3

Results

Interviews were conducted with 30 families (Table 6-2), representing a response
rate of 24.5%. Twenty parents (2 fathers, 18 mothers) were interviewed as their
child was under 12 years of age. Ten interviews were conducted with the childhood
cancer patients. Interviews were conducted with 18 healthcare workers, yielding a
response rate of 33%. Responses from participants were divided into three main
themes: 1) Attitude and impact of ETF; 2) Information and support regarding ETF;
and 3) Clinical management of ETF. Responses from the patient participants and
the healthcare workers were compared.
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Table 6-2 Demographics of participants and healthcare workers
Patient (n=30)
Age (mean ± SD) years
Sex (M:F)
Stage of treatment (n)
On treatment
Receiving maintenance therapy
Post treatment

9.54 ± 5.16
13:17
10
5
15

Diagnosis
ALL*
AML†
Wilms’ Tumour
Brain Tumour
Neuroblastoma
Other
Healthcare Workers (n= 18)

9
3
3
8
2
5

Position
Consultant
5
Fellow
2
Clinical Nurse Consultant
2
Clinical Nurse Educator
1
Registered Nurse
6
Allied Health
2
* ALL, Acute Lymphoblastic Leukaemia; †AML, Acute Myeloid Leukaemia

6.3.1

Attitudes toward, and impact of, enteral nutrition

Participants were asked to recall their views regarding ETF prior to and after use.
The emerging themes and representative comments are displayed in Table 6-3.
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Table 6-3 Views of enteral tube feeding from patients, parents and healthcare
workers
Themes

n

Representative Patient
Comments (n=30)

n

Representative
Healthcare worker
comments (n=18)

Prior to enteral nutrition
Positive
Ensure good
nutrition

9

“It would just give you
piece of mind that they are
getting the nutrition that
they need” (Mother:
female, CNS tumour, 8
yrs).

4

“Positives in terms of
delivery of essential
nutrients, vitamins”
(Fellow).

Less pressure
on the child to
eat/less conflict

7

“When I found out about it
I felt a huge amount of
relief that I wouldn’t have
to struggle with trying to
eat” (Patient: male,
Biphenotypic Leukaemia,
17 yrs).

4

“Enteral feeding is often a
way of diffusing conflict
....the last thing you need
is to have the [patient]
fighting with the mother
and father about what they
can and can’t get in”
(Consultant).

Weight gain

7

“When a child is sick and
thin its body can't fight as
well as it can if it is healthy
and nourished so if she
had dropped enough
weight we would have
definitely have done it”
(Mother: female, ALL*, 2
yrs).

1

“It means that they are
going to either hopefully
maintain their weight or
not lose significant weight,
so to try to minimise
toxicity of regimens”
(Fellow).

Easier to give
medication

2

“NG† tube might be really
easy because of the
medication...It needs to
get in and...with NG tube
at least you have that
option to just give it even if
[the patient] like[s] it or
not. (Mother, male, ALL, 5

4

“It is often also a good
way to give medications”
(Fellow).
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yrs).
Less time in
hospital

Negative
How it
looks/makes
them look sick

0

1

“[EN‡] usually means
getting out of hospital
[and] having some control
and having some time at
home” (Consultant).

8

“I didn't want him to have
[ETF], maybe it was just
admitting that he was
really sick then just to look
it” (Mother: male,
medulloblastoma, 11 yrs).

16

“..the patients are quite
reluctant...because of ...
the body image, and you
can see it and it makes
them look sick .... it
certainly separates them
from normal teenagers”
(Clinical Nurse
Consultant).

Invasive

7

“I never, ever wanted to
have a tube down my
nose the central line ...
just seems to be … less
intrusive in a way but
down the nose and down
my throat that always
appeared horrible to me
and I wasn’t very happy
with it” (Patient: male,
MDS, 13 yrs).

1

“I think parents view things
like NG tubes as invasive”
(Fellow).

Uncomfortable

7

“I have noticed just from
being in hospital was that
the children who had it
...find it incredibly
uncomfortable and they
couldn't understand why
they had to have it and so
they were constantly
pulling it out” (Mother;
female, ALL, 5 yrs).

4

“I think parents view NG
tubes as .... uncomfortable
in the children...when they
have not experienced it
firsthand ..... probably the
only time they witness NG
tubes in other kids on the
ward is when they watch
them go in .... that is a
little bit traumatic, but
once it is in, it is not a
major issue” (Fellow).

Insertion
procedure

0

4

“We have to pass the NG
tube and so i think that ....
frowned upon by the
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parents, they try and avoid
the tube feeding for as
long as possible because
they don't want that tube
inserted” (Registered
Nurse).
Worried about
how the patient
will cope

3

“You are sort of anxious
about it, how [the patient]
would cope with it”
(Mother; female, NHL§, 8
yrs).

0

Failure by
parents

2

2

Having to use
formula

2

“I think is some of [the
parents] feel that they are
not succeeding as
parents” (Mother: male
Wilms’ Tumour, 2 yrs).
“I was still breastfeeding
[and] I felt a little bit funny
because I hadn't
particularly wanted her to
have formula at all. I was
expecting her to go from
breastfeeding to solids
and then just cut out the
breastfeeding and purely
solids” (Mother; female,
AML, 2 yrs).

Extra work at
home

1

“You have the other
machines at home and
you have to put it all in at
night and you know it's
kind of another add on
thing” (Mother: male, ALL,
5 yrs).

0

Unnatural

1

“It are just my own gut
feeling that there must be
a reason why when we
are sick we don't want to
eat. ... but, wouldn't it
make sense that if our
body doesn't want to eat
that we don't need food?”
(Mother: female, AML, 4

0
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0

“Some parents see it as a
failure on their part and so
they are reticent to admit
defeat” (Consultant).

yrs).
Concerns about
reaction to the
tape used

1

“I would have had no
problem with it, only that
she seriously sensitive
skin and it has got to get
tapped to her face”
(Mother: female,
neuroblastoma, 6
months).

0

After enteral nutrition
Positive
Weight gain

10

“I really hate it to be
8
honest but I do know that
right now, it’s the only way
I can really gain weight”
(Patient: male, MDS, 13
yrs).

“The main positives is
maintaining weight,
maintaining nutrition and
that's getting the calories
in and having them
healthier” (Consultant).

Better nutrition

9

“You felt reassured that
[the patient] was getting
the nutrition in because
even when she was
eating, it was just like
crappy stuff so there was
nothing good or nutritious
about it” (Mother: female,
NHL, 8 yrs).

9

“I do think the relief of
knowing that your child is
getting their nutritional
requirements can remove
some stress. Especially if
you're a family where food
is a big part of your life
and nutrition” (Social
worker).

Less
stress/anxiety

8

“Once we said okay and
he got [ETF] we sort of
[felt] relieved, like this
pressure just lifted off our
shoulders and we didn't
have to fight with him”
(Mother; male,
medulloblastoma, 7 yrs).

9

“I think a big plus with it, is
that it does relieve a lot of
the eating stress at the
home, so [the parents] can
chill out and have good
times instead of constantly
fighting about, [food]”
(Consultant).

Patient got
used to the
tube

7

“Every time [the patient]
cried, [when] they tried to
put in [the tube], but after

1

“One of the big
advantages is once you
get the tube in it is well
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that she was fine again”
(Mother: female, Wilms’
Tumour, 8 yrs).

tolerated, once you get
past the first couple of
days and it is not
uncomfortable anymore”
(Consultant).

Less pressure
to eat

6

“We didn't have to be
stressed any more about
making [the patient] eat all
the time which is a real
constant battle between
him and I” (Mother: male,
medulloblastoma, 11 yrs).

3

“[ETF] is a lot easier on
the patient as well when
they are not getting forced
to eat a whole bunch of
stuff that they just can’t
tolerate” (Registered
Nurse).

Easier for
medications

4

“All the medicines [the
patient] didn't like to take
and the pills ... we could
throw straight down the
tube that was an
advantage” (Mother: male,
neuroblastoma, 11 yrs).

2

“[ETF] makes medications
easier” (Registered
Nurse).

Could feed
while child was
asleep

2

“It gave me a bit of piece
of mind that if she didn't
eat during the day at least
she was getting some
nutrition
overnight” (Mother:
female, AML, 2 yrs).

1

“[ETF] makes the feeding
easier; the parents can do
it at night time”
(Registered Nurse).

Less time in
hospital

1

“I don't have that
stress that if I don't eat I
am going to end up back
in hospital” (Patient:
female, medulloblastoma,
17 yrs).

4

“[ETF] as opposed to
TPN, is very helpful, and
... you can do it as an
outpatient so it increases
[the “[Patient’s] discharge
capability too, because in
the past the children might
have needed to stay in
hospital because they
can't eat” (Fellow).

12

“I didn’t particularly like
the way that it identifies
you as a sick person”
(Patient: male, 17 yrs,

0

Negative
How it looks

138

Biphenotypic Leukaemia).
Insertion
procedure

11

“The negatives, when they
had to put it down, I really
was quite insistent that
they put it down when she
was under general
anaesthetic because she
had them pretty much
every week.” (Mother:
female, AML, 2 yrs).
“There was always that
part of me that didn't like it
because I felt like it was
causing [the patient] so
much discomfort with the
vomiting and also with the
tube itself.” (Mother:
female, AML, 4 yrs).

9

“NG tubes are very
traumatic putting them
down is horrendous it
doesn't really matter about
the age of the child”
(Registered Nurse).

Vomiting up the
tube

7

10

If it’s [ETF] not successful,
and the tube keeps getting
thrown up or the child
keeps throwing up, then....
it’s just too hard” (Clinical
Nurse Consultant).

Uncomfortable

6

“ [The patient] kept saying
that it felt really funny on
her neck, an
uncomfortable feeling
having that thing going
down your neck” (Mother:
female, NHL, 8 yrs).

3

“It [ETF] feels
uncomfortable and they
[the patient] often say that
discourages them from
feeling like they want to
eat at other times because
it sits at the back of their
throat and it hurts a bit to
swallow” (Clinical Nurse
Consultant).

Makes patient
feel sick

5

“I’ve always felt sick and
I’ve always felt worse
having the feeds
continuous” (Patient:
male, MDS, 17 yrs).

0

Issues with
tape on the
face

5

“The tape and stuff was a
bit irritating, ... I thought it
would get a bit inflamed,
[on the face]” (Mother:
male, neuroblastoma, 11
yrs).

1

“You have got the tape on
the cheek; there was one
child who has a bad fungal
infection underneath that
so that is again a rare
downside” (Consultant).

Sleep
deprivation

2

“During the night the
machines always turning

6

“I imagine if you lived in
the house, you would find
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and it constantly makes
noise and when it runs out
it beeps and everyone has
to get up and fix it”
(Patient, female,
medulloblastoma, 17 yrs).

they have got a fair bit of
sleep deprivation around
it” (Consultant).

Type of formula

2

“The nutritionist was fairly
hesitant to switch from the
ordinary milk to the predigested stuff and once he
was on the pre-digested
stuff he really settled
down” (Mother: male, ALL,
5 yrs).

0

Impact on
family

2

“I was opening my
baggage all the time
because I would be
carting different tins, with
the food” (Mother: male,
neuroblastoma, 11 yrs).

5

“It [ETF] limits what you
can do. In terms of where
you want to go or if you go
on holiday, you have to
bring pump” (Clinical
Nurse Consultant).

Impact on long
term feeding

1

“I was concerned that
because she was being
tube fed for most of it, it
would affect her [eating]
long-term” (Mother:
female, AML, 2 yrs).

1

“Once they [the patient]
have been out from
transplant for many
months and still on
nasogastric feeds, then
certainly there can be
some anxiety about the
return of normal appetite
and normal feeding habits”
(Fellow).

Risk of
aspiration

0

3

“I have been involved in
where there has been a
concern about aspiration
on a chronic basis which
might have been
exacerbated by having a
nasogastric tube in”
(Consultant).

Cost

0

2

“It can be an ongoing cost
issue trying to get feed.”
(Clinical Nurse
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Consultant).
Diarrhoea

1

Tube blocking

0

“At one stage he did 17
diarrhoeas a day” (Mother:
male, ALL, 5 yrs).

1

“Negatives for nasogastric
enteral feeding is
diarrhoea” (Fellow).

4

“Problems occur if the
tubes then blocks and we
have to take it out and put
a new one in; you get
some frustration and
aggression as to why did
the tube block” (Fellow).

* ALL, Acute Lymphoblastic Leukaemia; † EN, Enteral Nutrition; ‡ NG, Nasogastric;
§NHL, Non-Hodgkin’s Lymphoma

6.3.1.1 Prior to use of enteral nutrition
The main positive aspects expressed by the participants regarding ETF prior to its
use were: 1) Ensuring good nutrition (n=9); 2) Less pressure on the patient and
family to get the child to eat (n=7); and 3) To promote weight gain (n=7). The
healthcare workers described similar positives which included: 1) Better nutrition
(n=4); and 2) Less conflict between parents and patients relating to oral intake
(n=4). Healthcare workers also described a positive of ETF as being ‘easier to give
medications’

“When I found out about it I felt a huge amount of relief that I wouldn’t have to
struggle with trying to eat” (Patient: male, Biphenotypic Leukaemia, 17 yrs).

The main concerns expressed by participants prior to its use included: 1) The
physical appearance on the child’s face (n=8); 2) Their concern it was invasive
(n=7); 3) The degree of discomfort from the enteral feeding tube once inserted
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(n=7). The same negative aspects were expressed by healthcare workers. The
healthcare workers confirmed that the most common reason for concern from
parents and patients was the physical appearance after insertion of the tube (n=16).
They also suggested that concerns about discomfort from the tube would be a
challenge for patients (n=4).

“I think parents view nasogastric (NG) tubes

as .... uncomfortable in the

children...when they have not experienced it firsthand..... probably the only time they
witness NG tubes in other kids on the ward is when they watch them go in .... that
is a little bit traumatic, but once it is in, it is not a major issue” (Oncology Fellow).

6.3.1.2 After use of enteral nutrition
Once ETF had been initiated, the positives described by both the patients and
parents appeared to match their views prior to insertion. The key positives included:
1) Weight gain (n=10); 3) Better nutrition (n=9); 3) Less worry (n=8); and 4) Less
pressure to eat (n=6). A proportion of this group also commented that their child “did
get used” to the tube (n=7). The positive views of the healthcare workers also
remained the same and were similar to the views of the parents and patients.

“Once we said okay and he got [ETF] we sort of [felt] relieved, like this pressure just
lifted off our shoulders and we didn't have to fight with him” (Mother; male,
medulloblastoma, 7 yrs).

Parent and patient negative views regarding ETF, however appeared to change
once the tube had been inserted, with the primary concern expressed relating to the
insertion procedure. This did not appear to have been a focus prior the initiation of
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ETF. Participants also commented that the constant emesis of the tube was a
problem. The other negatives of ETF after the insertion, described by the
participants, related to feeling awkward in public with the tube as it was so visible.

“There was always that part of me that didn't like it because I felt like it was causing
[the patient] so much discomfort with the emesis and also with the tube itself.”
(Mother: female, AML, 4 yrs).

The healthcare workers’ views regarding the negative perceptions surrounding ETF
once it had been utilised, appeared to agree with that of the parents and the
patients. The healthcare workers were aware of the concerns with the tube insertion
process and emesis of the tube. Healthcare workers also viewed sleep deprivation,
as a result of use of the feeding pump at home, as a potential difficulty for parents
and patients. None of the parents or patients interviewed spontaneously described
this as a concern. Healthcare workers did not spontaneously discuss the possibility
that the physical appearance of the tube would continue to be a challenge for
families after insertion

“I imagine if you lived in the house, you would find they have got a fair bit of sleep
deprivation around it” (Physician).

6.3.2

Information about enteral nutrition

Parents reported first receiving information about ETF from various sources. These
included: doctors (n=13), the dietitian (n=11) and nursing staff (n=3). One parent
reported that they sought information regarding ETF from other families. For parents
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of children who did not receive ETF during their treatment (n=8), many reported that
tube feeding was not mentioned as a possibility during their child’s treatment (n=5).
Some parents reported that they may have found out information on ETF when their
child was first diagnosed, but were unable to confirm this. They reported that they
received a lot of information at diagnosis and were unable to focus on all the
information provided due to the stress of their child’s cancer diagnosis (n= 6).

“It is all a bit of a blur, there may have been information in amongst everything but
until it was actually, like you say, crunch time, we didn't really think about it” (Mother:
female, AML, 4 yrs).

Half of the patients interviewed did not recall receiving any information on the use of
ETF (5/10) during their treatment.

“I wasn’t given any information. It was just “You’re going to get a NG [nasogastric]
tube put in” (Patient: female, AML, 17 yrs)
Three of the seven physicians reported that they raised the possibility of the use of
ETF at the initial diagnosis. One physician stated they did not mention it at
diagnosis.
“The amount of detail you go into can vary from family to family and you wouldn't
talk about it at the very beginning of diagnosis generally because they are still
getting over the shock of the new diagnosis and the treatment plan so it wouldn't
feature in those discussions but at a later stage it definitely does.” (Pediatric
oncology fellow)
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It appears that ETF is mentioned as a possibility to patients and their parents when
there is a concern about weight loss or poor feeding. The majority of healthcare
workers reported that the dietitian was the one to discuss the use of ETF with
parents and patients (n = 9).

“Our greatest resource is our dietitian . We are very much guided by that in terms of
whether there are concerns about calories.... a large proportion of [ETF] is guided by
a combination of looking at the weight and clinical assessment and then getting
guidance from the dietitian as to what is appropriate.” (Paediatric oncology fellow)

6.3.2.1 Decision process
The decision process and criteria for the use of ETF appeared to vary, with no
standardized criteria. Half of the healthcare workers (n=9) reported that weight loss
was the main criteria used for ETF initiation, though the amount of weight loss
varied from five percent to 15% loss of body weight. Many healthcare workers relied
on the dietitian to provide advice as to when ETF needed to be initiated (n=6). It
appeared that some healthcare workers and parents would have preferred there to
be a more specific criteria for initiation.

“I think there is a lot of um-ing and ah-ing and from a decision about whether we
enteral feed or not..... We still don't have a line in the sand.... kids need a line of
sand” (Clinical Nurse Consultant).
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6.3.3

Clinical management of enteral nutrition

6.3.3.1 Insertion procedure
There appeared to be similar views regarding the insertion procedure between the
parents, the patients and the healthcare workers. Of the parents and patients
interviewed, eight (40%) and three (30%) respectively, reported that the insertion
procedure was a negative experience due to the pain and discomfort with the
procedure.

“I found that really quite traumatic for her and for me” (Mother: female, AML, 2 yrs).

A similar percentage of healthcare workers (50%; n=9) considered the insertion
procedure a negative experience for patients.

6.3.3.2 Use of sedation for insertion
A small number of parents (n=4) and patients (n=2) reported that the use of
midazolam, improved the insertion procedure.

The parents reported that each

nasogastric tube insertion was different and that the methods used varied.

“It is much more comfortable for him to have the Midaz[olam]. It just takes the edge
off, just relaxes him I think a little bit more than, you know he knows what's coming”
(Mother: male, medulloblastoma, 7 yrs).

A number of healthcare workers (n=8) reported that using Midazolam, for the
insertion procedure, improved the experience of tube insertion.
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“A lot of the time we use Midazolam and it tends to be a bit ad hoc. There's been
one occasion where I've tried to get the pain team to do some nitrous [oxide]
but they refused.” (Physician).
6.3.4

Recommendation to other parents

Despite the large number of problems with the ETF insertion procedure, blockage of
tubes, and emesis, a large number of parents (n=12) would still recommend the use
of ETF to other families. Many parents (n=13) also felt that their perception of ETF
changed to a more positive view after use.

“I'd be surprised if rational parents didn't see the positive... I don't see how overall
you can't see it as a net positive. It is another thing to have to manage and it's
another thing protruding out of the patient’s body and all that stuff but it's a means to
an end.

I certainly wouldn't have it any other way because what's the

alternative?)” (Father: female, Brain tumour, 3 yrs).

6.4

Discussion

Nutrition interventions, in the form of ETF, play a key role in the management and
treatment of pediatric oncology patients. Recent literature has shown that proactive
ETF is achievable (135). This study showed that parents/patients and healthcare
workers could all see

positive and negative aspects of ETF, as well as the

management of ETF, in a similar way. Discordant views between the
patients/parents and healthcare workers appeared around the decision making
process and when information was provided on the use of ETF.
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Decision making of patients (and their parents) in the healthcare setting is complex.
Information provision alone may not be adequate enough to enable quality decisions
to be made (252). Physician understanding of the patient’s experience in
combination with the provision of information on evidence for the use of the medical
intervention (253) is more likely to encourage compliance with the recommended
treatment. This study demonstrated that healthcare workers appeared to understand
patients’ and parents’ challenges surrounding ETF. Therefore effective information
provision and decision support may be the missing link in the process for initiating
ETF use. Differences in perceptions between parents and physicians regarding the
sufficiency of information surrounding ETF has been shown to be a difficulty with
parents of non-oncology children (146). This difference in perceptions between the
parents/patients and the healthcare workers also appeared in the pediatric oncology
setting. A focus on the form and timing of the information provision may be needed
to ensure that uptake of ETF in an appropriate timeframe if achieved.

The physicians varied in regards to whether they provide information on ETF at
diagnosis or at other points during treatment. The parents did acknowledge that
even if this information had been provided at diagnosis, they may not have been
able to recall this information due to the stress receiving a cancer diagnosis for their
child. The literature has shown that parents feel overwhelmed by the information
given at their child’s cancer diagnosis (254, 255). This may lead to a poor recall of
all of the information provided to them (256). It may be that providing information on
ETF at diagnosis is not appropriate at such a stressful time. Physicians may need to
ensure information on ETF is given to parents and patients separate to diagnosis
but before nutrition becomes a concern for the patient and parents. This information
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may also need to be standardized across all the medical teams. Further work is
needed to determine the appropriate timing of information provision to families
regarding the use of ETF during cancer treatment.

Shared decision making is a process in which patient treatment decisions are made
in collaboration with the patient (257). The clinician provides information on the
benefits and harms for all treatment options and a joint decision is made regarding
the treatment plan (257). Shared decision making is not always used in the clinical
setting but is encouraged to improve patient outcomes, including patient satisfaction
(258). Shared decision making may allow the discordant views between patients
and clinicians regarding the use of ETF to be improved (257). Use of decision aids
may be one way of standardizing and improving the provision of information on ETF
to pediatric oncology patients and their families, especially when facing a decision
that involves competing values (such as balancing appearance and comfort with
better nutrition) (259). Decision aids provide unbiased, balanced, and non-directive
information about a procedure. They differ from standard education materials as
they provide options to the patient (260) and allow them to participate in the decision
making process (261). Decision aids have been shown to have a positive influence
in patient-physician decision making (261). The use of decision aids has been
suggested as a way to improve the quality of decision making for use of ETF for
parents of children with neurological disabilities (147) and carers of adults with
severe dementia (262). Incorporating decision aids into the pediatric oncology
setting may be one way to improve uptake of this form of nutritional intervention.
Use of a decision aid with standardised information may also address challenges
around the differing criteria for use of ETF between clinicians. Development of the
decision aid in consultation with clinicians may allow agreement to be reached on
the criteria for initiation of ETF based on published literature.
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Peer knowledge sharing has also been discussed as a factor for improving decision
making in the healthcare setting (260). Few parents and patients in this study sought
information from their peers. The majority of information on ETF came from
healthcare workers, such as their physician, dietitian and nursing staff. Many
parents stated they would recommend the use of ETF to other parents if asked.
Peer knowledge sharing could be utilized as a standard practice to improve the
information provision and subsequently improve the decision making process.

After ETF was commenced, the concerns from parents and patients, centered on
the practical aspects of the tube. These negatives included the invasive nature of
the insertion procedure, emesis of the nasogastric tube, and discomfort in using the
nasogastric tube and how visible the nasogastric tube was in public. Interestingly,
none of the parents or patients who participated in the study mentioned the tube
insertion procedure as an area of concern prior to the tube being inserted. Although
it is not possible to alter some of the negative aspects discussed above, such as the
physical appearance of the tube, introduction of

psychological preparation (4),

cognitive-behavioural techniques (263) and utilization of play therapists may lessen
the distressing nature of the procedure.

6.4.1

Limitations

This study provides insight into potential reasons for a reluctance to use ETF for
many patients and parents, though there are several limitations of this study that
need to be addressed. For the majority of participants, this study relied on
retrospective recall of their views of ETF and could have subsequently introduced
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recollection bias. Future studies should assess patient and parental views on ETF
prior to and after initiation. A participation rate of 24% could suggest that the results
from this study were not representative of all childhood cancer patients and their
parents. We did, however, continue interviewing until information saturation was
achieved.

A recent review of qualitative study sample sizes revealed that our

sample size is similar to many other qualitative studies that also achieved saturation
(264).

6.5

Conclusion

Parents, patients and healthcare workers perceived the positive and negative
aspects of ETF in a similar way. There appears to be discordance between
patients/parents and the healthcare workers in relation to the information provided to
them on the use of ETF. This uncertainty in the methods and timing of information
provision on the use of ETF may be contributing to a less than optimal use of this
method of nutrition support. By standardizing and improving the methods used for
the information provision of ETF, the concerns surrounding the use of ETF with
pediatric oncology patients may be reduced. Introduction of tools such as decision
aids and peer knowledge sharing may help to optimize the use of ETF in pediatric
oncology patients.

6.5.1

Implications

This chapter provides information on the decision making process for the initiation of
enteral tube feeding. The uncertainty in the methods and timing of information
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provision on the use of tube feeding may be contributing to a less than optimal use
of this method of nutrition support. This may also be a reason for parents using
enteral tube feeding as a way of coercing their child to eat. Improving the methods
of information provision around, not only enteral tube feeding, but all methods of
nutrition support may not only improve uptake of the appropriate nutritional
interventions but improve the feeding practices of parents during their child’s cancer
therapy. This may have implications on long-term dietary intake of survivors of
childhood cancer. The third section in this thesis examines the hypothesis that taste
and smell dysfunction may be implicated in the problem of developing healthy eating
habits in childhood cancer survivors. The next chapter is a review of the prevalence
of taste and smell dysfunction in cancer patients, both during and after treatment.
The review also assesses the relationship between taste and smell dysfunction and
oral intake
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7 REVIEW OF TASTE AND SMELL DISORDERS RESULTING FROM CANCER
AND CHEMOTHERAPY5

Chapters 3 and 4 found young survivors of childhood cancer are not meeting
recommended nutritional guidelines. It also appears that young survivors of
childhood cancer are not returning to the dietary habits they had established prior to
their cancer diagnosis. The reason for these changing dietary habits seen in cancer
survivors is unknown. Cancer patients report a change in taste and smell during
their cancer therapy but the role this plays on dietary habits during and after cancer
treatment is not clear. This chapter summarises the literature on taste and smell
changes during and after cancer therapy. This chapter also summarises the
evidence for the association of taste and smell changes and food intake and
whether taste and smell changes are seen in cancer survivors. The findings of this
chapter have been accepted for publication in Current Pharmaceutical Design

7.1

Introduction

Smell, taste and food intake are tightly intertwined (265, 266). Flavour perception is
not solely related to taste but is also mediated by olfactory receptors when
mastication of food occurs (267, 268). The sensory properties of foods can influence

5

This chapter has been accepted for publication in the following peer reviewed journal:

Cohen J, Wakefield CE, Laing DJ. Review of taste disorders resulting from cancer and
chemotherapy. Current Pharmaceutical Benefits
JC undertook the review, JC & CW contributed to data analysis and JC, CW & DL
contributed to manuscript development
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both the selection and amount consumed of that food (269). An alteration in taste or
smell function can lead to a change in a person’s quality of life as well as altering
food intake and nutritional status (270). In the general population, those with a
chemosensory dysfunction that occurred after birth may have one of three reactions
regarding food. They may increase their food intake to compensate for the lack of
food flavour, decrease their food intake because of the lack of enjoyment of the food
(271, 272) or continue to eat their normal diet. For many people suffering with
chemosensory disorders the aetiology is idiopathic (273). Other causes of
chemosensory disorders include sinus diseases, upper respiratory infection and
head trauma (273). Chemosensory loss is an under-recognized issue in the general
population, and there are conflicting data regarding prevalence of smell or taste loss
(273-279)

Radiotherapy, used as a treatment modality for cancer treatment, is another well
recognized cause of chemosensory dysfunction (273, 280). However, for many
cancer patients, chemotherapy is the primary form of treatment and its short and
long term effect on chemosensory dysfunction is less well understood.
Chemotherapy

targets

rapidly

dividing

cancer

cells

(49).

Unfortunately,

chemotherapy cannot distinguish between cancer and non-cancer cells (50, 281),
resulting in potentially severe short and long term side effects. Non-cancer cells that
are more likely to be affected by chemotherapy include cells in hair follicles, blood
and bone marrow, gastrointestinal tract and the reproductive tract (265), causing
side-effects such as nausea, vomiting, mucositis and diarrhoea. Taste and smell
receptor cells also rapidly turn over (282, 283) and the division mechanism has been
suggested to be sensitive to the effects of chemotherapy (281, 284).
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Anorexia and poor appetite are commonly described in cancer patients (285).
Malnutrition is a significant challenge for patients undergoing treatment for cancer,
and rates may be as high as 80% in adult patients (286) and 50% in paediatric
patients (46). Malnutrition in cancer patients is associated with increased infections,
leading to an increase in mortality (112-114), and this is likely to be independent of
disease severity (115).

Poor nutrition during cancer treatment

can lead to an

increased length of hospital stay (111), reduced quality of life, reduced treatment
tolerance and increased treatment side-effects, potentially leading to poorer
outcomes (6, 14). Malnutrition also reduces the absorption of chemotherapy drugs
(116) and may be one explanation of poorer survival outcomes in underweight
patients (114). In children with cancer, malnutrition can have more significant long
term effects such as growth stunting (84) and cognitive/developmental delay (83).

An alteration of chemosensory function could also affect a patient whose oral intake
is already affected by cancer (287). The senses of taste and smell are integral in
motivating a person’s food preferences (270, 288) and both child and adult cancer
patients commonly attribute difficulties maintaining food intake to the altered taste
developed during treatment (127, 265, 289). Altered chemosensory function in
patients with cancer may also lead to food aversions (266), further changing food
preferences. Chemosensory dysfunction has been associated with a decreased
energy and nutrient intake (271), nutrient deficiencies (290) and malnutrition (287).
A loss in sensory perception can also affect a person’s quality of life (291).

Given the potential medical, behavioural and psychological impact of chemosensory
dysfunction in adult and child cancer patients, this review aims to provide a
comprehensive overview of the prevalence of taste and smell disorders in cancer
patients undergoing chemotherapy.

A narrative review will be conducted in
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accordance with the published Economic and Social Research Council guidance
(292). This form of review is generally considered ideal where a broad overview is
required that synthesises both current empirical evidence and theoretical
understanding (38). This review will first summarise the potential causes of taste
and smell dysfunction in cancer patients and discuss the methodology used to
assess chemosensory dysfunction. The review will then summarise the prevalence
of taste and smell dysfunction, assessed using both objective and subjective
measures of assessment, in both patients on treatment and survivors of cancer. The
review will then summarise the prevalence of taste and smell dysfunction, assessed
using a variety gustatory and olfactory test, in both patients on treatment and
survivors of cancer. The review will also summarise the impact that chemosensory
dysfunction has on quality of life and oral intake and will also review the efficacy of
interventions to improve chemosensory dysfunction in cancer patients.

7.2

Summary of gustation

An alteration in taste perception can be categorized as ageusia (reduced taste),
dysgeusia (altered taste) (293), hypergeusia (increased sensitivity) or hypogeusia
(decreased sensitivity) (287). Taste sensations have previously been categorized
into four distinct groups: salty, sour, bitter and sweet. Recent work has also
identified the taste of umami as a fifth taste quality, said to be a savoury flavour
(294, 295). Fatty acids may also be a taste quality, though further work is needed to
confirm this (296). Taste receptors are located on the papillae on the tongue and
soft palate. These receptors regenerate regularly (49) although the time required for
this in humans has not been firmly established (284, 287). The sense of taste comes
from the detection of chemicals by the taste receptors. The taste receptors are
innervated by three separate cranial nerves: 1) facial nerve (CNVII); 2)
glossopharyngeal nerve (CN IX); 3) vagal nerve (CNX) and when activated, carry
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the taste information to the cerebral cortex (297, 298). Recent work suggests that
taste cells in the gut are sensitive to tastes (295).

7.2.1

Potential causes of gustation abnormalities in cancer patients

The mechanisms for taste abnormalities in cancer patients remain poorly
understood. Damage to the sensory receptor cells is considered a primary cause of
taste disorders in this population (274). Damage may be caused by a decrease in
the number of normal receptor cells, changes on the taste receptor surface or an
interruption in neural coding (274). The perception of taste sensations in the central
nervous system may also be altered if chemotherapy agents cross the blood-brain
barrier (299). Chemotherapy drugs may also interfere or damage sensory neurons,
altering

taste

pathways

(274).

These

drugs,

including

platinum

based

chemotherapy, cyclophosphamide, doxorubicin, 5-FU and methotrexate, are known
to be associated with taste and smell changes (284). Cancer patients may also
receive supportive care medicines, such as antibiotics and antihypertensive
medication that are associated with disorders of taste and smell (300).
Chemotherapy drugs, antibiotics and analgesics contain bitter tasting compounds
which can diffuse into the taste, via secretion into the saliva (287) causing a bitter or
metallic taste (274). A dry mouth is a common side effect from cancer therapy and
can alter taste perception (301).

Poor oral hygiene, gastrointestinal reflux and

infections have also been associated with taste changes in cancer patients (290).

7.2.2

Assessment of gustatory function

Most methods used to assess gustatory function, either assess patients’ detection
thresholds, their recognition thresholds (274), or their identification ability (275).
Recognition thresholds provide a measure of taste sensitivity and identification
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ability, while detection thresholds do not include the classification of a basic taste
(302). Electrogustometry is a measure of taste sensitivity. This method uses a mild
anodal current on the tongue, (303) which causes a metallic taste (304). Detection
of the taste is through direct stimulation of the gustatory nerve (304). A downside of
this method is that it does not measure the ability of a person to identify tastants
(305).

Taste strips, which use filter paper containing different concentrations of four tastes
(salty, sour, bitter and sweet), have been used to assess gustatory function in local
regions of the tongue (268). Gustatory function with these tastes has also been
measured using whole mouth tests which involve liquid solutions or tablets at
different concentrations of the four tastants (57). A version of the whole mouth
method for children, using 10ml solutions and four concentrations of the above four
tastants, has produced normative data from hundreds of children aged nine to
twelve years (276, 277, 306). Tests for the detection of the taste of umami have
only been established in recent years, with some work using discs of filter paper
impregnated with monosodium glutamate (MSG) (307).

7.3

Summary of Olfaction

The nasal cavity contains olfactory receptors that are activated when odorant
molecules bind to them (291). Olfactory receptors are located on the dendrites of
olfactory neurons, leading to a direct conduit to the cortex and subcortex (308) via
cranial nerve I (265). Olfactory neurons are able to regenerate (265), and the
regeneration time is dependent on the extent and type of damage to the mitotic
basal cells and olfactory epithelium (284). A reduction in olfactory function can be
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categorized as anosmia (inability to smell); hyposmia (reduced sensitivity);
hyperosmia (increased sensitivity) or dysosmia (distorted perception) (273).

7.3.1

Potential causes of olfaction abnormalities in cancer patients?

The causes of smell dysfunction in the general population may include: 1) traumatic
olfactory loss; 2) viral-induced olfactory loss; 3) exposure to toxic agents (265); 4)
age; and 5) chronic rhinosinusitis(307). For cancer patients, olfactory dysfunction is
likely related to chemotherapy destroying the rapidly dividing olfactory basal cells in
the olfactory epithelium (281), (300). Chemotherapy may also cause patients to
become sensitive to odours, (265) causing food aversions and a loss of appetite
(281). This may be caused by the compounds in the chemotherapy drugs diffusing
from the nasal capillaries to the olfactory receptors (308). Changes in smell
sensitivity in cancer patients may also relate to pseudo hallucinations of odours that
others cannot sense (309). Cancer patients may also report an increase in
sensitivity to smells, though the aetiology remains unknown (309).

7.3.2

Objective measures of olfaction

The most common tests of olfactory function measure odour identification ability,
odour detection or odour recognition thresholds (275, 276, 306, 310, 311). Odour
identification testing is performed by assessing a person’s identification of common
odours (275, 306, 311). The original method developed to produce normative data
for odour identification was the University of Pennsylvania Smell Identification Test
(UPSIT). This method uses 40 common odourants which are microencapsulated,
requiring study participants to “scratch and sniff” the odour (267). A four point forced
choice method is used to determine the odour presented (267). A short version of
the UPSIT is The Brief Smell Identification Test (312). Both are available
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commercially. Another commercially available method for measuring olfaction is the
German “Sniffin sticks” test which uses smell containing felt tip pens, allowing the
odour to be presented in a uniform way. Once the odour is presented to the
participant, the identification of the odour is achieved using a forced choice method
(311).

Another test is the Connecticut Chemosensory Clinical Research Center test which
measures both threshold and odour identification, with the odour presented to one
nostril at a time (313). n-Butyl alcohol is used as the stimulus in the odour threshold
component of the test. For odour identification, 10 common odourants are presented
to the participant and identification is done with the aid of a list of 20 examples
(313). There are a number of other tests available that measure odour
discrimination, memory, and suprathreshold, odour intensity and pleasantness
perception (314, 315), but little if any normative data are available from these and
the reliability of the data from these tests varies (315). As such, comparisons of
prevalence of odour dysfunction between studies using different methods need to be
interpreted with caution.

The above methods to detect odor dysfunction were not developed for use with
children. One study recently used ‘sniffin’ sticks and UPSIT tests with children,
however, the scores were generally lower than considered acceptable for validating
a general or specific olfactory dysfunction (316). A 16 odor identification test which
was developed for use with children aged over five years, at Sydney Children’s
Hospital in Australia (275, 276, 306) has been used with hundreds of children at
schools and in the Sydney Children’s Hospital to produce normative data. This
method involves participants sniffing opaque bottles containing the odorant.
Identification is with a three picture - three word forced choice task (306, 317).
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7.4

Prevalence of taste and smell alterations in cancer patients

Ten studies have assessed taste function in cancer patients (Table 7-1). Eight
studies reported decreased taste sensitivity (n=407) (109, 271, 318-323) and one
study reported no effect on taste function (n=12) (324). Two studies found both
increased sensitivity and decreased sensitivity to specific tastes. Nishjima et al,
2013 reported an increased sensitivity to sweet, salty and sour tastes and
decreased taste sensitivity to bitter (325), while Caputo and colleagues reported
increased sensitivity to bitter but decreased sensitivity to salty and sweet (326).

161

Table 7-1 Summary of studies assessing taste function in cancer patients
Hyperguesia
(increased sensitivity)

No effect

Hypoguesia
(decreased sensitivity)

Nishjima 2013 (filter paper strips : sweet,
sour, salty)
Caputo 2012
(wholemouth: bitter)

Steinbach 2012 (taste
strips)

Berteretche 2004
(electrogustometry)
Nishjima 2013 (filter paper:
bitter)
Steinbach 2010 (taste strips:
bitter)
Sanchez-Lara 2010 (whole
mouth: sweet, bitter)
Caputo 2012 (whole mouth:
salty, sweet)
Strasser 2008 (whole mouth:
4% bitter, 33% sour, 35% salty,
4% sweet (% with a higher
detection threshold)
Steinbach 2009 (taste strips:
salty, sour, bitter, sweet)
Oversen 1991
(electrogustometry)
Cohen 2012 (whole mouth;
40% of participants)
Skolin 2006 (whole mouth:
bitter)

Several objective methods have been used to assess taste and smell function in
cancer patients (Table 7-3). Two studies that assessed taste sensitivity using
electrogustometry found higher detection thresholds in cancer patients than in
control groups (318, 320). Use of whole mouth methods to assess taste detection
found higher sweet (271) and salty scores (326) compared with controls.
Interestingly, Caputo et al, (2012) (326) found lower detection bitter scores
compared with controls, whereas Sanchez-Lara and colleagues (2010) (271)
reported the opposite. Reasons for this discrepancy in these results are unknown as
both studies used similar participant groups and testing methods. Strasser and
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colleagues (2008) (323) assessed the taste detection of 41 cancer patients and
found a low prevalence of bitter and sweet dysfunction (4%), but higher rates of sour
and salty dysfunction (33% and 35% respectively. Two studies have used taste test
strips to assess taste function. In one study of 12 patients with ovarian cancer, no
significant decrease in taste function during their chemotherapy treatment was found
(322). However, a study of 87 breast and gynaecological cancer patients found that
their taste function decreased significantly after chemotherapy infusion (322). Two
studies assessed taste detection and recognition in paediatric cancer patients. One
study of children undergoing a bone marrow transplant (BMT) reported that 40% of
the patients experienced a taste dysfunction (319). Taste function appeared to
resolve within two months post-transplant. The second study assessed 10 paediatric
cancer patients during chemotherapy treatment and found higher thresholds for
bitter taste than controls (109).

A total of seven studies assessed olfactory function in cancer patients undergoing
chemotherapy with conflicting results (Table 7-3). One study reported decreased
odour detection (n=87) (321) and another reported no effect on odour detection (n=
15) (327). The results for odour identification were mixed, with four studies reporting
decreased identification (n= 130) (319, 321, 324, 328), one study reporting an
increase in identification (n= 69) and three studies reporting no effect (n= 46) (322).
Two studies assessed odour sensitivity with one study finding a decreased odour
threshold (n= 87) (321) and two studies finding no effect (n= 120) (320, 322).

The majority of studies (Table 7-2) assessing olfactory function in cancer patients
used “Sniffin sticks”. Yakirevitch et al, 2005 reported a prevalence of olfactory
dysfunction of 5% in patients with solid tumours (328). Two of these studies found a
statistically significant decrease in olfactory function compared with controls after
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chemotherapy infusion (321, 324). These findings were not repeated when the
olfactory function of 69 breast cancer patients were compared with normative data
and no difference in odour threshold was found (322). Olfactory function assessed
using the European Test of Olfactory Capabilities also found no difference in odour
detection and identification between 15 bronchial cancer patients and 15 healthy
controls (327). The only study assessing olfactory function in paediatric BMT
patients reported a prevalence of dysfunction of 30%, with symptoms resolving
within two months (319).
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Table 7-1 Summary of findings of taste and smell dysfunction
Author, year

N (age range)

Cancer Type

Chemotherapy

Measures

Findings

Joussain et al, 2013
(327)

15 cancer patients
(63.46 ± 6.16 yrs)
15 control (65.9 ±
4.93 yrs)

Bronchial

Cisplatin

European Test of
Olfactory Capabilities
(ETOC)

Berteretche et al,
2004 (318)

110 cancer patients
(58.5±11 yrs)
170 controls
(60.5±11.6 yrs)
12 (56.5 ± 9.8 yrs)

Not specified

Alkylating agents,
antimetabolites,
Antispindle agents,
Intercalating agents, other
Carboplatinum (plus taxol)

Electrogustometric
detection threshold

No difference in odour
detection (p> 0.05) and
identification (p>0.05
between patients and
controls
Cancer patients had
significantly higher taste
detection thresholds than
controls (p=0.02)
Cancer patients had a
significant decrease in
olfactory identification (p =
0.019) after chemotherapy;
olfactory function had
recovered after 3 months

Steinbach et al, 2012
(324)

Ovarian

Smell: “Sniffin Stick”;
Taste: Taste strips

No significant decrease in
taste function after
chemotherapy
Nishijima et al, 2013
(325)

23 (58.0± 11.5 yrs)

Gynecological

Taxane, carboplatin
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Subjective assessment
using the Common
Terminology Criteria for

48% self-reported taste
disturbances
Electrogustometry:

Adverse Events
Electrogustometry; Filter
paper disc testing

Steinbach et al, 2010
(322)

69 (52.4±10.4 yrs)

Breast

NS#

Taste strips; “Sniffin
Sticks”

Sánchez-Lara et al,
2010 (271)

30 cancer patients
(56.0 ± 15 yrs)
30 controls (49.4 ±
11yrs)

NS

Whole mouth method
using solutions (sweet,
bitter and umami)

Caputo et al, 2012
(326)

29 cancer patients
(50.1± 11.7 yrs)

Breast, lung,
prostate,
multiple
myeloma and
lymphoma
Breast, uterus,
prostate and

NS

Whole mouth detection
method using single
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Decreased taste sensitivity
in the chorda tympani nerve
field. Increased taste
sensitivity in the greater
petrosal nerve field
Filter paper testing:
Increased taste sensitivity
for sweet, salty, and sour &
decrease taste sensitivity
for bitter
Smell
Compared with normative
data, no significant
difference in odour
threshold, but better scores
for odour identification and
odour discrimination.
Taste
A significantly decreased
taste sensitivity value
compared with controls for
sour only
Cancer patients had a
higher sweet detection
(p=0.03) and bitter
recognition thresholds
(p=0.04) than controls
Cancer patients had higher
detection scores for salty,

44 controls (49.5 ±
16.3 yrs

head and neck
cancer

concentration of bitter,
salty, sour and sweet.

Strasser et al, 2008
(323)

41 cancer patients

Breast, prostate,
lung and other

Docetaxel
Paclitaxel

Self-reported taste (VAS
*scale)
Whole mouth detection
for salty, sour, sweet
and bitter at a single
concentration

Steinbach et al, 2009
(321)

87 (53.5 ± 10.5 yrs)

Breast and
gynaecological

CMP:
(Cyclophosphamide,
methotrexate, fluorouracil)
Anthracycline
Anthracycline & taxane
Platinum

“Sniffin sticks”; Taste
strips (sweet, sour, salty
& bitter)

Yakirevitch et al,
2005 (328)

21 (mean: 53.6yrs)

Solid tumours

Cisplatin

“Sniffin Sticks”

Ovesen et al, 1991
(320)

51 cancer patients
(mean: 64 yrs)
29 controls (mean:
62yrs)

Lung, ovarian,
breast

Lung cancer: Cisplatin,
vindesine, etoposide,
vincristine, doxorubicin,
tenoposide,
cyclophosphamide,
CCNU, and
hexamethylamine, or
monotherapy with
tenoposide or etoposide

Electrogustometric
detection threshold
Olfactory detection
threshold
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sweet, (p< 0.05)and lower
bitter detection scores than
controls (p< 0.05)
85% self-reported taste
alterations
After chemotherapy, a
number of patients had
higher detection thresholds:
4% bitter; 33% sour; 35%
salty; 4% sweet.
Higher detection thresholds
after chemotherapy infusion
A decrease in the smell
threshold, discrimination
and identification score
after chemotherapy infusion
Only 5% of patients had
decreased smell
identification after
chemotherapy infusion
Higher electrical taste
threshold in cancer patients
than controls ( P< 0.001)
No difference in smell
thresholds between the
cancer and control group

Cohen et al, 2012
(319)

10 (mean: 12.5yrs)

Bone marrow
transplant
patients

Skolin et al, 2006
(109)

10 cancer patients
(mean: 14.5yrs)
10 controls

Leukaemia, solid
tumour,
lymphoma,
central nervous
system tumour

Ovarian: Carboplatin,
cisplatin, and etoposide or
with cyclophosphamide,
Adriamycin (doxorubicin),
and 5-flu-orouracil
Breast:
cyclophosphamide,
epirubicin, and 5fluorouracil or
monotherapy epirubicin
NS

NS

* VAS: Visual Analogue Scale; #NS: Not specified
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16 odour identification
test
Taste detection and
identification test (bitter,
salty, sweet, sour)
Taste recognition
thresholds (bitter, salty,
sour and sweet).

40% of cancer patients had
a taste dysfunction
30% of cancer patients had
a smell dysfunction
Patients had higher
thresholds for bitter
taste than controls.
Patients had more taste
recognition errors
compared with control

7.5

Assessment of taste and smell dysfunction in cancer patients

Table 4 shows the results of eight studies that assessed taste and smell function.
Unfortunately, there are no validated methods for assessing self-reported taste and
smell function (302). Fifty percent of the studies used a 16-item taste and smell
questionnaire which measures self-reported taste and smell alteration (329-332).
One study indicated that 60% of general cancer patients had taste and/or smell
alterations (n=192) (330), while others reported that 69% of lung cancer patients
(n= 89), 86% of lung, gastrointestinal, breast and prostate cancer patients (n=
66)(331) and 75% of lung, breast, gastrointestinal and general patients (n=
518)(333) experienced taste and smell alterations. Self-reported smell changes
alone was reported in 3% of general cancer patients (n= 192), 5% of lung,
gastrointestinal, breast and prostate cancer patients (n=66) and 10% of breast,
gastrointestinal and gynaecological cancer patients (n=518).

Using a two item scale, two studies assessed taste function in breast and
gynaecological patients (n= 109)(299) and lung, colorectal and pancreatic cancer
patients (n= 197) (334) and found approximately 70% of patients surveyed reported
changes in taste. Patients receiving Irinotecan appeared to have a higher report of
taste changes than those receiving Gemcitabine and a platinum containing
chemotherapy (334). The results were in contrast to another study of breast and
gynaecological cancer patients, with less taste changes occurring for those
receiving gemcitabine (299).

In another breast cancer study (n=45), 84% of

patients complained of taste alterations (335). A total of 68% of colon, breast, lung,
lymphoma and ovarian cancer patients reported taste changes assessed via a 41item taste change questionnaire (284).
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Table 7-3 Summary of studies assessing olfactory function in cancer patients

Odour detection
Odour identification

Odour threshold

Decreased

No effect

Steinbach
2009
(sniffin sticks)
Steinbach
2012
(sniffin sticks)
Steinbach
2009
(sniffin sticks)
Yakrevitch
2005
(sniffin sticks: 5% of
participants)
Cohen 2012 (odor
identification: 30% of
participants)
Steinbach
2009
(sniffin sticks)

Joussain
2013
(ETOC)*
Joussain
2013 Steinbach
(ETOC)*
(sniffin sticks)
Yakrevitch
2005
(sniffin sticks: 95% of
participants)
Cohen 2012 (odor
identification: 70% of
participants)

Steinbach
2010
(sniffin sticks)
Oversen
1991
(detection threshold
method)

* ETOC: European test of olfactory capabilities
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Increased

2010

Table 7-2 Summary of findings of taste and smell alteration
Author, year

N (age)

Cancer Type, age range

Measures

Findings

Brisbois et al, 2011(330)

192 (64.3 ±12.4 yrs)

Lung, breast, genitourinary,
gastrointestinal, neuroendocrine
system , hematological
conditions

Taste and smell survey

60 % taste and smell
alteration
26% taste only
3% smell only

McGreevey et al, 2014
(332)
Hutton et al, 2007 (331)

89 (69± 9 yrs)

Lung cancer

Taste and smell survey

66 (65.4 ± 12.4 yrs)

Lung , gastrointestinal, breast &
prostate

Taste and smell survey

69% taste and smell
alteration
86% taste and smell
alteration
52% taste and smell
30% taste only
5% smell only

Jensen et al, 2008 (335)

45 cancer patients
(mean age: 45yrs)

Breast cancer

Bernhardson et al, 2008
(333)

518 (58.71 ±
10.77yrs)

Breast, gastrointestinal,
gynecological and other

Subjective assessment
using standardized
questions of perceived
taste disturbances
Taste and smell survey

Gamper et al, 2012 (299)
Zabernigg et al, 2010

109 (61.0 ±12.8)
197 (65.2 ±10.4)

Breast and gynecological
Lung, pancreatic and colorectal
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Taste alteration scale
Taste alteration scale

84% self-reported taste
changes

75% taste and smell
alteration
10% smell only
35% taste only
71% taste alteration
70 % taste alteration

(334)
Wickham et al, 1999 (336)

284 (58 ± 15 yrs)

Colon, breast, lung, lymphoma,
ovarian

QoL: Quality of life
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41-item taste change
questionnaire

68% taste alteration

7.6

Chemosensory dysfunction in cancer survivors

Taste and smell receptors in cancer patients are said to regenerate within a finite
time with some studies indicating a time-scale of 10-30 days (281, 284). For this
reason, researchers hypothesize that chemosensory dysfunction should not affect
patients once they have recovered from their cancer therapy.

Steinbach et al,

(2009) (321) assessed chemosensory function in 87 breast and gynaecological
cancer patients before, during and after their chemotherapy. This study reported
olfactory and gustatory function returned to normal three months after completion of
therapy (321). In a study of 12 patients with ovarian cancer, olfactory function
returned to normal after three months from completion of chemotherapy (324). Two
other studies assessed paediatric haematopoietic stem cell transplant (HSCT)
patients after treatment completion and found chemosensory function normalized
after two months (319, 337).

Much of the work assessing taste and smell function in adult cancer survivors has
focused on patients who had undergone HSCT using self-report measures. In an
assessment of 50 haematological cancer patients, 20% of the patients reported
taste or smell changes 100 days post-HSCT (293).

In contrast, Mattson et al,

(1992) found that taste and smell dysfunction continued up to one year after HSCT
(338).

7.7

Chemosensory dysfunction and effect on oral intake in cancer patients

Food aversions can occur if an unpleasant experience occurs in conjunction with
food ingestion (271). Studies exploring the influence of taste changes and food
intake during chemotherapy remain inconclusive (339). However, some evidence
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suggests that there is an association between chemosensory dysfunction and
changes in oral intake in cancer patients. For example, in an assessment of 192
advanced cancer patients, those with a self-reported change in taste function
consumed 20-25% fewer calories per day, had greater weight loss and had a poorer
quality of life than those who reported no taste and smell alteration (330). A similar
trend was seen in lung cancer patients, with those reporting taste and smell
alterations having decreasing energy intake (332). Furthermore, Sanchez-Lara et al,
(2010) (271) found that in a group of 30 adult cancer patients, those with a higher
sweet detection threshold or a higher bitter recognition threshold had a lower energy
and nutrient intake (271). One assessment of 42 cancer patients reported an
association between those with self-reported taste changes and decreased appetite
(340). Taste and smell alterations were also associated with a decreased appetite in
breast and gynaecological cancer patients (299) and lung, colorectal and pancreatic
cancer patients (334). Importantly, when assessed separately, taste and smell
dysfunction is associated with a decreasing energy intake (331).

Not all patients however, report that taste and smell changes influence their intake.
A qualitative study of 21 adult cancer patients with chemosensory loss showed that
for several of the patients interviewed, their oral intake did not change as a result of
this dysfunction (341). Bernhardson et al, (2009) (309) compared patients who had
self-reported smell dysfunction alone, with those who reported both a taste and
smell dysfunction. Those with a smell dysfunction alone appeared to have fewer
difficulties with weight loss, appetite and oral intake. This study provides some early
data that taste and smell dysfunction in combination may be a stronger driver of the
dietary intake of cancer patients, than smell dysfunction alone. Since the flavor of
food is comprised of smell and taste stimuli, this finding is not surprising.
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7.8

Chemosensory changes and quality of life

For many cancer patients, taste changes can affect their quality of life (274, 336). In
a study of 45 breast cancer patients, 10% of those with a self-reported taste
dysfunction indicated that this was their most distressing oral symptom (335).
Another study involving 314 cancer patients with self-reported taste and smell
alteration, found that over 50% reported high distress as a result of their
chemosensory symptoms. Almost 30% of this group also reported that it impacted
their daily life (342). In a study of 284 cancer patients, 40% reported that taste
changes were moderately distressing and 18.6% reported that their taste changes
affected their lives (336). A similar finding was seen in a cohort of breast and
gynaecological cancer patients, with those with a self-reported chemosensory
dysfunction being more likely to report a depressed mood (333). Taste and smell
dysfunction may be associated with fatigue in breast and gynaecological cancer
patients (299) and lung, pancreatic and colorectal cancer patients (334). Taste
alterations during chemotherapy can also affect activities of daily living such as
grocery shopping, cooking meals and socializing with friends (340).

7.9

Intervention studies and strategies to improve/ prevent taste and smell
dysfunction

There are few therapeutic options for the treatment of chemosensory dysfunction
(298). Although zinc deficiency may be associated with taste disorders (343), there
is little evidence to suggest that zinc supplementation improves taste function for
people with taste disorders in the general population (344). As regards to cancer
patients, a double-blind, placebo controlled randomized controlled trial of 58 patients
found that zinc supplementation did not prevent taste and smell dysfunction (345).
Glutamine, a branched-chain amino acid, is thought to play a role in the prevention
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of chemotherapy-induced neurotoxicity (346). However, a randomized controlled
trial of glutamine in 52 patients undergoing cancer treatment, found no impact on the
incidence of taste disorders in an adult cancer population (323).

Encouragingly, the canniboid, delta-9-tetrahydrocannabinol (THC) may be effective
in improving appetite and oral intake in cancer patients (347). Brisbois et al, (2011)
assessed the effect of THC on taste and smell, appetite and food intake in 46
patients with cancer in a randomized controlled trial (24 controls) (294) and found
that compared with placebo, THC patients exhibited significantly improved
chemosensory perception, appetite, food intake and quality of life (294). In another
approach, miraculin, a protein in a West African fruit, was tested for its ability to
mask unpleasant flavors in a cross-over trial. Although the sample size was small
and the trial was not blinded, there was some suggestion that consumption of this
protein improved the taste of food for all participants while undergoing
chemotherapy. For some participants, this improvement in taste translated to an
improvement in oral intake (348). Further testing is required to confirm these results.

Patients use multiple strategies to manage chemosensory dysfunction and to
improve oral intake. In a qualitative study of 12 patients with taste and smell
alteration, patients described several strategies, including: 1) Trial and error to
determine tolerable foods; 2) Having a selection of quick and easy foods available to
consume; 3) Limiting social interactions; and 4) Working through the symptoms
(349). It appears that strategies to cope with chemosensory dysfunction, such as the
use of herbs and spices and avoidance of cooking smells, are not very effective
(342). In a qualitative study of 21 patients with cancer, participants were unable to
report any strategies that could alleviate their taste and smell changes (350). When
cancer patients were provided with an educational intervention on strategies to
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manage taste changes, only 16% of participants felt that the intervention helped “a
lot” (340). There is only one study providing data suggesting that a nutritional
intervention can improve intake. In that study, a combination of flavour enhancers in
food and nutritional education was used with 107 adult cancer patients (54
intervention: 53 control)(351). The intervention group received 13 bottles of food
flavour enhancers in combination with food preparation information. The intervention
group had

improved nutritional status and physical functioning compared with

controls, though there was no difference in macronutrient intake or quality of life
between the two groups (351).

7.10 Discussion

This review summarizes studies that have assessed taste and smell dysfunction in
cancer patients undergoing chemotherapy. Overall there was some suggestion of
lower taste sensitivity in adult and child cancer patients in 80% of the studies
reviewed. The results were not as clear for studies that assessed olfactory function.
Nevertheless, there appeared to be a higher incidence of odor identification
dysfunction in patients with cancer undergoing chemotherapy when compared with
the general population. Overall, the results for changes in odor detection and
identification for patients with cancer were inconclusive. Eight studies assessed
taste and smell function using self-reported measures. The incidence of taste and
smell function, assessed by such imprecise methods ranged from 60% in general
cancer patients (330) to 86% in lung, gastrointestinal, breast and prostate cancer
patients (331).
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There were methodological limitations in the studies in this review. For example,
there was little consistency in the assessment methods used, making cross-study
comparisons difficult. Of the included studies, four different methods were used to
assess taste function: 1) whole mouth testing; 2) filter paper discs; 3) taste strips
and 4) electrogustometry. Similarly, four methods were used to assess odor
function: 1) “Sniffin sticks”; 2) ETOC; 3) odor identification; and 4) odor detection. In
addition, a variety of self-report tools were used that did not compare results with a
control group. Our review concurs with that of Gamper et al, 2012 and Bolton and
Keast, 2012, who were unable to make firm conclusions regarding the occurrence of
chemosensory dysfunction in cancer patients due to methodological limitations in
many of the studies (302, 339).

Very few studies have assessed the prevalence of chemosensory dysfunction in
paediatric cancer patients undergoing chemotherapy.

The limited studies suggest

that taste and smell dysfunction is prevalent during chemotherapy treatment and
BMT. There is a dearth of literature assessing the association of taste and smell
dysfunction with appetite, oral intake and QoL in childhood cancer patients. A recent
systematic review of symptom experiences of children and adolescents with cancer
reported nausea and vomiting to be one of the most commonly identified symptoms
(10). Taste and smell alterations were not a key symptom identified by paediatric
patients in the review. The varying cognitive abilities of children of differing ages
makes it difficult to standardize chemosensory testing (276). What remains unclear
from the systematic review of cancer symptoms is whether it is difficult for children
to articulate taste and smell alterations. Recent work has shown that many cancer
patients have poor dietary habits after cancer treatment, especially those who have
survived a diagnosis of childhood cancer (202, 352). There remains a dearth of
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literature regarding taste and smell function in survivors of childhood cancer and
whether this is contributing factor the survivor’s poor nutritional intake.

Overall, this review provides evidence that chemosensory dysfunction may be
associated with a poor appetite, potentially leading to a poor nutritional intake and
weight loss. The data were predominantly derived from self-reports of taste
alterations and appetite by patients. The senses of taste and smell are an integral
part of the experience of eating, but only represent part of the sensations
experienced (349). A person’s dietary habits and food intake are driven by their
enjoyment of the food (353). It may be that severe chemosensory dysfunction
reduces food enjoyment leading to reduced oral intake (331, 336). The tests used to
assess chemosensory function are not necessarily in line with the patient’s
experience of eating (333). Food texture, temperature (349), touch and emotional
state of mind (354) may be just as important as taste and smell for driving a patient’s
food intake and preferences (344). Most studies of chemosensory function in cancer
patients assess taste and smell in isolation. Other factors contributing to food intake
and food preferences in cancer treatment have not been assessed.

Despite the conflicting evidence for changes in the senses of smell and taste, this
review also provides evidence for a relationship between chemosensory dysfunction
and its effect on quality of life in patients undergoing treatment for cancer. Selfperceived taste alterations appear to affect mood and can increase fatigue (299,
333, 334). Taste alterations are also associated with a higher level of distress for
cancer patients (309, 335), leading to changes in their daily activity (284, 309).
Unfortunately, despite these important effects, this review demonstrated that the
available chemosensory interventions are largely ineffective. It may be that
interventions are ineffective because they aim to improve perceived taste or smell of
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food, but have not considered flavour or texture. Given that taste and smell changes
are often unique to each individual cancer patient, it may be that future interventions
might be more effective if tailored to the needs of individual patients, rather than
offering a generalized intervention to all affected patients.

7.11 Conclusion

This review summarizes the available evidence for the role of taste and smell
dysfunction and on the food intake, appetite and quality of life of patients undergoing
chemotherapy treatment for cancer. Both adult and child cancer patients should be
counselled about the potential impact that taste and smell dysfunction could have on
their appetite and oral intake during their cancer therapy. Further work is required to
ascertain the taste and smell function of both adult and child survivors of cancer.

7.11.1 Implication

This chapter summarised the available literature on taste and smell changes during
and after chemotherapy treatment for both adult and child cancer patients. There
appears to be a high incidence of self-reported taste and smell alterations occurring
during chemotherapy treatment. It also appears that taste and smell changes are
altering the dietary intake of cancer patients. There is some suggestion that taste
and smell changes may persist well after the cancer therapy is completed in adult
cancer patients. The next chapter is a study on the taste and smell function in a
cohort of survivors of childhood cancer.
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8 TASTE AND SMELL DYSFUNCTION IN CHILDHOOD CANCER SURVIVORS6

Chapter 7 identified that taste and smell dysfunction is seen in cancer patients
undergoing chemotherapy treatment. Taste and smell alteration was shown to be
associated with an increase in distress, a reduction in appetite and may be
contributing towards poor nutritional status in cancer patients. There is also some
suggestion that taste and smell alteration may continue to be an issue well after
cancer therapy has been completed. This chapter describes the findings from a
study assessing taste and smell function in a cohort of survivors of childhood
cancer. This study was published in Appetite.

8.1

Introduction

One potential side-effect of cancer therapy is reduced or altered taste and smell
function (265). Both taste and smell receptor cells rapidly turn over and are
produced from dividing basal cells (282, 283). The division mechanism is sensitive
to the effects of chemotherapy and/or radiotherapy (284). The senses of taste and
smell are integral in motivating a person’s food preferences (270, 288) and both
child and adult cancer patients commonly attribute difficulties maintaining food
intake to the altered taste developed during treatment (127, 265, 289). Altered taste

6

This chapter has been published in the following peer reviewed journal:

Cohen J, Laing DG, Wilkes FJ, Chan A, Gabriel M, Cohn RJ. Taste and smell dysfunction in
childhood cancer survivors. Appetite. 2014;75;135-40
JC & RC designed the study, JC & AC undertook data collection, JC, DL & AC contributed to
data analysis, FW provided statistical support and JC, DL, FW & RC contributed to
manuscript development
The key findings have been peer reviewed and presented by JC at ANZCHOG ASM, 2014.
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in cancer patients has also been associated with decreased energy and nutrient
intake (271), potentially leading to nutrient deficiencies (290).

Although the taste and smell receptor cells are replaced regularly over several
weeks and longer, cancer therapy can potentially lead to long term taste and smell
receptor damage. This occurs due to an alteration in the structure of the receptors or
a decrease in the number of normal receptor cells (290). Long-term taste and smell
dysfunction has been documented in the adult oncology population (182, 355).
Patients who have received radiation therapy for head and neck cancer and those
who have undergone a Hematopoietic Stem Cell Transplant (HSCT) demonstrate
taste dysfunction, after their cancer treatment, up to seven and three years
respectively. (287, 355)

Survivors of childhood cancer have been shown to have poor dietary habits (16, 17,
202) and preferences for high fat foods (153). In the general population, those with
a documented taste or smell dysfunction can alter their food intake, either by
compensating for the lack of flavour in foods with an increase in intake, or
decreasing their intake due to a lack of enjoyment of the food (271, 331). Taste
dysfunction has also been associated with obesity in both adults and children (356,
357) in the general population. The taste and smell function of childhood cancer
survivors (CCS) has not been previously assessed. If CCS are found to have a taste
or smell dysfunction this may be one factor influencing their food preferences and
dietary intake. The aim of this study was to assess smell and taste function in this
population and to determine whether this influences food preferences which could in
turn influence their dietary intake. To this end, it was hypothesised that the CCS
level of taste and smell functioning would be related to food liking scores.
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8.2

8.2.1

Methods

Study participants

Participants were CCS who were at least 5 years since cancer treatment completion
and who attended the long-term follow-up clinics for a their yearly review, at Sydney
Children’s Hospital, Randwick and the Children’s Hospital Westmead, Australia,
between July and September 2011. Participants were excluded from participation if
they were under the age of 12 years, did not speak English or were pregnant.
Participants were also excluded if they had known problems with swallowing as the
testing required participants to swallow a small amount of the tasting solutions. The
study protocol was approved by The Royal Alexandra Hospital for Children Ethics
Committee (Approval No. 11/CHW/24) and informed consent was obtained from all
participants

8.2.2

Demographics

Demographic information collected from the medical records of participants
included, age, sex, cancer diagnosis, type of treatment received, time since
treatment completion and current medications.

8.2.3

Taste identification

Taste function was assessed by the ability to identify four different tastes – sweet,
sour, salty and bitter across five different concentrations, and five samples of water.
Each participant was familiarised with the test procedure by sipping a few millilitres
of a moderate strength solution each child was familiarized with the test by being
asked to sip a solution (2–3 ml of a single sample) that was moderately sweet
(sucrose, 0.36 M; Sigma, Sydney, Australia), salty (sodium chloride, 0.18 M; BDH,
Sydney, Australia), sour (citric acid, 0.009 M; BDH) and bitter (quinine
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hydrochloride, 0.0001 M; Aldrich, Sydney, Australia), respectively, and water
(Nobles Ultra Pure Water, Sydney, Australia). Test tastant concentrations were
prepared by dissolving analytical grade sucrose (0.05, 0.08, 0.12, 0.20, 0.32 M,
Sigma, Sydney, Australia) citric acid (0.0038, 0.0062, 0.0100, 0.0159, 0.0256M
BDH, Sydney, Australia), sodium chloride (0.07, 0.11, 0.18, 0.28, 0.46 BDH) and
quinine hydrochloride (0.00009, 0.00016, 0.00026, 0.00041, 0.00065M, Aldrich,
Sydney, Australia) in purified drinking water (Nobles Ultra Pure Water, Sydney). For
each of the 25 samples, participants were presented with a small amount of tastant
solution and then asked to select one of three labelled photographs which best
described the taste they had sampled. The photographs were a pictorial
representation of the tastant. The photographs also contained the name of the three
tastants represented e.g. sweet, sour, salty, bitter or water. The assessor read out
all three names to the participant (276) before they made their choice. The 25
tastants were presented to each participant in a random order with a 20-30 second
break between the assessment of each tastant. Participants were advised to rinse
their mouth with pure water between each sample.

For each tastant, participants who identified less than four out of the five
concentrations for each individual tastant were considered to have impairment in
their ability to detect that taste (276). This criteria was established from normative
data for children (n=232) and adults (n= 56) older than five years, using the same
test procedure (276). The same criteria for taste impairment has been used with
participants with cystic fibrosis (317), chronic kidney disease (358) and healthy
school children (306).

184

8.2.4

Smell identification

Smell function was assessed by determining the ability of participants to identify 16
common odorants including Dettol™ (a common antiseptic product based on
chloroxylenol), sour, baby powder, fishy, grassy, paint, flowers, strawberry, cheesy,
petrol, spicy, onion, Vicks VapoRub™ (odour of mentholated topical cream), minty,
orange and chocolate. The 16 odorants were diluted to a total volume of 20ml with
odourless dipropylene glycol (Fluka 99% pure) and placed in individual opaque
squeeze bottles which each participant was shown how to squeeze and sniff from
the bottle (276). The participants were then presented with three labelled
photographs and asked to pick the one most representative of the smell they had
just been presented. The photographs were a pictorial representation of the odorant
combined with the name of the odorant. The test was developed not only for adults
but for use with children from five years of age (276). It was developed with children
five to nine years old (n=232) and adults (n=56). Early data indicated that children
from nine years of age performed similarly to adults (277). In addition, it has been
shown to have a test-retest reliability of 0.98 (306) indicating a high level of
reliability. A score of less than 13 out of a possible 16 (e.g. more than four smells
incorrectly identified) was defined as an olfactory impairment (276).

8.2.5

Quality of Life (QoL)

The Functional Assessment of Anorexia/Cachexia Treatment QoL scale (FAACT)
was used for participants greater than 18 years of age and the Pediatric Functional
Assessment of Anorexia Cachexia (Peds-FAACT) used for participants less than 18
years of age. These tools are validated in this population to measure health related
quality of life (359, 360) and contain an additional items section on issues relating to
anorexia/cachexia. This tool was used as a subjective measure of the severity of
food-related symptoms such as taste change and poor appetite.
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8.2.6

Food liking

A 94-item food liking questionnaire was used to elicit participant’s food preferences
(361, 362). The questionnaire required participants to rate their attitudes towards a
range of common foods on a scale of 0 to 5, with 0 = not having tried a food, 1 =
hating a food, up to 5 = loving the food. The responses were then sorted according
to 10 food groups; meat/fish, vegetarian foods other than vegetables, bakery goods,
breakfast foods, convenience foods/takeaways, dairy foods, fruit, snacks, green
vegetables/salad and other vegetables. The mean liking scores for each of the 10
categories were calculated. The higher the mean score, the more likely the food
group was “liked”. This data was then analysed to illustrate trends in participant’s
food likes.

8.2.7

Statistical analysis

Statistical analyses were performed using IBM SPSS version 19 (IBM Corp.,
Armonk, New York). Previous research in clinical and non-clinical populations using
the same taste and smell tests utilised here indicate that the majority of people
score towards the high-functioning end of the scale on both of these tests (306, 317,
319). Since the underlying distribution of these smell and taste tests are non-normal,
and the comparisons between treatment groups involved small and uneven group
sizes, non-parametric statistics were considered the most appropriate method of
analyses for the current data (363). Differences and associations were considered
significant at p<.05 (2-tailed). Bonferroni corrections were applied to alpha for all
subsequent post-hoc tests to reduce the chance of type I error (363). The specific
analyses used to examine each of the variables are described in the respective
results sections. Where Bonferroni corrections have been applied, the relevant
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adjusted alpha level is indicated alongside the reported results and significance
values.
8.3

8.3.1

Results

Demographics

Fifty-five childhood cancer survivors were approached to participate in the study of
which 51 (93%) were recruited. The mean age of the participants was 19.69 (±7.09)
years and a mean of 12.4 (±6.87) years had passed since completion of their
treatment (Table 8-1).
Table 8-1 Demographics of childhood cancer survivors
Characteristic
Sex (male:female)
Age at assessment,
Mean (SD)(range): Years
Age at diagnosis,
Mean (SD)(range): Years
Time since treatment completion
Mean (SD)(range): Years
Cancer diagnosis (n)

24:27

ALL*
AML**
Neuroblastoma
Wilms’ tumour
Rhabdomyosarcma
Lymphoma
Medulloblastoma
Ewing’s Sarcoma
Osteosarcoma
Other
Treatment (n)
Chemotherapy
Chemotherapy + Radiotherapy
Cranial Radiotherapy
Abdominal Radiotherapy
Head and Neck Radiotherapy

18
1
4
4
3
4
2
2
3
10

19.69 (7.09)(12-40)
5.27 (4.05)(0-17)
12.40 (6.87)(5-38)
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27
17
6
2
1

8
7
4

Other sites
HCST#
Total Body Irradiation

* ALL: Acute Lymphoblastic Leukaemia ** AML: Acute Myeloid Leukaemia # HSCT:
Haematopoietic stem cell transplant (HSCT)

8.3.2

Taste

Taste dysfunction was found in 14 of the 51 participants (27.5%). Of those with a
taste dysfunction, five (9.8%), eight (15.7%), four (7.8%) and six (11.8%) had a
sweet, sour, salty or bitter dysfunction, respectively. Seven participants had a
dysfunction involving one tastant only, five had a dysfunction involving two tastants
and two had a dysfunction involving three tastants. No patient had a dysfunction
involving all four tastants. A Friedman’s ANOVA test indicated the total scores for
sweet (4.47 ± 0.67), sour (4.45 ± 0.86), salty (4.61 ± 0.70), bitter (4.47 ± 0.92) and
water (4.45 ± 1.12) were not significantly different (p=0.490).

A series of Spearman’s correlation tests found no significant relationship between
taste scores and the age at diagnosis (rho= -0.078; p= 0.585) or years since
treatment completion (rho= -0.101; p=0.481). When these variables were correlated
with individual tastant scores there was a significant negative correlation between
age and bitter score (rho= -.357; p = 0.01) suggesting that as age increased
participants were less able to identify a bitter taste. No other significant results were
found. When the participants were separated into three treatment types
(chemotherapy (n=27), chemotherapy + radiotherapy (n=17), HSCT (n=7)) a
Kruskall-Wallis test indicated that there were no significant differences in total taste
scores between the treatment types. It should be noted that the power to find
differences between treatment types was limited by small group sizes, for analyses
between the three treatment types the power ranged between 0.18 and 0.34.
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8.3.3

Smell

Of the 51 participants, six participants (11.8%) were identified as having some
degree of a smell dysfunction. Two (3.9%) identified only nine of the 16 odors and
were classified as hyposmic (i.e. significant loss of smell function). Four of the
participants were slightly hyposmic with scores of 11 and 12 out of 16 respectively.
Sour and flower odorants were the least identified odorants while Vicks VapoRub™,
minty and paint were identified by all the participants (Figure 9.1).

Figure 8-1 Percentage of participants who correctly identified each odorant

A series of Spearman’s correlation tests found no significant relationship between
smell scores and age of participants (rho=-0.223; p=0.116), time since treatment
completion (rho=-0.178; p=0.211), or age at diagnosis (rho= -0.165; p=0.248). A
comparison of the smell scores between the three treatment groups (chemotherapy
(n=27), chemotherapy + radiotherapy (n=17), HSCT (n=7)) using a Kruskall-Wallis
test found a significant difference (p=0.013). Post-hoc Mann-Whitney tests indicated
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the odour identification scores for the chemotherapy-only group were significantly
higher than for the HSCT group [p=0.004; Bonferroni adjusted α= 0.0167]. Again, it
should be noted that the small group sizes limited power to find significant
differences between treatment types (power ranged 0.18 to 0.34). Of the six
participants with hyposmia, four of these received a HSCT transplant of which two
received total body irradiation (TBI) as part of their treatment. No other significant
differences were found when comparing the treatment groups.

8.3.4

Food liking

The final mean score for each food category was out of five with the higher the
score, the more likely the food was “liked” (Figure 9.2). The data showed that the
most “liked” foods were non-dairy liquids (4.0), followed by takeaway (3.84) and
snacks (3.8). The least “liked” food groups were the salads and greens (3) followed
by breakfast cereal (3.03), vegetarian food (3.14) and then vegetables (3.3).
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Figure 8-2 Mean liking scores for each food category

Spearman’s correlations indicated a significant negative correlation between smell
score and liking for snacks (rho=-0.294, p =0.036). Thus, as the smell score
decreased the liking for snacks increased. In contrast, a significant positive
correlation was found between smell score and salad/greens, (rho=0.404, p=0.003),
suggesting that as the smell score increased liking of salad/greens also increased.
Mann-Whitney tests comparing the food liking scores between those with and
without a smell dysfunction found significantly higher mean food liking scores
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(possible score out of five) for those without a smell dysfunction for dairy foods (2.90
vs. 3.56; p=0.027), fruit (2.14 vs. 3.92; p= 0.001) and salad/greens (1.61 vs. 3.19;
p= 0.0001). No significant differences or correlations were found between the food
groupings and the taste scores. The treatment group numbers were small; therefore
results should be interpreted with caution. The results of this study indicate that the
differences in food liking for those with and without a smell dysfunction along with
the above significant correlations provide partial support for the hypothesis that
smell function is related to CCS food liking.
8.3.5

Quality of life

Results from the additional concerns section of the QoL tool indicated that the
participants had no significant food related concerns (Table 8-2).

Table 8-2 Mean score for questions in additional concerns section of the
Functional Assessment of Anorexia/Cachexia Treatment QoL scale
FAACT Question

Mean ± SD*

I have a good appetite
2.80 ± 1.34
The amount I eat is sufficient to meet my
2.92 ± 1.13
needs
I am worried about my weight
1.33 ± 1.43
Most food tastes unpleasant to me
0.35 ± 0.86
I am concerned about how thin I look
0.37 ± 0.78
My interest in food drops as soon as I try
0.29 ± 0.74
to eat
I have difficulty eating rich or “heavy”
0.35 ± 0.93
foods
My family or friends are pressuring me to
0.33 ± 0.83
eat
I have been vomiting
0.12 ± 0.39
When I eat, I seem to get full quickly
0.80 ± 1.32
I have pain in my stomach area
0.29 ± 0.65
My general health is improving
2.80 ± 1.39
* Possible values: 0 = Not at all; 1 = A little bit; 2 = somewhat; 3 =
very much
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Range
0-4
0-4
0-4
0-3
0-3
0-4
0-4
0-4
0-2
0-4
0-2
0-4
Quite a bit; 4 =

For example, the mean score for the section on “food tasting bad” was rated low.
Correlation tests showed there were no significant relationships between smell and
taste function (total scores) and any food-related QoL measure.

Mann-Whitney

tests comparing the individual QoL domains between those with a taste dysfunction
and those who did not, found a significantly higher QoL score for those with a taste
dysfunction in response to “My general health is improving” (3.46 vs. 2.29 p=0.016).
There were no QoL associations found when comparing those with and without a
smell dysfunction.

8.4

Discussion

The results of this study in CCS demonstrate that 27.5% (n=14) had some degree of
taste dysfunction and 4% (n=2) had a significant smell dysfunction. There was an
absence of relationships between taste, food liking and QoL and the modest
relationship between smell dysfunction and liking for healthy foods.

The prevalence of a taste dysfunction in adult oncology patients during
chemotherapy has been reported to be as high as 40% (271) using objective
measures or 86% using subjective measures such as self-report (331). In the
paediatric oncology population, prevalence rates of a taste dysfunction do not exist
though it has been reported to be an issue during cancer therapy (127, 337). A taste
dysfunction during the more intensive paediatric HSCT has been reported to be
around 40% (319).

The findings in this study show a high prevalence of some degree of taste
dysfunction in survivors of childhood cancer. Some studies have suggested that
taste dysfunction continues well after treatment completion (182, 355) but this is the
first study to assess this in a cohort of survivors of childhood cancer. There are
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wide variations in the prevalence rates of taste dysfunction in the general
population. Taste disorders have been reported to range from 0.85% [34] to 20%
[35]. The prevalence rates have been found using a wide variety of methodology for
taste assessment and make it difficult to adequately compare findings. A relevant
comparison of our prevalence rate of a taste dysfunction of 27% (n=14) in the CCS,
is with a group of healthy, nine to 12 year old Australian children (n=432). The
group of healthy Australian children exhibited a taste loss prevalence of 10% using
the same taste test as used with the CCS and with the same criterion for defining
taste loss (277).

Accordingly, the prevalence of taste loss of CCS is higher than the general
population and is a potential undesirable outcome as a result of the cancer itself or
the treatment received. The mechanism(s) for taste loss in the present group of
cancer patients is unknown. Possible explanations include a reduction in the number
of taste and smell receptors as a result of the cytotoxic effects of treatment; changes
in the rate of turnover of receptor cells, changes induced in the structure of
receptors affecting the delivery of taste and smell molecules to taste and smell
receptors, or abnormalities in the reestablishment of synaptic connections at the end
of cancer treatment (270).

The incidence of smell dysfunction in the present study (3.9%; (n=2)) is slightly
higher than the a 1.9% found using the present 16-odour identification test with a
cohort of nine to 12 year old Australian children (277). Although the numbers are
small in this study there is the suggestion that the smell dysfunction can be
influenced by the type of treatment received. Four of the six participants who had a
smell dysfunction underwent a HSCT of whom two received TBI. This may reflect
greater and more lasting damage to the olfactory system with the more intensive
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treatment.

Further work investigating taste function may be warranted with this

group.

The results from this study indicate childhood cancer survivors appear to
“like” less healthy food groups such as flavoured beverages, takeaway and snacks
over healthier food groups such as vegetables and salad. These results are
consistent with previous research findings with childhood cancer survivors who
displayed unhealthy eating habits, such as a poor vegetable intake and a high fat
and sugar intake (16, 17, 202). Despite these findings there did not appear to be any
association with food likes and taste function. In partial support of the hypothesis,
there did appear to be some association with a smell dysfunction and a reduced
liking of dairy, fruit and salad/greens. Further work is needed to confirm whether
taste or smell dysfunction is affecting CCS’s food choices.

Whilst taste and smell function does not appear to have a key role in the long term
food likes of CCS, research suggests that treatment for malignancies may still have
an influence on food preferences through the development of food aversions. It has
been reported that the likelihood of an individual selecting a food for a second time
is related to their prior experiences (364). This may be relevant to the development
of food aversions in the setting of cancer treatment as taste and smell alterations
during the period of the disease and subsequent treatments coupled with symptoms
of nausea and vomiting may have resulted in negative experiences during feeding
(290, 339). The effect of food aversions may be even more pronounced in those
receiving treatment for cancer at very young ages as food preferences are thought
to be largely established through experiences with food in the first 3 years of life
(218)
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The results from the QoL tool indicate that this cohort have an acceptable QoL as
demonstrated by the ratings of participants which corresponded to low levels of
concern about weight and appetite. Participants did not report that “food tasted bad”
despite 27.5% (n=14) of this cohort displaying some form of taste dysfunction.
Furthermore, there was no association found between QoL scores and taste and
smell scores. Previous studies suggest that QoL is influenced by perceived level of
olfactory dysfunction rather than actual degree of dysfunction (365, 366). It may be
that a similar phenomenon occurs with taste dysfunction.

8.5

Conclusion

It is concluded that a degree of taste dysfunction occurs in pediatric long term
cancer survivors although no relationships were found between taste function and
food likes, and taste function and Qol. Future work should compare taste and smell
function of childhood cancer patients and survivors with appropriate healthy
controls. It does not appear that a smell dysfunction were as prevalent though the
incidence may be slightly higher than the general population. It is known that CCS
have undesirable food habits therefore larger prospective longitudinal studies are
needed to further understand the reasons for these poor dietary habits. Further work
is also needed to assess whether taste dysfunction plays a role in these dietary
habits.

8.5.1

Implications

The final study in the thesis provides evidence that taste and smell dysfunction is an
issue is survivors of childhood cancer. This study provides one piece of the puzzle in
determining the aetiology behind the permanent changes seen in the dietary habits
of survivors of childhood cancer. The next chapter is the final chapter in this thesis.

196

Chapter 9 provides a summary of the findings from this thesis and provides
recommendations that have implications for both clinical practice and for future
research.
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9 DISCUSSION
Over the last 50 years survival rates for children with cancer have improved. For the
majority of patients, childhood cancer is no longer considered an acute disease with
high short term morbidity and mortality, but a chronic disease with the potential for
long term poor outcomes. The goals of the medical treatment for paediatric cancer
patients is to maximise cure rates while trying to prevent the risk of long term
deleterious effects of cancer therapy. Nutritional support is an important part of the
management of paediatric oncology patients. The goal of nutritional therapy has
been to prevent under-nutrition, ensuring adequate growth and development.
Results from this thesis are providing the first evidence that the nutritional
management of paediatric cancer patients needs to change. It needs to follow the
goals of the medical treatment particularly with regard to preventing long term
deleterious effects from the cancer therapy period. Childhood cancer survivors have
inadequate nutrient intake early after treatment completion and it appears that
young childhood cancer survivors’ dietary habits do not return to what they were
pre-diagnosis, often to their detriment.

Poor nutritional intakes and obesity are

emerging as longer term problems. Clinicians may need to alter the aims of the
nutritional management of cancer patients being mindful that any decisions made
during cancer therapy may affect the nutritional intake of patients’ long term. At
present there are no effective evidence-based interventions available that aim to
improve the nutritional intake of survivors of childhood cancer.
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9.1

Summary of findings

This thesis has confirmed the central hypothesis that the nutritional management
decisions made during treatment for childhood cancer are primarily about the short
term goal of promoting an adequate energy intake to prevent under nutrition. The
research undertaken was grounded in clinical practice, using an in depth case study
of a specialist paediatric oncology clinic in Sydney, Australia. A number of separate
but related investigations took place to address specific questions (and related subhypotheses) and highlight the way forward for improved practice. The first part of the
thesis aimed to identify and articulate the problem of childhood nutrition in the
cancer acute care and survival (Figure 9-1).

Figure 9-1 Schema of hierarchy of studies used within the context of research
in practice
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9.1.1

Confirming the problem

The first part of the thesis examined the hypothesis that there is a significant
nutrition related problem in childhood cancer survivors. The first study (Chapter 3)
showed that young childhood cancer survivors did appear to have a poor dietary
intake, similar to that seen in the literature for adult survivors of childhood cancer.
Fifty-four percent of young childhood cancer survivors were consuming above their
estimated energy requirements. Fifty, 32 and 44 percent of children did not meet
requirements for folate, calcium, and iron respectively. There was a significant trend
for increasing BMI percentiles from diagnosis to time of assessment (56.29 vs.
67.17, P = 0.01). Results from the child feeding questionnaire showed that parents
were more likely to monitor and use a restrictive form of parenting to control their
child's food intake rather than pressure their child to eat (P = 0.001). This study
indicated the extent and nature of the nutritional problem in this clinical group.

The results from chapter 4 showed that the majority of parents of childhood cancer
survivors found their child’s nutritional intake changed dramatically during the active
treatment phase. This result was not unexpected as poor dietary intake during
treatment has been well document in the literature. Of concern was that some of the
dietary habits established during treatment appeared to continue once treatment
had been completed. Three main themes emerged regarding parental perceptions
of young childhood cancer survivors’ current intake as compared with their prediagnosis eating habits: (1) decreased fruit and vegetable intake, (2) increased
consumption of "junk food," and (3) increased portion sizes. The eating habits seen
in the young cancer survivors were substantively different to that described by
parents of the control group.
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Many parents also appeared to shift their concerns about their child’s weight. Prior
to their child’s cancer illness most of the parents reported their child’s weight had not
been a concern. During treatment their focus had been prevention of weight loss but
on completion of treatment their focus shifted towards concern about their child
being overweight. Although most of the children who participated in the study were
not yet considered overweight, their rising BMIs indicated that the parents’ concern
was justified. The dietary habits and higher than recommended energy intake, would
likely be one of the contributing factors in young cancer survivor’s rising BMIs. This,
in turn, will be putting them at greater risk of long term cancer side effects such as
metabolic syndrome, cardiovascular disease and obesity. This second study
qualified the nature of the problem in terms of the social context in which the
nutritional intakes become a major concern.

9.1.2

Examining practice

The second part of this thesis hypothesised that clinicians may not be accounting for
the potential long-term impact of nutrition decisions on survivors of childhood
cancer, specifically related to actual feeding practices during and following treatment
completion.

The first study in this section

(Chapter 5) involved a systematic review that

delivered a total of three studies on nutritional interventions of all childhood cancer
survivors, both adult and child. The studies were heterogeneous in regards to the
methods of the interventions and a meta-analysis was unable to be performed. One
study found an improvement in calcium intake and calcium supplementation in an
intervention in adult survivors of childhood cancer aimed at osteoporosis prevention.
The second study found that a single group intervention improved the self-reported
improvement in health food intake, though there was no improvement in self201

reported junk food intake. Overall the quality of these studies was poor, there was
no focus on improving dietary intake and none of the studies focused on young
cancer survivors early after treatment completion. The results indicated a need to
research practice in more detail.

Research done by our research team has shown that parents are using many
negative feeding practices to ensure their child consumes adequate food to prevent
under nutrition during their cancer therapy. This study also indicated that a
significant part of these negative practices involved threatening their child with
enteral tube feeding (known as instrumental feeding) if they consuming an adequate
oral intake. Long term child feeding practices and food preferences are established
when children are young and parent practices such as instrumental feeding, have
been associated with poor dietary intake in adults in the non-cancer population. As
demonstrated in the introductory review for the thesis (chapter 2), under-nutrition is
a significant issue during cancer therapy and nutritional supplementation in the form
of enteral tube feeding is an important part of this management.

The second study in this section (Chapter 6) found there appeared to be common
perceptions of the purposes and impact of ETF among patients, parents and
healthcare workers. Both positive (good nutrition, weight gain and decreased
anxiety) and negative (physical appearance, invasive insertion procedure and
comfort) aspects of EN were discussed. There were some discordant perceptions
regarding the timing and type of information provided on the use of ETF, as well as
the decision making process used. Decision making in the healthcare setting is
complex and information provision alone does not necessarily help with timely and
appropriate decisions for families. This research found that by standardizing and
improving the methods used for the commencement of ETF, family distress
surrounding the use of ETF with paediatric oncology patients may be reduced.
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9.1.3

Exploring the impact of taste and smell

The final section of this thesis hypothesised that taste and smell may be implicated
in the problem of developing healthy eating habits in childhood cancer survivors.
The first study in this section (Chapter 7) w found self-reported taste and smell
alterations are prevalent in upwards of 86% of cancer patients. There was also
some evidence for decreased taste sensitivity in cancer patients when assessed
using objective tests. In some patients, taste and smell alterations continued well
after their cancer treatment had been completed. Taste and smell alterations in
patients with cancer appeared to increase their distress, reduce appetite and
contribute towards a poor nutritional status.

In light of this review the second study in this section, and the final study in the
thesis, found that survivors of childhood cancer do have a greater incidence of taste
and smell changes, compared to the general population. Twenty-seven percent of
survivors of childhood cancer had some form of smell dysfunction. This was
considerably higher than the 10% of smell dysfunction reported in the literature for
the general population, using similar methods of assessment. The incidence of smell
dysfunction was 10% of the cancer survivors studied which again is higher than the
one to two percent smell dysfunction reported in the general population. The child
cancer survivors' appeared to "like" the less healthy food groups such as flavoured
beverages, takeaway and snacks over healthier food groups such as vegetables
and salad. No correlation was found between those with a taste dysfunction and
their food "likes". Thus it appears that taste and smell may contribute substantially to
the problem of assuring adequate nutrition in childhood cancer and survival, and
further research is warranted in this area.
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9.2

Limitations

As stated earlier, this thesis is presented as a case study of clinical practice in a
defined setting. The data collected for these studies, focused on a specialist
paediatric oncology site in Sydney, Australia With the exception of study 8 which
recruited participants across two paediatric oncology units within Sydney, Australia,
all the data were collected from this site. The demographics of the participants in
this thesis may not be representative of the childhood cancer population within
Australia and internationally, especially those from developing countries. Further
case studies, such as the one conducted here would add to this knowledge. In
addition the studies conducted in the thesis can be repeated with a wider
demographic representation of childhood cancer patients.

From a methods perspective, the response rate for both the dietary intake study
and the enteral feeding study were low. This may relate to the use of mail-out
surveys to recruit the participants or due to the burden of using three-day food
diaries to collect dietary intake data (367). Since the completion of the dietary intake
study, a food frequency questionnaire (FFQ), the Australian Child and Adolescent
Eating Survey (ACAES), has been validated for use among Australian children and
adults (368). There is a lower responder burden associated with the

FFQ has

compared with food records (367) and its use in future studies may improve
response rates. The ACAES provides a measure of both nutrient intake and food
variety scores. Food variety scores are positively associated with good health
outcomes (369). This is advantageous for determining which food groups may need
targeting in future interventions (369). Recent literature has shown that multiple 24hour recalls may be more accurate in determining energy intake than FFQs in
survivors of childhood cancer. For future interventions, in which weight loss and
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subsequently energy intake, is the primary outcome, 24 hour recalls could be used
as a measure of dietary intake.

The empirical component of the thesis involved discrete primary data collection and
analysis (Chapters 3, 4, and 8) which employed a cross-sectional study design. As
discussed in chapter one, a cross-sectional study limits the ability to determine a
causal relationship (370) . Using a cross-sectional methodology does provide an
assessment of the prevalence of the outcome and information for the generation of
hypothesis on causal relationships (33). The results from the cross-sectional studies
in this thesis have provided evidence of the need for a focus on the nutritional intake
of childhood cancer survivors early off treatment. It has also provided targets for
intervention in this patient cohort. Future studies could assess the changing dietary
patterns during treatment and into survival using a prospective longitudinal study
design. This will also provide the researchers with the opportunity to assess the
mechanism involved with this permanent change in dietary habits.

9.3

Conclusions

As childhood cancer is no longer an acute condition with poor outcomes and high
morbidity and mortality, it should be treated as a chronic condition. The results from
my research confirm my hypothesis that dietary habits of childhood cancer patients
developed during cancer therapy are continuing once treatment has completed. In
addition, the poor dietary intake seen in adult survivors of childhood cancer is likely
manifesting itself early after treatment completion. There now needs to be greater
awareness of the link between the nutrition decisions made during the cancer
therapy and how they may be affecting the child’s nutritional intake well after cancer
therapy is completed. At the very least, nutritional interventions to improve the
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dietary habits of survivors of childhood cancer need to be initiated soon after
treatment completion. Ideally a focus on long-term healthy dietary habits may need
to occur during cancer therapy.

9.4

Implications for clinical practice

This research was grounded in changing clinical practice. The following
recommendations are for dietitians and clinicians working with childhood cancer
patients:

9.4.1

Models of care

The current standard of dietetic care in paediatric oncology is to provide funding for
a dietitian to see patients during the acute phase of cancer therapy. This thesis
highlights the need for the health service to recognise that paediatric oncology no
longer just about treating disease but is about health protection. Paediatric oncology
centres should be considering enhancing funding models for the provision of longterm dietetic follow-up as part of standard care. Medical conditions such as cystic
fibrosis and type I diabetes are considered chronic conditions and their care model
provides significant funding for a dietitian to review and manage patients on a
regular basis. Cancer centres may need to utilise the same model of care as other
such chronic paediatric diseases, providing regular nutritional assessment and
follow-up to paediatric cancer patients once treatment is complete.

The referral criteria for nutritional interventions may need to be altered. The current
model is reactive, where referrals are made to a deititian once weight loss or a
reduction in oral intake is seen in the patient. This model is used because the
current funding model is not adequate to allow all patients to be assessed early in
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their cancer journey. This thesis provides early evidence that the poor dietary habits
and parenting practices seen during treatment are continuing once therapy is
completed. This has implications for survivors who are at a high risk of early-onset
chronic health conditions. The dietetics model should be changed to a proactive
model in which all patients are counselled on good nutritional practices early on in
their cancer journey.

9.4.2

Dietetic practice

As the prevention or treatment of under-nutrition has been the focus of the dietary
management of childhood cancer patients, recommendations for nutritional support
have been based on increasing the energy intake of a patient’s diet. This has been
to the detriment of good nutritional practices. The mantra of “eat whatever you like”
has been recited among both dietitians and clinicians for many years. In light of the
shift towards childhood cancer being considered a chronic disease, these practices
need to also change. Dietitians should no longer focus on improving a patient’s
energy intake in isolation. Parents and carers should be counselled on the use of
healthy high energy diets in combination with maintaining intake as close to the
dietary guidelines as possible.

Dietitians could consider providing education and counselling to parents and
patients on using positive feeding practices to encourage their child to consume an
adequate intake during their child’s cancer treatment. The constant pressure to get a
child to consume an adequate intake may be causing long term issues with food
aversions. Parents should avoid using the threat of the insertion of a nasogastric
tube to get their child to eat. Parents and clinicians need to view nasogastric tube
insertion as part of standard practice of care rather than something that is used as a
last resort. The practice of prophylactic nasogastric tube insertion may reduce
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parental stress surrounding their child’s food intake, thereby potentially avoiding
these negative feeding practices. If a child has a nasogastric tube in to ensure an
adequate nutritional status is maintained throughout treatment then parents may feel
more comfortable encouraging a healthy diet when their child does eat. Constant
exposure to a greater food variety on treatment has the potential to improve the
dietary habits of childhood cancer patients once their treatment is complete.

9.4.3

Food service

At present, the meals and snacks provided to the patients in the hospital
environment, do not necessarily reflect good nutritional practices. Many of the foods
are heavily processed, the vegetables are inedible, and the mid-meal snacks
provided include items such as chocolate and sweet biscuits, high sugar yoghurts
and flavoured milks and high sugar muffins. In light of the results from the thesis, a
review of the food service system in paediatric oncology units is required. The foods
provided to the patients, especially mid-meal snacks should complement the
education regarding healthy high energy foods. The snacks should be low in
saturated fat and sugar but high in energy and provide other nutritional benefits. The
paediatric oncology unit currently provides patients and families with fruit for
consumption, and could consider providing vegetables as well. This may encourage
families to cook healthier meals to provide to their child when an inpatient. Funding
for a nutrition assistant could also allow cooking demonstrations on the wards to
also encourage childhood cancer patients to have a positive relationship with food.

Commercially prepared oral nutritional supplements and some of the supplements
used for enteral tube feeding may not represent good nutritional practices. Many of
the oral supplements are very high in sugar to help with palatability, but if used as a
sole source of nutrition, are likely increasing the patient’s intake of sugar above that
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recommended in the dietary guidelines. The use of commercially prepared
supplements is an important part of dietetic practice to provide the patient with
additional energy and nutrients. To enable a continuation with the practice of using a
healthy high energy diet to prevent weight loss, the nutritional supplements should
reflect this. The paediatric oncology unit could provide blenders and high energy
healthy drink recipes for the parents to make for their children while they are an
inpatient. Use of healthy high energy drinks provides an opportunity for the patient
to consume a greater amount of fruit and vegetables in an easy to consume format.

Although consumption of non-processed food is preferable, supplying freshly
cooked meals and snacks to patients in the hospital may not be practical. Parents
have a limited capacity to cook meals due to the time constraints involved with
looking after a sick child as well as a lack of resources available in the hospital to
cook for their child. Many patients also find it difficult to consume hot meals due to a
hypersensitivity to smells. Many families rely on highly processed packaged food to
ensure their child consumes an adequate energy intake though these foods don’t
usually provide any other nutrients. Clinicians and dietitians could partner with the
food industry to develop more appropriate snacks which are not only high in energy
and palatable but be based on fruit and vegetables as a way to reinforce this
concept of healthy high energy.

9.4.4

Dietetic education

Childhood cancer is not the only paediatric condition in which improvements in
treatment have meant that diseases which were once associated with early mortality
are now considered chronic disease. Clinicians who work with paediatric patients
with conditions such as Cystic Fibrosis, renal disease and HIV are also finding their
patients are at a higher risk of chronic disease, such as cardiovascular disease, than
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their peers. Dietitians are also becoming aware of the importance of promoting good
nutritional practices (not just high energy) in young patients with these conditions
and are starting to change their practice accordingly. Clinical based nutrition
research should not only focus on nutrient intake but food variety and dietetic
education given to the patient should reflect this.

The education of dietetic students must also start to reflect this change in dietetic
practice. Many students are still being educated on the use of commercially
prepared snacks and supplements as well as sugar-sweetened beverages as the
first line of dietetic practice. Although these will still remain an important part of
dietetic practice they should not be considered the first option in dietetic practice.
Dietetic students should be educated in providing and trialling food based
recommendations with their patients first, before the use of commercially snacks
and supplements.

9.5

Directions of future research

A number of research questions have been proposed as a result of this thesis and
have provided a focus for nutritional interventions for young cancer survivors early
after treatment completion. Our research team has commenced the development of
an intervention (ReBoot-kids) which aims to improve fruit and vegetable intake and
reduce non-core food intake in young cancer survivors early after their treatment
completion. The aim of this study is to determine whether dietary habits of childhood
cancer survivors can be improved early after treatment completion. The long-term
aim is reducing the incidence of chronic health conditions in adult survivors of
childhood cancer.
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The prevention of poor dietary habits in childhood cancer patients should ideally be
a focus during treatment. To reflect the recommendations from this thesis on the
importance of focusing on healthy high energy diet education, a need assessment
will be undertaken with parents and carers on the paediatric oncology ward, to
clarify their views on the current dietetic care model. There is a dearth of research
assessing the dietary intake of cancer patients during treatment as focus has been
on energy intake alone. An assessment of the nutritional intake of childhood cancer
patients should also be undertaken to provide targets for interventions on treatment.
The results of this research will be used to design education materials reflecting the
use of a healthy high energy diet, and to improve the food service model.

The thesis has also provided a focus for an intervention for improving the
information provision regarding nutritional support options during cancer therapy.
Results from this thesis as well as previous work completed at our centre show that
uptake of nutritional support such as ETF can be delayed. Parents are using poor
feeding practices such as forcing their child to eat to prevent their need for ETF.
These feeding practices also have the potential to cause long-term oral aversions
and poor dietary habits after treatment completion. Research has begun on
developing and pilot testing a decision aid for use with childhood cancer patients
regarding decisions on nutrition supplementation. The aim is to provide adequate
education to parents about the benefits and risks of all nutrition support options in a
timely manner. The long-term goal is to ensure parents are adequately informed
about their child’s nutrition choices. This may reduce the poor parent feeding
practices seen in this patient cohort thereby preventing poor dietary habits from
developing during and after cancer therapy.
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The results from this thesis will inform a longitudinal study assessing the change in
childhood cancer patient’s dietary habits during their cancer therapy and beyond.
The longitudinal study will focus on assessing nutrient intake, food variety and
dietary habits of childhood cancer patients. This study will also assess potential
predictors and of the changing dietary habits and intake. Such predictors will
include:
•

Taste and smell changes

•

Parental feeding practices

•

Development of learned aversions

•

Lack of repeated exposure

•

Change in appetite regulation

The longitudinal study will aim to confirm the hypothesis generated from this thesis
that the dietary habits of childhood cancer patients permanently change as a result
of their cancer therapy. A secondary aim will be to determine the aetiology and
predictors of the change in dietary habits. The results from the longitudinal study will
then drive future dietary interventions for children while on cancer therapy with the
long-term aim to reduce their risk of long-term metabolic conditions associated with
survivors of childhood cancer.

I hope that results from this thesis combined with future research on dietary habits
and dietary practice will ensure that survivors of childhood cancer will have a QoL
equal, if not better than their peers.

212

REFERENCES
1.

Butterworth CEJ. The Skeleton in the Hospital Closet. Nutr Today.
1974;9(2):4-8.

2.

Filler RM, Jaffe N, Cassady JR, Traggis DG, Das JB. Parenteral nutritional
support in children with cancer. Cancer. 1977;39(6):2665-9.

3.

Van Eys J. Malnutrition in children with cancer: incidence and consequence.
Cancer. 1979;43(5 Suppl):2030-5.

4.

Ladas EJ, Sacks N, Meacham L, Henry D, Enriquez L, Lowry G, et al. A
multidisciplinary review of nutrition considerations in the pediatric oncology
population: a perspective from children's oncology group. Nut Clin Pract.
2005;20(4):377-93.

5.

Bowman LC, Williams R, Sanders M, Ringwald-Smith K, Baker D, Gajjar A.
Algorithm for nutritional support: Experience of the Metabolic and Infusion
Support Service of St. Jude children's Research Hospital. Inter J Cancer.
1998:76-80.

6.

Andrassy RJ, Chwals WJ. Nutritional support of the pediatric oncology
patient. Nutrition. 1998;14(1):124-9.

7.

Bauer J, Jurgens H, Fruhwald MC. Important aspects of nutrition in children
with cancer. Adv Nutr. 2011;2(2):67-77.

8.

Rickard KA, Coates TD, Grosfeld JL, Weetman RM, Baehner RL. The value
of nutrition support in children with cancer. Cancer. 1986;58(8 Suppl):190410.

9.

Gaynor EP, Sullivan PB. Nutritional status and nutritional management in
children with cancer. Arch Dis Child. 2015:100: 1169.

10.

Kestler SA, LoBiondo-Wood G. Review of symptom experiences in children
and adolescents with cancer. Cancer Nurs. 2012;35(2):E31-49.
213

11.

Skolin I, Hursti U-KK, Wahlin YB. Parents' perception of their child's food
intake after the start of chemotherapy. J Pediatr Oncol Nurs. 2001;18(3):12436.

12.

Rickard KA, Grosfeld JL, Coates TD, Weetman R, Baehner RL. Advances in
nutrition care of children with neoplastic diseases: a review of treatment,
research, and application. J Am Diet Assoc. 1986;86(12):1666-76.

13.

Gerhardt CA, Baughcum AE, Johnston A, Vannatta K, Hobart Davies W,
Mackner LM, et al. Parent perceptions of nutritional issues during their child's
treatment for cancer. J Pediatr Hematol Oncol. 2006;28(7):454-60.

14.

Mauer AM, Burgess JB, Donaldson SS, Rickard KA, Stallings VA, van Eys J,
et al. Special nutritional needs of children with malignancies: a review. JPEN
J Parenter Enteral Nutr. 1990;14(3):315-24.

15.

Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows
AT, et al. Chronic health conditions in adult survivors of childhood cancer. N
Engl J Med. 2006;355(15):1572-82.

16.

Demark-Wahnefried W, Werner C, Clipp EC, Guill AB, Bonner M, Jones LW,
et al. Survivors of childhood cancer and their guardians. Cancer.
2005;103(10):2171-80.

17.

Robien K, Ness KK, Klesges LM, Baker KS, Gurney JG. Poor adherence to
dietary guidelines among adult survivors of childhood acute lymphoblastic
leukemia. J Pediatr Hematol Oncol. 2008;30(11):815-22.

18.

Smith WA, Li C, Nottage KA, Mulrooney DA, Armstrong GT, Lanctot JQ, et
al. Lifestyle and metabolic syndrome in adult survivors of childhood cancer: a
report from the St. Jude Lifetime Cohort Study. Cancer. 2014;120(17):274250.

214

19.

Slawson DL, Clemens LH, Bol L. Research and the clinical dietitian:
Perceptions of the research process and preferred routes to obtaining
research skills. J Am Diet Assoc. 2000;100(10):1144-8.

20.

Eck LH, Slawson DL, Williams R, Smith K, Harmon-Clayton K, Oliver D. A
model for making outcomes research standard practice in clinical dietetics. J
Am Diet Assoc. 1998;98(4):451-7.

21.

Fink R, Thompson CJ, Bonnes D. Overcoming barriers and promoting the
use of research in practice. J Nurs Admin. 2005;35(3):121-9.

22.

Health NIo. NIH clinical research trials and you: U.S. Department of Health
and Human Services; 2015 [updated July 2015; cited 2015 22nd
September].

http://www.nih.gov/health-information/nih-clinical-research-

trials-you/basics].
23.

Barlow DH. On the relation of clinical research to clinical practice: Current
issues, new directions. J Consult Clin Psych. 1981;49(2):147.

24.

Daniel G, Wakefield CE, Ryan B, Fleming CA, Levett N, Cohn RJ.
Accommodation in pediatric oncology: parental experiences, preferences
and unmet needs. Rural Remote Health. 2013;13(2):2005.

25.

Holt A. Using the telephone for narrative interviewing: A research note. Qual
Res. 2010;10(1):113-21.

26.

Pluye P, Hong QN. Combining the power of stories and the power of
numbers: mixed methods research and mixed studies reviews. Public
Health. 2014;35(1):29.

27.

Johnson RB, Onwuegbuzie AJ, Turner LA. Toward a definition of mixed
methods research. J Mixed Meth Res. 2007;1(2):112-33.

28.

Morgan DL. Practical strategies for combining qualitative and quantitative
methods: Applications to health research. Qual Health Res. 1998;8(3):36276.
215

29.

Shneerson CL, Gale NK. Using Mixed Methods to Identify and Answer
Clinically

Relevant

Research

Questions.

Qual

Health

Res.

2015:1049732315580107.
30.

Coleman K, Norris S, Weston A, Grimmer-Somers K, Hillier S, Merlin T, et al.
NHMRC additional levels of evidence and grades for recommendations for
developers of guidelines. Canberra: NHMRC. 2005.

31.

Mann C. Observational research methods. Research design II: cohort, cross
sectional, and case-control studies. Emerg Med J. 2003;20(1):54-60.

32.

Bowen HP, Wiersema MF. Matching method to paradigm in strategy
research: Limitations of cross-sectional analysis and some methodological
alternatives. Strat Manage J. 1999;20(7):625-36.

33.

Levin KA. Study design III: Cross-sectional studies. Evidence-based
Dentistry. 2006;7(1):24-5.

34.

Swift J, Tischler V. Qualitative research in nutrition and dietetics: getting
started. J Human Nutr Diet. 2010;23(6):559-66.

35.

Harris JE, Gleason PM, Sheean PM, Boushey C, Beto JA, Bruemmer B. An
introduction to qualitative research for food and nutrition professionals. J Am
Diet Assoc. 2009;109(1):80-90.

36.

Louise Barriball K, While A. Collecting Data using a semi‐structured
interview: a discussion paper. J Advan Nurs. 1994;19(2):328-35.

37.

Torraco RJ. Writing integrative literature reviews: Guidelines and examples.
Human Resource Develop Rev. 2005;4(3):356-67.

38.

Green BN, Johnson CD, Adams A. Writing narrative literature reviews for
peer-reviewed journals: secrets of the trade. J Chiro Med. 2006;5(3):101-17.

39.

Whittemore R, Knafl K. The integrative review: updated methodology. J
Advan Nurs. 2005;52(5):546-53.

216

40.

Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best
evidence for clinical decisions. Ann Int Med. 1997;126(5):376-80.

41.

Bero L, Rennie D. The Cochrane Collaboration: preparing, maintaining, and
disseminating systematic reviews of the effects of health care. JAMA.
1995;274(24):1935-8.

42.

Jadad AR, Cook DJ, Jones A, Klassen TP, Tugwell P, Moher M, et al.
Methodology and reports of systematic reviews and meta-analyses: a
comparison of Cochrane reviews with articles published in paper-based
journals. JAMA. 1998;280(3):278-80.

43.

Australian Institute of Health and Welfare 2012. A picture of Australia’s
children 2012. Cat. no. PHE 167. Canberra: AIHW

44.

Children's Cancer Institute. Childhood cancer survival in Australia, 19952004. Viertel Centre for Research in Cancer Control, Cancer Council
Queensland and the Australian Paediatric Cancer Registry 2010.

45.

Coates TD, Rickard KA, Grosfeld JL, Weetman RM. Nutritional support of
children with neoplastic diseases. Surg Clin N Amer. 1986;66(6):1197-212.

46.

Brinksma A, Huizinga G, Sulkers E, Kamps W, Roodbol P, Tissing W.
Malnutrition in childhood cancer patients: a review on its prevalence and
possible causes. Crit Rev Oncol Hematol. 2012;83(2):249-75.

47.

Teitelbaum D, Guenter P, Howell WH, Kochevar ME, Roth J, Seidner DL.
Definition of terms, style, and conventions used in A.S.P.E.N. guidelines and
standards. Nutr Clin Pract. 2005;20(2):281-5.

48.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009.
CA: Canc J Clin. 2009;59(4):225-49.

49.

Alcoser PW, Rodgers C. Treatment strategies in childhood cancer. J Pediatr
Nurs. 2003;18(2):103-12.

217

50.

Pizzo P, Poplack D. Principles and Practice of Pediatric Oncology. 6th
Edition ed. Philadelphia Pa: Lippincott Williams & Wilkins; 2011.

51.

Bryant R. Managing side effects of childhood cancer treatment. J Pediatr
Nurs. 2003;18(2):113-25.

52.

Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and
vomiting: current and new standards in the antiemetic prophylaxis and
treatment. Eur J Cancer. 2005;41(2):199-205.

53.

Thorp N. Basic principles of paediatric radiotherapy. Clin Oncol (R Coll
Radiol). 2013;25(1):3-10.

54.

Ullrich NJ, Embry L. Neurocognitive dysfunction in survivors of childhood
brain tumors. Semin Pediatr Neurol. 2012;19(1):35-42.

55.

Packer RJ, Sutton LN, Atkins TE, Radcliffe J, Bunin GR, D'Angio G, et al. A
prospective study of cognitive function in children receiving whole-brain
radiotherapy

and

chemotherapy:

2-year

results.

J

Neurosurg.

1989;70(5):707-13.
56.

Sanders JE. Bone marrow transplantation for pediatric malignancies. Pediatr
Clin North Am. 1997;44(4):1005-20.

57.

Locatelli L, Giorgiani, G., Di-Cesare-Merlone, A., Merli, O., Sparta, V. &
Moretta, F. The changing role of stem cell transplantation in childhood. Bone
Marrow Transpl. 2008;41:S3-S7.

58.

Burgio GR, Locatelli F. Transplant of bone marrow and cord blood
hematopoietic stem cells in pediatric practice, revisited according to the
fundamental

principles

of

bioethics.

Bone

Marrow

Transpl.

1997;19(12):1163-8.
59.

Mateos MK, O'Brien TA, Oswald C, Gabriel M, Ziegler DS, Cohn RJ, et al.
Transplant-related mortality following allogeneic hematopoeitic stem cell

218

transplantation

for

pediatric

acute

lymphoblastic

leukemia:

25-year

retrospective review. Pediatr Blood Cancer. 2013;60(9):1520-7.
60.

Filipovich AH. Diagnosis and manifestations of chronic graft-versus-host
disease. Best Pract Res Clin Haematol. 2008;21(2):251-7.

61.

Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al.
National Institutes of Health consensus development project on criteria for
clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging
working group report. Biol Blood Marrow Transpl. 2005;11(12):945-56.

62.

Hastings Y, White M, Young J. Enteral nutrition and bone marrow
transplantation. J Pediatr Oncol Nurs. 2006;23(2):103-10.

63.

Langdana A, Tully N, Molloy E, Bourke B, O'Meara A. Intensive enteral
nutrition support in paediatric bone marrow transplantation. Bone Marrow
Transpl. 2001;27(7):741-6.

64.

Rodgers C. Weight gain and height velocity in young children 1 year
following bone marrow transplant: a single institution study. J Pediatr Oncol
Nurs. 2004;21(6):358-63.

65.

Sefcick A, Anderton D, Byrne JL, Teahon K, Russell NH. Naso-jejunal
feeding in allogeneic bone marrow transplant recipients: results of a pilot
study. Bone Marrow Transpl. 2001;28(12):1135-9.

66.

Szeluga DJ, Stuart RK, Brookmeyer R, Utermohlen V, Santos GW.
Nutritional support of bone marrow transplant recipients: a prospective,
randomized clinical trial comparing total parenteral nutrition to an enteral
feeding program. Cancer Res. 1987;47(12):3309-16.

67.

Weisdorf S, Hofland C, Sharp HL, Teasley K, Schissel K, McGlave PB, et al.
Total parenteral nutrition in bone marrow transplantation: a clinical
evaluation. J Pediat Gastr Nutr. 1984;3(1):95-100.

219

68.

Papadopoulou A. Nutritional considerations in children undergoing bone
marrow transplantation. Eur J Clin Nutr. 1998;52(12):863-71.

69.

Uderzo C, Rovelli A, Bonomi M, Fomia L, Pirovano L, Masera G. Total
parenteral nutrition and nutritional assessment and leukaemic children
undergoing bone marrow transplantation. Eur J Cancer. 1991;27(6):758-62.

70.

Raguso CA, Genton L, Dupertuis YM, Pichard C. Assessment of nutritional
status in organ transplant: Is transthyretin a reliable indicator? Clin Chem
Lab Med. 2002;40(12):1325-8.

71.

Taskinen M, Saarinen-Pihkala UM. Increase in height during the first year
after bone marrow transplantation reflecting nutritional status of children.
Bone Marrow Transpl. 1998;22(7):689-92.

72.

Iestra JA, Fibbe WE, Zwinderman AH, Romijn JA, Kromhout D. Parenteral
nutrition following intensive cytotoxic therapy: an exploratory study on the
need for parenteral nutrition after various treatment approaches for
haematological malignancies. Bone Marrow Transpl. 1999;23(9):933-9.

73.

Yamanaka H, Takeda E, Takata K, Syutou E, Miyamoto K, Watanabe T, et
al. Total parenteral nutrition on energy metabolism in children undergoing
autologous peripheral blood stem cell transplantation. J Med Invest.
1998;44(3-4):199-203.

74.

Papadopoulou A, Williams MD, Darbyshire PJ, Booth IW. Nutritional support
in

children

undergoing

bone

marrow

transplantation.

Clin

Nutr.

1998;17(2):57-63.
75.

Jelliffe DB. The assessment of the nutritional status of the community. World
Health Organization Monograph Series. 1966;53.

76.

Soeters PB, Reijven PLM, Bokhorst-de van der Schueren MAE, Schols
JMGA, Halfens RJG, Meijers JMM, et al. A rational approach to nutritional
assessment. Clin Nutr. 2008;27(5):706-16.
220

77.

Chopra M, Galbraith S, Darnton-Hill I. A global response to a global problem:
the epidemic of overnutrition. Bulletin of the World Health Organization.
2002;80(12):952-8.

78.

Kalm LM, Semba RD. They starved so that others be better fed:
remembering Ancel Keys and the Minnesota experiment. J Nutr.
2005;135(6):1347-52.

79.

Krehl WA. A concept of optimal nutrition. Am J Clin Nutr. 1956;4(6):634-41.

80.

Souba WW. Drug therapy - Nutritional support. N Engl J Med.
1997;336(1):41-8.

81.

Gallagher-Allred CR, Voss AC, Finn SC, McCamish MA. Malnutrition and
clinical outcomes: the case for medical nutrition therapy. J Am Diet Assoc.
1996;96(4):361-6.

82.

Norman K, Pichard C, Lochs H, Pirlich M. Prognostic impact of diseaserelated malnutrition. Clin Nutr. 2008;27(1):5-15.

83.

Mehta NM, Corkins MR, Lyman B, Malone A, Goday PS, Carney LN, et al.
Defining pediatric malnutrition: a paradigm shift toward etiology-related
definitions. JPEN J Parenter Enteral Nutr. 2013;37(4):460-81.

84.

Becker PJ, Nieman Carney L, Corkins MR, Monczka J, Smith E, Smith SE,
et

al.

Consensus

statement

of

the

Academy

of

Nutrition

and

Dietetics/American Society for Parenteral and Enteral Nutrition: indicators
recommended for the identification and documentation of pediatric
malnutrition (undernutrition). J Acad Nutr Diet. 2014;114(12):1988-2000.
85.

Smith D, Stevens M, Booth I. Malnutrition at diagnosis of malignancy in
childhood: common but mostly missed. Europ J Pediatr. 1991;150:318-22.

86.

Cole TJ, Flegal KM, Nicholls D, Jackson AA. Body mass index cut offs to
define thinness in children and adolescents: international survey. BMJ.
2007;335(7612):194.
221

87.

Waterlow JC. Classification and definition of protein-calorie malnutrition. Br
Med J. 1972;3(5826):566-9.

88.

Waterlow JC, Buzina R, Keller W, Lane JM, Nichaman MZ, Tanner JM. The
presentation and use of height and weight data for comparing the nutritional
status of groups of children under the age of 10 years. Bulletin of the World
Health Organization. 1977;55:489-98.

89.

Sacks N, Ringwald-Smith K, Hale G. Nutritional support. In: Altman AJ,
editor. Supportive Care of Children with Cancer. Baltimore and London: The
Johns Hopkins University Press; 2004. p. 243-61.

90.

Murphy AJ, White M, Davies PS. The validity of simple methods to detect
poor nutritional status in paediatric oncology patients. Br J Nutr.
2009;101(9):1388-92.

91.

Murphy AJ, White M, Davies PS. Body composition of children with cancer.
Am J Clin Nutr. 2010;92(1):55-60.

92.

White M, Davies P, Murphy A. Validation of percent body fat indicators in
pediatric oncology nutrition assessment. J Pediatr Hematol Oncol.
2008;30(2):124-9.

93.

Mosby TT, Barr RD, Pencharz PB. Nutritional Assessment of Children With
Cancer. J Pediatr Oncol Nurs. 2009;26(4):186-97.

94.

Brinksma A, Roodbol PF, Sulkers E, Hooimeijer L, Sauer PJJ, Sonderen Ev,
et al. Weight and Height in Children Newly Diagnosed With Cancer. Pediatr
Blood Cancer. 2015;62:269-73.

95.

Esbenshade AJ, Simmons JH, Koyama T, Koehler E, Whitlock JA, Friedman
DL. Body mass index and blood pressure changes over the course of
treatment of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer.
2011;56(3):372-8.

222

96.

Withycombe JS, Post-White JE, Meza JL, Hawks RG, Smith LM, Sacks N, et
al. Weight patterns in children with higher risk ALL: A report from the
Children's Oncology Group (COG) for CCG 1961. Pediatr Blood Cancer.
2009;53(7):1249-54.

97.

Brinksma A, Roodbol PF, Sulkers E, Kamps WA, de Bont ESJM, Boot AM, et
al. Changes in nutritional status in childhood cancer patients: A prospective
cohort study. Clin Nutr. 2015;34:66-73.

98.

Picton SV. Aspects of altered metabolism in children with cancer. Int J
Cancer Suppl. 1998;11:62-4.

99.

Baracos

VE.

Cancer-associated

cachexia and

underlying

biological

mechanisms. Annu Rev Nutr. 2006;26:435-61.
100.

Stephens N, Fearon K. Annorexia, cachexia and nutrition. Medicine.
2008;36(2):78-81.

101.

Tisdale MJ. Cancer anorexia and cachexia. Nutr. 2001;17(5):438-42.

102.

Fearon K, Arends J, Baracos V. Understanding the mechanisms and
treatment options in cancer cachexia. Nature Rev Clin Oncol. 2013;10(2):909.

103.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al.
Definition and classification of cancer cachexia: an international consensus.
Lancet Oncol. 2011;12(5):489-95.

104.

Jensen GL. Inflammation as the key interface of the medical and nutrition
universes: a provocative examination of the future of clinical nutrition and
medicine. J Parenter Enteral Nutr. 2006;30(5):453-63.

105.

Sala A, Pencharz P, Barr RD. Children, cancer, and nutrition - A dynamic
triangle in review. Cancer. 2004;100(4):677-87.

106.

Tisdale

MJ.

Cancer

cachexia:

manifestations. Nutr. 1997;13(1):1-7.
223

metabolic

alterations

and

clinical

107.

Baggott C, Dodd M, Kennedy C, Marina N, Miaskowski C. Multiple
symptoms in pediatric oncology patients: a systematic review. J Pediatr
Oncol Nurs. 2009;26(6):325-39.

108.

Hanigan MJ, Walter GA. Nutritional support of the child with cancer. J
Pediatr Oncol Nurs. 1992;9(3):110-8.

109.

Skolin I, Wahlin YB, Broman DA, Koivisto Hursti UK, Vikstrom Larsson M,
Hernell O. Altered food intake and taste perception in children with cancer
after start of chemotherapy: perspectives of children, parents and nurses.
Support Care Cancer. 2006;14(4):369-78.

110.

Murphy AJ, Wells JC, Williams JE, Fewtrell MS, Davies PS, Webb DK. Body
composition in children in remission from acute lymphoblastic leukemia. Am
J Clin Nutr. 2006;83(1):70-4.

111.

Hecht C, Weber M, Grote V, Daskalou E, Dell’Era L, Flynn D, et al. Disease
associated malnutrition correlates with length of hospital stay in children. Clin
Nutr. 2015;34:53-9.

112.

Sala A, Rossi E, Antillon F, Molina AL, de Maselli T, Bonilla M, et al.
Nutritional status at diagnosis is related to clinical outcomes in children and
adolescents with cancer: a perspective from Central America. Eur J Cancer.
2012;48(2):243-52.

113.

Antillon F, Rossi E, Molina AL, Sala A, Pencharz P, Valsecchi MG, et al.
Nutritional status of children during treatment for acute lymphoblastic
leukemia in Guatemala. Pediatr Blood Cancer. 2013;60(6):911-5.

114.

Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, et al.
Mortality in overweight and underweight children with acute myeloid
leukemia. JAMA. 2005;293(2):203-11.

224

115.

Loeffen EAH, Brinksma A, Miedema KGE, de Bock GH, Tissing WJE.
Clinical implications of malnutrition in childhood cancer patients—infections
and mortality. Support Care Cancer. 2015;23:143-50.

116.

Murry DJ, Riva L, Poplack DG. Impact of nutrition on pharmacokinetics of
anti-neoplastic agents. Int J Cancer Suppl. 1998;11:48-51.

117.

Schaible

UE,

Kaufmann

SH.

Malnutrition

and

infection:

complex

mechanisms and global impacts. PLoS Med. 2007;4(5):e115.
118.

Butturini AM, Dorey FJ, Lange BJ, Henry DW, Gaynon PS, Fu C, et al.
Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin
Oncol. 2007;25(15):2063-9.

119.

White M, Murphy AJ, Hallahan A, Ware RS, Fraser C, Davies PS. Survival in
overweight and underweight children undergoing hematopoietic stem cell
transplantation. Eur J Clin Nutr. 2012;66(10):1120-3.

120.

Aplenc R, Zhang MJ, Sung L, Zhu X, Ho VT, Cooke K, et al. Effect of body
mass in children with hematologic malignancies undergoing allogeneic bone
marrow transplantation. Blood. 2014;123(22):3504-11.

121.

Van Eys J. Benefits of nutritional intervention on nutritional status, quality of
life and survival. Int J Cancer Suppl. 1998;11:66-8.

122.

Ladas EJ, Sacks N, Brophy P, Rogers PC. Standards of nutritional care in
pediatric oncology: results from a nationwide survey on the standards of
practice in pediatric oncology. A Children's Oncology Group study. Pediatr
Blood Cancer. 2006;46(3):339-44.

123.

Tyc VL, Vallelunga L, Mahoney S, Smith B, Mulhern R. Nutritional and
treatment-related characteristics of pediatric oncology patients referred or
not referred for nutritional support. Med Pediatr Oncol. 1995;25(5):379-88.

225

124.

Rickard KA, Coates TD, Grosfeld JL, Weetman RM, Provisor AJ, Baehner
RL. Role of nutrition support in the management of children with cancer.
Prog Clin Biol Res. 1983;132D:179-92.

125.

Bolton J, Shannon L, Smith V, Abbott R, Bell SJ, Stubbs L, et al. Comparison
of short-term and long-term palatability of six commercially available oral
supplements. J Hum Nutr Diet. 1990;3:317-21.

126.

Green R, Horn H, Erickson JM. Eating experiences of children and
adolescents with chemotherapy-related nausea and mucositis. J Pediatr
Oncol Nurs. 2010;27(4):209-16.

127.

Skolin I, Wahlin YB, Broman DA, Koivisto Hursti U-K, Vikstrom Larsson M,
Hernell O. Altered food intake and taste perception in children with cancer
after start of chemotherapy: perspectives of children, parents and nurses.
Support Care Cancer. 2006;14(4):369-78.

128.

Holmes S. Food avoidance in patients undergoing cancer chemotherapy.
Support Care Cancer. 1993;1(6):326-30.

129.

Dovey TM, Staples PA, Gibson EL, Halford JC. Food neophobia and
‘picky/fussy’eating in children: A review. Appetite. 2008;50(2):181-93.

130.

Galloway AT, Fiorito LM, Francis LA, Birch LL. ‘Finish your soup’:
counterproductive effects of pressuring children to eat on intake and affect.
Appetite. 2006;46(3):318-23.

131.

Fleming CAK, Cohen J, Murphy A, Wakefield CE, Cohn RJ, Naumann FL.
Parent feeding interactions and practices during childhood cancer treatment.
A qualitative investigation. Appetite. 2015.

132.

Aquino VM, Smyrl CB, Hagg R, McHard KM, Prestridge L, Sandler ES.
Enteral nutritional support by gastrostomy tube in children with cancer. J
Pediatr. 1995;127(1):58-62.

226

133.

Bakish J, Hargrave D, Tariq N, Laperriere N, Rutka JT, Bouffet E. Evaluation
of dietetic intervention in children with medulloblastoma or supratentorial
primitive neuroectodermal tumors. Cancer. 2003;98(5):1014-20.

134.

den Broeder E, Lippens RJ, van't Hof MA, Tolboom JJ, van Staveren WA,
Hofman Z, et al. Effects of naso-gastric tube feeding on the nutritional status
of children with cancer. Eur J Clin Nutr. 1998;52(7):494-500.

135.

Sacks N, Hwang W-T, Lange BJ, Tan K-S, Sandler ES, Rogers PC, et al.
Proactive

enteral

tube

feeding

in

pediatric

patients

undergoing

chemotherapy. Pediatr Blood Cancer. 2014;61(2):281-5.
136.

Schmitt F, Caldari D, Corradini N, Gicquel P, Lutz P, Leclair M-D, et al.
Tolerance and efficacy of preventive gastrostomy feeding in pediatric
oncology. Pediatr Blood Cancer. 2012;59(5):874-80.

137.

Mercadante S. Parenteral versus enteral nutrition in cancer patients:
indications and practice. Support Care Cancer. 1998;6(2):85-93.

138.

Bowman LC, Williams R, Sanders M, Ringwald-Smith K, Baker D, Gajjar A.
Algorithm for nutritional support: experience of the Metabolic and Infusion
Support Service of St. Jude Children's Research Hospital. Int J Cancer
Suppl. 1998;11:76-80.

139.

Koletzko B, Goulet O, Hunt J, Krohn K, Shamir R, Parenteral Nutrition
Guidelines Working G, et al. 1. Guidelines on Paediatric Parenteral Nutrition
of the European Society of Paediatric Gastroenterology, Hepatology and
Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and
Metabolism (ESPEN), Supported by the European Society of Paediatric
Research (ESPR). Journal of Pediatric Gastroenterology & Nutrition.
2005;41 Suppl 2:S1-87.

140.

Pencharz PB. Aggressive oral, enteral or parenteral nutrition: prescriptive
decisions in children with cancer. Int J Cancer Suppl. 1998;11:73-5.
227

141.

Cohen J, Maurice L. Adequacy of nutritional support in pediatric blood and
marrow transplantation. J Pediatr Oncol Nurs. 2010;27(1):40-7.

142.

Lyman B. Metabolic complications associated with parenteral nutrition. J
Infus Nurs. 2002;25(1):36-44.

143.

Ladas EJ, Post-White J, Hawks R, Taromina K. Evidence for symptom
management in the child with cancer. J Pediatr Hematol Oncol.
2006;28(9):601-15.

144.

Jones L, Watling RM, Wilkins S, Pizer B. Nutritional support in children and
young people with cancer undergoing chemotherapy. Cochrane Database of
Systematic Reviews. 2010(7):CD003298.

145.

Montgomery K, Belongia M, Haddigan Mulberry M, Schulta C, Phillips S,
Simpson PM, et al. Perceptions of nutrition support in pediatric oncology
patients and parents. J Pediatr Oncol Nurs. 2013;30(2):90-8.

146.

Brotherton A, Abbott J, Hurley M, Aggett PJ. Home enteral tube feeding in
children following percutaneous endoscopic gastrostomy: perceptions of
parents, paediatric dietitians and paediatric nurses. J Hum Nutr Diet.
2007;20(5):431-9.

147.

Mahant S, Jovcevska V, Cohen E. Decision-making around gastrostomyfeeding in children with neurologic disabilities. Pediatr. 2011;127(6):e147181.

148.

Oeffinger KC, Hudson MM, Landier W. Survivorship: childhood cancer
survivors. Primary Care; Clinics in Office Practice. 2009;36(4):743-80.

149.

Oeffinger KC, Adams-Huet B, Victor RG, Church TS, Snell PG, Dunn AL, et
al. Insulin resistance and risk factors for cardiovascular disease in young
adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol.
2009;27(22):3698-704.

228

150.

Nathan PC, Ford JS, Henderson TO, Hudson MM, Emmons KM, Casillas
JN, et al. Health behaviors, medical care, and interventions to promote
healthy living in the Childhood Cancer Survivor Study cohort. J Clin Oncol.
2009;27(14):2363-73.

151.

Faienza MF, Delvecchio M, Giordano P, Cavallo L, Grano M, Brunetti G, et
al. Metabolic syndrome in childhood leukemia survivors: a meta-analysis.
Endocrine. 2015; 353-360

152.

Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of
the teachable moment: promoting long-term health after the diagnosis of
cancer. J Clin Oncol. 2005;23(24):5814-30.

153.

Arroyave WD, Clipp EC, Miller PE, Jones LW, Ward DS, Bonner MJ, et al.
Childhood cancer survivors' perceived barriers to improving exercise and
dietary behaviors. Oncol Nurs Forum. 2008;35(1):121-30.

154.

Dickerman JD. The late effects of childhood cancer therapy. Pediatr.
2007;119(3):554-68.

155.

Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima
TI, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a
review of published findings. J Clin Oncol. 2009;27(14):2339-55.

156.

Neville

KA,

Cohn

RJ,

Steinbeck

KS,

Johnston

K,

Walker

JL.

Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in
survivors of childhood cancer: prevalence and risk factors. J Clil Endocr
Metab. 2006;91(11):4401-7.
157.

Stolley MR, Sharp LK, Arroyo C, Ruffin C, Restrepo J, Campbell R. Design
and recruitment of the Chicago Healthy Living Study: a study of health
behaviors in a diverse cohort of adult childhood cancer survivors. Cancer.
2009;115(18 Suppl):4385-96.

229

158.

Mulhern RK, Tyc VL, Phipps S, Crom DB, Barclay D, Greenwald C, et al.
Health-related behaviours of survivors of childhood cancer. Med Pediatr
Oncol. 1995;25:159-65.

159.

Tyc VL, Hadley W, Crockett G. Prediction of health behaviors in pediatric
cancer survivors. Med Pediatr Oncol. 2001;37(1):42-6.

160.

Hudson MM, Mulrooney DA, Bowers DC, Sklar CA, Green DM, Donaldson
SS, et al. High-risk populations identified in Childhood Cancer Survivor Study
investigations: implications for risk-based surveillance. J Clin Oncol.
2009;27(14):2405-14.

161.

Aziz NM. Cancer survivorship research: challenge and opportunity. Journal
of Nutr. 2002;132(11 Suppl):3494S-503S.

162.

Bond SA, Han AM, Wootton SA, Kohler JA. Energy intake and basal
metabolic rate during maintenance chemotherapy. Arch Dis Child.
1992;67(2):229-32.

163.

Reilly JJ, Brougham M, Montgomery C, Richardson F, Kelly A, Gibson BE.
Effect of glucocorticoid therapy on energy intake in children treated for acute
lymphoblastic leukemia. J Clin Endo Metab. 2001;86(8):3742-5.

164.

Reilly JJ, Ventham JC, Ralston JM, Donaldson M, Gibson B. Reduced
energy expenditure in preobese children treated for acute lymphoblastic
leukemia. Pediatr Res. 1998;44(4):557-62.

165.

Johannsen DL, Johannsen NM, Specker BL. Influence of parents' eating
behaviors and child feeding practices on children's weight status. Obesity.
2006;14(3):431-9.

166.

Branen LJ, Fletcher JW. Comparison of older adolescent' recollections of
their current eating habits and their childhood food practices. J Nutr Educ
1999;31:304-10.

230

167.

Anzman SL, Birch LL. Low inhibitory control and restrictive feeding practices
predict weight outcomes. J Pediatr. 2009;155(5):651-6.

168.

Anzman SL, Rollins BY, Birch LL. Parental influence on children's early
eating environments and obesity risk: implications for prevention. Int J Obes
(Lond). 2010;34(7):1116-24.

169.

Constanzo PR, Woody EZ. Domain-specific parenting styles and their impact
on the child's development of particular deviance: the example of obesity
proneness. J Soc Clinic Psych. 1985;4:425-45.

170.

Daniels SR. The Use of BMI in the Clinical Setting. Pediatr. 2009;124:S35S41.

171.

Birch LL, Fisher JO, Grimm-Thomas K, Markey CN, Sawyer R, Johnson SL.
Confirmatory factor analysis of the Child Feeding Questionnaire: a measure
of parental attitudes, beliefs and practices about child feeding and obesity
proneness. Appetite. 2001;36(3):201-10.

172.

Thompson FE, Byers T. Dietary assessment resource manual. Journal of
Nutr. 1994;124(11 Suppl):2245S-317S.

173.

National Health and Medical Research Council. Nutrient reference values for
Australia and New Zealand including recommended dietary intakes.
Canberra: Australian Government, Department of Health and Ageing; 2005.

174.

Schofield WN. Predicting basal metabolic rate, new standards and review of
previous work. Hum Nutr - Clin Nutr. 1985;39 Suppl 1:5-41.

175.

Mayer EI, Reuter M, Dopfer RE, Ranke MB. Energy expenditure, energy
intake and prevalence of obesity after therapy for acute lymphoblastic
leukemia during childhood. Hormone Res. 2000;53(4):193-9.

176.

Nathan PC, Jovcevska V, Ness KK, Mammone D'Agostino N, Staneland P,
Urbach SL, et al. The prevalence of overweight and obesity in pediatric
survivors of cancer. J Pediatr. 2006;149(4):518-25.
231

177.

Garmey EG, Liu Q, Sklar CA, Meacham LR, Mertens AC, Stovall MA, et al.
Longitudinal changes in obesity and body mass index among adult survivors
of childhood acute lymphoblastic leukemia: a report from the Childhood
Cancer Survivor Study. J Clin Oncol. 2008;26(28):4639-45.

178.

Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ. Obesity in
pediatric oncology. Pediatr Blood Cancer. 2005;45(7):881-91.

179.

Brouwer CAJ, Gietema JA, Kamps WA, de Vries EGE, Postma A. Changes
in body composition after childhood cancer treatment: impact on future
health status--a review. Crit Rev Oncol Hematol. 2007;63(1):32-46.

180.

Collins L, Nayiager T, Doring N, Kennedy C, Webber C, Halton J, et al.
Nutritional status at diagnosis in children with cancer I. An assessment by
dietary recall--compared with body mass index and body composition
measured by dual energy X-ray absorptiometry. J Pediatr Hematol Oncol.
2010;32(8):e299-303.

181.

Goran MI. Metabolic precursors and effects of obesity in children: a decade
of progress, 1990-1999. Am J Clin Nutr. 2001;73(2):158-71.

182.

Epstein LH, Myers MD, Raynor HA, Saelens BE. Treatment of pediatric
obesity. Pediatr. 1998;101(3 Pt 2):554-70.

183.

Reilly JJ, Ventham JC, Newell J, Aitchison T, Wallace WH, Gibson BE. Risk
factors for excess weight gain in children treated for acute lymphoblastic
leukaemia. Int J Obes Relat Metab Disord. 2000;24(11):1537-41.

184.

Commonwealth Scientific Industrial Research Organisation. 2007 Australian
National Children’s Nutrition and Physical Activity Survey- Main Findings. In:
Department of Health and Ageing, editor.: Australian Government; 2007.

185.

Warner JT, Bell W, Webb DK, Gregory JW. Daily energy expenditure and
physical activity in survivors of childhood malignancy. Pediatr Res.
1998;43(5):607-13.
232

186.

Cox CL, Montgomery M, Oeffinger KC, Leisenring W, Zeltzer L, Whitton JA,
et al. Promoting physical activity in childhood cancer survivors: results from
the Childhood Cancer Survivor Study. Cancer. 2009;115(3):642-54.

187.

Florin TA, Fryer GE, Miyoshi T, Weitzman M, Mertens AC, Hudson MM, et
al. Physical inactivity in adult survivors of childhood acute lymphoblastic
leukemia: a report from the childhood cancer survivor study. Cancer Epidem
Biomark Prevent. 2007;16(7):1356-63.

188.

Ventham JC, Reilly JJ. Childhood leukaemia: a model of pre-obesity. Proc
Nutr Soc. 1999;58(2):277-81.

189.

Winter C, Muller C, Hoffmann C, Boos J, Rosenbaum D. Physical activity
and childhood cancer. Pediatr Blood Cancer.54(4):501-10.

190.

Warner JT, Evans WD, Webb DK, Bell W, Gregory JW. Relative osteopenia
after treatment for acute lymphoblastic leukemia. Pediatr Res. 1999;45(4 Pt
1):544-51.

191.

Wasilewski-Masker K, Kaste SC, Hudson MM, Esiashvili N, Mattano LA,
Meacham LR. Bone mineral density deficits in survivors of childhood cancer:
long-term follow-up guidelines and review of the literature. Pediatr.
2008;121(3):e705-13.

192.

Branca F, Valtuena S. Calcium, physical activity and bone health--building
bones for a stronger future. Public Health Nutr. 2001;4(1A):117-23.

193.

Dhonukshe-Rutten RAM, de Vries JHM, de Bree A, van der Put N, van
Staveren WA, de Groot LCPGM. Dietary intake and status of folate and
vitamin B12 and their association with homocysteine and cardiovascular
disease in European populations. Eur J Clin Nutr. 2009;63(1):18-30.

194.

Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in
disease processes. Mol Genet Metab. 2000;71(1-2):121-38.

233

195.

Grant M, Kravits K. Symptoms and their impact on nutrition. Sem Oncol
Nurs. 2000;16(2):113-21.

196.

Barr RD. Nutrition, cancer, and children. Nutr. 2002;18(5):434-5.

197.

Clark HR, Goyder E, Bissell P, Blank L, Peters J. How do parents' childfeeding behaviours influence child weight? Implications for childhood obesity
policy. J Public Health. 2007;29(2):132-41.

198.

Birch LL. Development of food acceptance patterns in the first years of life.
Proc Nutr Soc. 1998;57(4):617-24.

199.

Birch LL. Psychological influences on the childhood diet. J Nutr. 1998;128(2
Suppl):407S-10S.

200.

Birch LL, Fisher JO. Development of eating behaviors among children and
adolescents. Pediatrics. 1998;101(3 Pt 2):539-49.

201.

Klesges RC, Stein RJ, Eck LH, Isbell TR, Klesges LM. Parental influence on
food selection in young children and its relationships to childhood
obesity.[Erratum appears in Am J Clin Nutr 1991 Dec;54(6):iv]. Am J Clin
Nutr. 1991;53(4):859-64.

202.

Cohen J, Wakefield CE, Fleming CAK, Gawthorne R, Tapsell LC, Cohn RJ.
Dietary intake after treatment in child cancer survivors. Pediatr Blood
Cancer. 2012;58(5):752-7.

203.

Moore LC, Harris CV, Bradlyn AS. Exploring the relationship between
parental concern and the management of childhood obesity. Mat Child
Health J. 2012;16(4):902-8.

204.

Miles MB, Huberman AM, editors. Qualitative data analysis: An expanded
sourcebook. 2nd ed. London: Sage; 1994.

205.

Denzin JM, Lincoln TS. Handbook of qualitative research. London: Sage
Publications; 1994.

234

206.

Hruschka DJ, Schwartz D, St, Picone-Decaro E, Jenkins RA, Carey JW.
Reliability in Coding Open-Ended Data: Lessons Learned from HIV Behav
Res. Field Methods. 2004;16(3):307-31.

207.

Sankar P, Wolpe PR, Jones NL, Cho M. How do women decide? Accepting
or declining BRCA1/2 testing in a nationwide clinical sample in the United
States. Community Genetics. 2006;9(2):78-86.

208.

National Health and Medical Research Council. Eat for Health; Austrlian
Dietary Guidelines. In: Ageing DoHa, editor. Canberra 2013.

209.

Mattes RD, Curran WJ, Jr., Alavi J, Powlis W, Whittington R. Clinical
implications of learned food aversions in patients with cancer treated with
chemotherapy or radiation therapy. Cancer. 1992;70(1):192-200.

210.

Schwartz MD, Jacobsen PB, Bovbjerg DH. Role of nausea in the
development of aversions to a beverage paired with chemotherapy treatment
in cancer patients. Physiol Behav. 1996;59(4-5):659-63.

211.

Yavuzsen T, Walsh D, Davis MP, Kirkova J, Jin T, LeGrand S, et al.
Components of the anorexia-cachexia syndrome: gastrointestinal symptom
correlates of cancer anorexia. Support Care Cancer. 2009;17(12):1531-41.

212.

Cox CL, McLaughlin RA, Rai SN, Steen BD, Hudson MM. Adolescent
survivors: a secondary analysis of a clinical trial targeting behavior change.
Pediatr Blood Cancer. 2005;45(2):144-54.

213.

Ness KK, Leisenring WM, Huang S, Hudson MM, Gurney JG, Whelan K, et
al. Predictors of inactive lifestyle among adult survivors of childhood cancer:
a

report

from

the

Childhood

Cancer

Survivor

Study.

Cancer.

2009;115(9):1984-94.
214.

Friedman DL, Freyer DR, Levitt GA. Models of care for survivors of
childhood cancer. Pediatr Blood Cancer. 2006;46(2):159-68.

235

215.

Landier W, Wallace WHB, Hudson MM. Long‐term follow‐up of pediatric
cancer survivors: Education, surveillance, and screening. Pediatr Blood
Cancer. 2006;46(2):149-58.

216.

Steinberger J, Sinaiko AR, Kelly AS, Leisenring WM, Steffen LM, Goodman
P, et al. Cardiovascular risk and insulin resistance in childhood cancer
survivors. J Pediatr. 2012;160(3):494-9.

217.

Stolley MR, Restrepo J, Sharp LK. Diet and physical activity in childhood
cancer

survivors:

a

review

of

the

literature.

Annal

Behav

Med.

2010;39(3):232-49.
218.

Skinner R, Wallace WHB, Levitt GA, Group UKCsCSGLE. Long-term followup of people who have survived cancer during childhood. Lancet Oncol.
2006;7(6):489-98.

219.

Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M,
et al. Cardiac outcomes in a cohort of adult survivors of childhood and
adolescent cancer: retrospective analysis of the Childhood Cancer Survivor
Study cohort. BMJ. 2009;339.

220.

Pereira MA, Kottke TE, Jordan C, O'Connor PJ, Pronk NP, Carreon R.
Preventing and managing cardiometabolic risk: the logic for intervention.
International J Enviro Res Public Health. 2009;6(10):2568-84.

221.

Oeffinger KC, Nathan PC, Kremer LCM. Challenges after curative treatment
for childhood cancer and long-term follow up of survivors. Pediatr Clin North
Am. 2008;55(1):251-73.

222.

Siviero-Miachon AA, Spinola-Castro AM, Guerra-Junior G. Detection of
metabolic syndrome features among childhood cancer survivors: a target to
prevent disease. Vasc Health Risk Manag. 2008;4(4):825-36.

223.

Lakka TA, Laaksonen DE. Physical activity in prevention and treatment of
the metabolic syndrome. Applied Physiol Nutr, Metab. 2007;32(1):76-88.
236

224.

Tota-Maharaj R, Defilippis AP, Blumenthal RS, Blaha MJ. A practical
approach to the metabolic syndrome: review of current concepts and
management. Curr Opin Cardiol. 2010;25(5):502-12.

225.

Rees K, Dyakova M, Ward K, Thorogood M, Brunner E. Dietary advice for
reducing cardiovascular risk. Cochrane Database Syst Rev. 2013;3.

226.

Oude Luttikhuis H, Baur L, Jansen H, Shrewsbury VA, O'Malley C, Stolk RP,
et al. Interventions for treating obesity in children. Cochrane Database of
Syst Rev. 2009(1):CD001872.

227.

Emond A, Emmett P, Steer C, Golding J. Feeding symptoms, dietary
patterns, and growth in young children with autism spectrum disorders.
Pediatrics. 2010;126(2):e337-42.

228.

Kuhn DE, Matson JL. Assessment of feeding and mealtime behavior
problems in persons with mental retardation. Behav Modif. 2004;28(5):63848.

229.

Lewis E, Kritzinger A. Parental experiences of feeding problems in their
infants with Down syndrome. Down Syn: Res Pract. 2004;9(2):45-52.

230.

Braam KI, van der Torre P, Takken T, Veening MA, van Dulmen‐den
Broeder E, Kaspers GJ. Physical exercise training interventions for children
and young adults during and after treatment for childhood cancer. The
Cochrane Library. 2013.

231.

Jones L, Watling RM, Wilkins S, Pizer B. Nutritional support in children and
young people with cancer undergoing chemotherapy. The Cochrane Library.
2010.

232.

Rai SN, Hudson MM, McCammon E, Carbone L, Tylavsky F, Smith K, et al.
Implementing an intervention to improve bone mineral density in survivors of
childhood acute lymphoblastic leukemia: BONEII, a prospective placebo-

237

controlled double-blind randomized interventional longitudinal study design.
Contemp Clin Trials. 2008;29(5):711-9.
233.

Hudson MM, Tyc VL, Jayawardene DA, Gattuso J, Quargnenti A, Greenwald
C, et al. Feasibility of implementing health promotion interventions to
improve health‐related quality of life. Int J Cancer. 1999;83(S12):138-42.

234.

Hudson MM, Tyc VL, Srivastava DK, Gattuso J, Quargnenti A, Crom DB, et
al. Multi-component behavioral intervention to promote health protective
behaviors in childhood cancer survivors: the protect study. Medic Pediatr
Oncol. 2002;39(1):2-1

235.

Mays D, Gerfen E, Mosher RB, Shad AT, Tercyak KP. Validation of a milk
consumption stage of change algorithm among adolescent survivors of
childhood cancer. J Nutr Educ Behav. 2012;44(5):464-8.

236.

Moyer-Mileur LJ, Ransdell L, Bruggers CS. Fitness of children with standardrisk acute lymphoblastic leukemia during maintenance therapy: response to
a home-based exercise and nutrition program. J Pediatr Hematol Oncol.
2009;31(4):259-66.

237.

Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ.
What is “quality of evidence” and why is it important to clinicians? BMJ.
2008;336(7651):995-8.

238.

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et
al. GRADE: an emerging consensus on rating quality of evidence and
strength of recommendations. BMJ. 2008;336(7650):924-6.

239.

Higgins J. Green S. Cochrane handbook for systematic reviews of
interventions version 5.1. 0. The Cochrane Collaboration. 2011;5(0).

240.

Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the
median, range, and the size of a sample. BMC Med Res Method. 2005;5:13.

238

241.

Mays D, Black JD, Mosher RB, Heinly A, Shad AT, Tercyak KP. Efficacy of
the Survivor Health and Resilience Education (SHARE) program to improve
bone health behaviors among adolescent survivors of childhood cancer.
Annals of Behav Med. 2011;42(1):91-8.

242.

Zelen M. The randomization and stratification of patients to clinical trials. J
Chronic Dis. 1974;27(7-8):365-75.

243.

Cohen J, Laing DG, Wilkes FJ, Chan A, Gabriel M, Cohn RJ. Taste and
smell dysfunction in childhood cancer survivors. Appetite. 2014;75:135-40.

244.

Sala A, Pencharz P, Barr RD. Children, cancer, and nutrition--A dynamic
triangle in review. Cancer. 2004;100(4):677-87.

245.

Deswarte-Wallace J, Firouzbakhsh S, Finklestein JZ. Using research to
change practice: enteral feedings for pediatric oncology patients. J Pediatr
Oncol Nurs. 2001;18(5):217-23.

246.

Pietsch JB, Ford C, Whitlock JA. Nasogastric tube feedings in children with
high-risk cancer: a pilot study. J Pediatr Hematol Oncol. 1999;21(2):111-4.

247.

Keller HH, Vesnaver E, Davidson B, Allard J, Laporte M, Bernier P, et al.
Providing quality nutrition care in acute care hospitals: perspectives of
nutrition care personnel. J Hum Nutr Diet. 2014;27(2):192-202.

248.

Tappenden KA, Quatrara B, Parkhurst ML, Malone AM, Fanjiang G, Ziegler
TR. Critical role of nutrition in improving quality of care: an interdisciplinary
call to action to address adult hospital malnutrition. J Acad Nutr Diet.
2013;113(9):1219-37.

249.

Brotherton A, Abbott J. Clinical decision making and the provision of
information in PEG feeding: an exploration of patients and their carers'
perceptions. J Hum Nutr Diet. 2009;22(4):302-9.

239

250.

Huang X, O’Connor M, Ke L-S, Lee S. Ethical and methodological issues in
qualitative health research involving children: A systematic review. Nurs
Ethics. 2014.

251.

Brotherton A, Abbott J, Aggett P. The impact of percutaneous endoscopic
gastrostomy feeding upon daily life in adults. J Hum Nutr Diet.
2006;19(5):355-67.

252.

Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision
aids for people facing health treatment or screening decisions. Cochrane
Database of Syst Rev. 2014(1).

253.

Epstein RM, Alper BS, Quill TE. Communicating evidence for participatory
decision making. JAMA. 2004;291(19):2359-66.

254.

Parker TM, Johnston DL. Parental perceptions of being told their child has

cancer. Pediatr Blood Cancer. 2008;51(4):531-4.
255.

Wakefield CE, Butow P, Fleming CAK, Daniel G, Cohn RJ. Family
information needs at childhood cancer treatment completion. Pediatr Blood
Cancer. 2012;58(4):621-6.

256.

Eden OB, Black I, MacKinlay GA, Emery AE. Communication with parents of
children with cancer. Pall Med. 1994;8(2):105-14.

257.

Hoffmann TC, Légaré F, Simmons MB, McNamara K, McCaffery K, Trevena
LJ, et al. Shared decision making: what do clinicians need to know and why
should they bother? MJA. 2014;201(1):35-9.

258.

Godolphin W. Shared decision-making. Healthcare Quarterly. 2009;12(Sp).

259.

Peate M, Watts K, Wakefield CE. The 'value' of values clarification in cancerrelated decision aids. Patient Educ Couns. 2013;90(2):281-3.
260.

O'Connor AM, Wennberg JE, Legare F, Llewellyn-Thomas HA,

Moulton BW, Sepucha KR, et al. Toward the 'tipping point': decision aids and
informed patient choice. Health Affairs. 2007;26(3):716-25.
240

261.

Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, et al.
Decision aids for people facing health treatment or screening decisions.
Cochrane Database of Syst Rev. 2011(10):CD001431.

262.

Mitchell SL, Tetroe J, O'Connor AM. A decision aid for long-term tube
feeding in cognitively impaired older persons. J Am Geriatr Soc.
2001;49(3):313-6.

263.

McCarthy M, Glick R, Green J, Plummer K, Peters K, Johnsey L, et al.
Comfort First: an evaluation of a procedural pain management programme
for children with cancer. Psychooncol. 2013;22(4):775-82.

264.

Mason M. Sample Size and Saturation in PhD Studies Using Qualitative
Interviews. Qual Soc Res. 2010;11(3).

265.

Comeau TB, Epstein JB, Migas C. Taste and smell dysfunction in patients
receiving chemotherapy: a review of current knowledge. Support Care
Cancer. 2001;9(8):575-80.

266.

Ravasco P. Aspects of taste and compliance in patients with cancer. Eur J
Oncol Nurs. 2005;9 Suppl 2:S84-91.

267.

Doty RL, Shaman P, Dann M. Development of the University of
Pennsylvania Smell Identification Test: A Standardized Microencapsulated
Test of Olfactory Function. Physiol Behav. 1984;32:489-502.

268.

Mueller C, Kallert S, Renner B, Stiassny K, Temmel AF, Hummel T, et al.
Quantitative assessment of gustatory function in a clinical context using
impregnated "taste strips". Rhinol. 2003;41(1):2-6.

269.

Sorensen LB, Moller P, Flint A, Martens M, Raben A. Effect of sensory
perception of foods on appetite and food intake: a review of studies on
humans. Int J Obes Relat Metab Disord. 2003;27(10):1152-66.

241

270.

Mattes RD, Cowart BJ, Schiavo MA, Arnold C, Garrison B, Kare MR, et al.
Dietary evaluation of patients with smell and/or taste disorders. Am J Clin
Nutr. 1990;51(2):233-40.

271.

Sanchez-Lara K, Sosa-Sanchez R, Green-Renner D, Rodriguez C, Laviano
A, Motola-Kuba D, et al. Influence of taste disorders on dietary behaviors in
cancer patients under chemotherapy. Nutr J. 2010;9:15.

272.

Hutton JL, Baracos VE, Wismer WV. Chemosensory dysfunction is a primar
factor in the evolution of declining nutritional status and quality of life in
patients with advance cancer. J Pain Symptom Manage. 2007;33(2):156-65.

273.

Spielman AI. Chemosensory function and dysfunction. Crit Rev Oral Biol
Med. 1998;9(3):267-91.

274.

Hovan AJ, Williams PM, Stevenson-Moore P, Wahlin YB, Ohrn KE, Elting
LS, et al. A systematic review of dysgeusia induced by cancer therapies.
Support Care Cancer. 2010;18(8):1081-7.

275.

Laing DG, Schaal B. Chemosensory function in infants and children. In:
Welge-Luessen A, Hummel T, editors. Management of Smell and Taste
Disorders. Stuttgart, Germany: George Thieme Verlag; 2014. p. 116-25.

276.

Laing DG, Segovia C, Fark T, Laing ON, Jinks AL, Nikolaus J, et al. Tests for
screening

olfactory

and

gustatory

function

in

school-age

children.

Otolaryngology - Head Neck Surg. 2008;139(1):74-82.
277.

Laing DG, Wilkes FJ, Underwood N, Tran L. Taste disorders in australian
aboriginal and non-aboriginal children. Acta Paaediatricia. 2011;100:126771.

278.

Pribitkin E, Rosenthal MD, Cowart BJ. Prevalence and causes of severe
taste loss in a chemosensory clinic population. Ann Otolo, Rhinol Laryngol.
2003;112(11):971-8.

242

279.

Vennemann MM, Hummel T, Berger K. The association between smoking
and smell and taste impairment in the general population. J Neurol.
2008;255(8):1121-6.

280.

McLaughlin L, Mahon S. A meta-analysis of the relationship among impaired
taste and treatment, treatment type, and tumor site in head and neck cancer
treatment survivors. Oncol Nurs Forum. 2014;41(3):E194-202.

281.

Boltong A, Keast R. Chemosensory Science in the Context of Cancer
Treatment: Implications for Patient Care. Chemosens Percep. 2015;
Published online 22nd May.

282.

Graziadei PP. Cell dynamics in the olfactory mucosa. Tissue Cell.
1973;5(1):113-31.

283.

Roper SD. The cell biology of vertebrate taste receptors. Ann Review
Neuroscience. 1989;12:329-53.

284.

Wickham RS, Rehwaldt M, Kefer C, Shott S, Abbas K, Glynn-Tucker E, et al.
Taste changes experiences by patients receiving chemotherapy. Oncol Nurs
Forum. 1999;26(4):697-706.

285.

Reilly CM, Bruner DW, Mitchell SA, Minasian LM, Basch E, Dueck AC, et al.
A literature synthesis of symptom prevalence and severity in persons
receiving active cancer treatment. Support Care Cancer. 2013;21(6):152550.

286.

Bozzetti F. Nutritional support of the oncology patient. Crit Rev Oncol
Hematol. 2013;87(2):172-200.

287.

Epstein JB, Barasch A. Taste disorders in cancer patients: pathogenesis,
and approach to assessment and management. Oral Oncol. 2010;46(2):7781.

288.

Drewnowski A. Taste preferences and food intake. Ann Rev Nutr.
1997;17:237-53.
243

289.

Wismer WV. Assessing alterations in taste and their impact on cancer care.
Curr. 2008;2(4):282-7.

290.

Hong JH, Omur-Ozbek P, Stanek BT, Dietrich AM, Duncan SE, Lee YW, et
al. Taste and odor abnormalities in cancer patients. J Support Oncol.
2009;7(2):58-65.

291.

Schiffman SS. Critical illness and changes in sensory perception. Proc Nutr
Soc. 2007;66(3):331-45.

292.

Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al.
Guidance on the conduct of narrative synthesis in systematic reviews. In:
Institute for Health Research UoL, editor. Lancaster2006.

293.

Epstein JB, Phillips N, Parry J, Epstein MS, Nevill T, Stevenson-Moore P.
Quality of life, taste, olfactory and oral function following high-dose
chemotherapy and allogeneic hematopoietic cell transplantation. Bone
Marrow Transpl. 2002;30(11):785-92.

294.

Nelson G, Chandrashekar J, Hoon MA, Feng L, Zhao G, Ryba NJ, et al. An
amino-acid taste receptor. Nature. 2002;416(6877):199-202.

295.

Satoh-Kuriwada S, Kawai M, Iikubo M, Sekine-Hayakawa Y, Shoji N,
Uneyama H, et al. Development of an umami taste sensitivity test and its
clinical use. PLoS ONE. 2014;9(4):e95177.

296.

Keast RS, Costanzo A. Is fat the sixth taste primary? Evidence and
implications. Flavour. 2015;4(1):5.

297.

Beidler LM, Smallman RL. Renewal of cells within taste buds. The J Cell
Biol. 1965;27(2):263-72.

298.

Heckmann JG, Heckmann SM, Lang CJ, Hummel T. Neurological aspects of
taste disorders. Arch Neurol. 2003;60(5):667-71.

299.

Gamper EM, Giesinger JM, Oberguggenberger A, Kemmler G, Wintner LM,
Gattringer K, et al. Taste alterations in breast and gynaecological cancer
244

patients receiving chemotherapy: prevalence, course of severity, and quality
of life correlates. Acta Oncol. 2012;51(4):490-6.
300.

Ackerman BH, Kasbekar N. Disturbances of taste and smell induced by
drugs. Pharmacotherapy. 1997;17(3):482-96.

301.

McLaughlin L, Mahon SM. Understanding taste dysfunction in patients with
cancer. Clin J Oncol Nurs. 2012;16(2):171-8.

302.

Gamper EM, Zabernigg A, Wintner LM, Giesinger JM, Oberguggenberger A,
Kemmler G, et al. Coming to your senses: detecting taste and smell
alterations in chemotherapy patients. A systematic review. J Pain Symptom
Manage. 2012;44(6):880-95.

303.

Lobb B, Elliffe DM, Stillman JA. Reliability of electrogustometry for the
estimation of taste thresholds. Clin Otolaryngol Allied Sci. 2000;25(6):531-4.

304.

Ikeda M, Tomita H. Clinical Assessment of Taste Disorders and Evaluation
of Zinc Therapy. In: Kurihara K, Suzuki N, Ogawa H, editors. Olfaction and
Taste XI: Springer Japan; 1994. p. 565-7.

305.

Stillman JA, Morton RP, Hay KD, Ahmad Z, Goldsmith D. Electrogustometry:
strengths, weaknesses, and clinical evidence of stimulus boundaries. Clin
Otolaryngol Allied Sci. 2003;28(5):406-10.

306.

Armstrong JE, Laing DG, Wilkes FJ, Laing ON. Olfactory function in
Australian aboriginal children and chronic otitis media. Chem Senses.
2008;33(6):503-7.

307.

Satoh-Kuriwada S, Kawai M, Noriakishoji., Sekine Y, Uneyama H,
SasanoTakashi. Assessment of Umami Taste Sensitivity. J Nutr Food
Sciences. 2012;S10.

308.

Bartoshuk LM. Chemosensory alterations and cancer therapies. NCI
Monographs. 1990;9:179-84.

245

309.

Bernhardson BM, Tishelman C, Rutqvist LE. Olfactory changes among
patients receiving chemotherapy. Eur J Oncol Nurs. 2009;13(1):9-15.

310.

Frank RA, Dulay MF, Gesteland RC. Assessment of the Sniff Magnitude
Test as a clinical test of olfactory function. Physiol Behav. 2003;78(2):195204.

311.

Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin' sticks': olfactory
performance assessed by the combined testing of odor identification, odor
discrimination and olfactory threshold. Chem Senses. 1997;22(1):39-52.

312.

Krantz EM, Schubert CR, Dalton DS, Zhong W, Huang GH, Klein BE, et al.
Test-retest reliability of the San Diego Odor Identification Test and
comparison with the brief smell identification test. Chem Senses.
2009;34(5):435-40.

313.

Cain WS, Rabin MD. Comparability of two tests of olfactory functioning.
Chem Senses. 1989;14(4):479-85.

314.

Doty RL. Office procedures for quantitative assessment of olfactory function.
Am J Rhinol. 2007;21(4):460-73.

315.

Doty RL, McKeown DA, Lee WW, Shaman P. A Study of the Test-retest
Reliability of Ten Olfactory Tests. Chem Senses. 1995;20:645-56.

316.

Schriever VA, Mori E, Petters W, Boerner C, Smitka M, Hummel T. The
"Sniffin' Kids" test--a 14-item odor identification test for children. PLoS ONE.
2014;9(6):e101086.

317.

Laing DG, Armstrong JE, Aitken M, Alistair C, Wilkes FJ, Jinks AL, et al.
Chemosensory function and food preferences of children with cystic fibrosis.
Pediatr Pulmonol. 2010;45:807-15.

318.

Berteretche MV, Dalix AM, d'Ornano AM, Bellisle F, Khayat D, Faurion A.
Decreased taste sensitivity in cancer patients under chemotherapy. Support
Care Cancer. 2004;12(8):571-6.
246

319.

Cohen J, Laing DG, Wilkes FJ. Taste and smell function in pediatric blood
and marrow transplant patients. Support Care Cancer. 2012;20(11):3019-23.

320.

Ovesen L, Sorensen M, Hannibal J, Allingstrup L. Electrical taste detection
thresholds and chemical smell detection thresholds in patients with cancer.
Cancer. 1991;68(10):2260-5.

321.

Steinbach S, Hummel T, Bohner C, Berktold S, Hundt W, Kriner M, et al.
Qualitative and quantitative assessment of taste and smell changes in
patients undergoing chemotherapy for breast cancer or gynecologic
malignancies. J Clin Oncol. 2009;27(11):1899-905.

322.

Steinbach S, Hundt W, Zahnert T, Berktold S, Bohner C, Gottschalk N, et al.
Gustatory and olfactory function in breast cancer patients. Support Care
Cancer. 2010;18(6):707-13.

323.

Strasser F, Demmer R, Bohme C, Schmitz SF, Thuerlimann B, Cerny T, et
al. Prevention of docetaxel- or paclitaxel-associated taste alterations in
cancer patients with oral glutamine: a randomized, placebo-controlled,
double-blind study. Oncologist. 2008;13(3):337-46.

324.

Steinbach S, Hundt W, Schmalfeldt B, Bohner C, Berktold S, Wolf P, et al.
Effect of platinum-containing chemotherapy on olfactory, gustatory, and
hearing function in ovarian cancer patients. Arch Gynecol Obstet.
2012;286(2):473-80.

325.

Nishijima S, Yanase T, Tsuneki I, Tamura M, Kurabayashi T. Examination of
the taste disorder associated with gynecological cancer chemotherapy.
Gynecol Oncol. 2013;131(3):674-8.

326.

Caputo JB, Campos SS, Pereira SM, Castelo PM, Gaviao MB, Marques LS,
et al. Masticatory performance and taste perception in patients submitted to
cancer treatment. J Oral Rehabil. 2012;39(12):905-13.

247

327.

Joussain P, Giboreau A, Fontas M, Laville M, Hummel T, Souquet PJ, et al.
Cisplatin chemotherapy induces odor perception changes in bronchial
cancer patients. Lung Cancer. 2013;82(1):168-70.

328.

Yakirevitch A, Talmi YP, Baram Y, Weitzen R, Pfeffer MR. Effects of cisplatin
on olfactory function in cancer patients. Br J Cancer. 2005;92(9):1611-3.

329.

Bernhardson B-M, Tishelman C, Rutqvist LE. Self-reported taste and smell
changes

during

cancer

chemotherapy.

Support

Care

Cancer.

2008;16(3):275-83.
330.

Brisbois TD, de Kock IH, Watanabe SM, Baracos VE, Wismer WV.
Characterization of chemosensory alterations in advanced cancer reveals
specific chemosensory phenotypes impacting dietary intake and quality of
life. J Pain Symptom Manage. 2011;41(4):673-83.

331.

Hutton JL, Baracos VE, Wismer WV. Chemosensory dysfunction is a primary
factor in the evolution of declining nutritional status and quality of life in
patients with advanced cancer. J Pain Symptom Manage. 2007;33(2):15665.

332.

McGreevy J, Orrevall Y, Belqaid K, Wismer W, Tishelman C, Bernhardson
BM. Characteristics of taste and smell alterations reported by patients after
starting treatment for lung cancer. Support Care Cancer. 2014;22(10):263544.

333.

Bernhardson BM, Tishelman C, Rutqvist LE. Self-reported taste and smell
changes

during

cancer

chemotherapy.

Support

Care

Cancer.

2008;16(3):275-83.
334.

Zabernigg A, Gamper EM, Giesinger JM, Rumpold G, Kemmler G, Gattringer
K, et al. Taste alterations in cancer patients receiving chemotherapy: a
neglected side effect? Oncologist. 2010;15(8):913-20.

248

335.

Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brunner N, Nauntofte B.
Oral mucosal lesions, microbial changes, and taste disturbances induced by
adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 2008;106(2):217-26.

336.

Wickham RS, Rehwaldt M, Kefer C, Shott S, Abbas K, Glynn-Tucker E, et al.
Taste changes experienced by patients receiving chemotherapy. Oncol Nurs
Forum. 1999;26(4):697-706.

337.

Barale K, Aker SN, Martinsen CS. Primary taste thresholds in children with
leukemia undergoing marrow transplantation. J Parenter Enteral Nutr.
1982;6(4):287-90.

338.

Mattsson J, Westin S, Edlund S, Remberger M. Poor oral nutrition after
allogeneic stem cell transplantation correlates significantly with severe graftversus-host disease. Bone Marrow Transpl. 2006;38(9):629-33.

339.

Boltong A, Keast R. The influence of chemotherapy on taste perception and
food hedonics: a systematic review. Cancer Treat Rev. 2012;38(2):152-63.

340.

Rehwaldt M, Wickham R, Purl S, Tariman J, Blendowski C, Shott S, et al.
Self-care strategies to cope with taste changes after chemotherapy. Oncol
Nurs Forum. 2009;36(2):E47-56.

341.

Bernhardson BM, Tishelman C, Rutqvist LE. Chemosensory changes
experienced by patients undergoing cancer chemotherapy: a qualitative
interview study. J Pain Symptom Manage. 2007;34(4):403-12.

342.

Bernhardson BM, Tishelman C, Rutqvist LE. Taste and smell changes in
patients receiving cancer chemotherapy: distress, impact on daily life, and
self-care strategies. Cancer Nurs. 2009;32(1):45-54.

343.

Yagi T, Asakawa A, Ueda H, Ikeda S, Miyawaki S, Inui A. The role of zinc in
the treatment of taste disorders. Recent Pat Food Nutr Agric. 2013;5(1):4451.
249

344.

Nagraj SK, Naresh S, Srinivas K, Renjith George P, Shrestha A, Levenson
D, et al. Interventions for the management of taste disturbances. Cochrane
Database of Syst Rev. 2014;11:CD010470.

345.

Lyckholm L, Heddinger SP, Parker G, Coyne PJ, Ramakrishnan V, Smith TJ,
et al. A randomized, placebo controlled trial of oral zinc for chemotherapyrelated taste and smell disorders. J Pain Pall Care Pharmacother.
2012;26(2):111-4.

346.

Gaurav K, Goel R, Shukla M, Pandey M. Glutamine: A novel approach to
chemotherapy-induced toxicity. Ind J Med Paediatr Oncol. 2012;33(1):13-20.

347.

Kramer

JL.

Medical

marijuana

for

cancer.

CA:

a

Cancer

J

Clinicians.65(2):109-22.
348.

Wilken MK, Satiroff BA. Pilot study of "miracle fruit" to improve food
palatability for patients receiving chemotherapy. Clin J Oncol Nurs.
2012;16(5):E173-7.

349.

Bernhardson BM, Olson K, Baracos VE, Wismer WV. Reframing eating
during chemotherapy in cancer patients with chemosensory alterations. Eur
J Oncol Nurs. 2012;16(5):483-90.

350.

Bernhardson B-M, Tishelman C, Rutqvist LE. Chemosensory changes
experienced by patients undergoing cancer chemotherapy: a qualitative
interview study. J Pain Symptom Manage. 2007;34(4):403-12.

351.

Schiffman SS, Sattely-Miller EA, Taylor EL, Graham BG, Landerman LR,
Zervakis J, et al. Combination of flavor enhancement and chemosensory
education improves nutritional status in older cancer patients. J Nutr Health
Aging. 2007;11(5):439-54.

352.

Cohen J, Wakefield C, Tapsell L, Walton K, Fleming C, Cohn R. Exploring
the views of parents regarding dietary habits of their
young cancer-surviving children. Support Care Cancer. 2015;23(2):463-71.
250

353.

Boltong A, Keast R, Aranda S. Experiences and consequences of altered
taste, flavour and food hedonics during chemotherapy treatment. Support
Care Cancer. 2012;20(11):2765-74.

354.

Boltong A, Keast RS, Aranda SK. A matter of taste: making the distinction
between taste and flavor is essential for improving management of
dysgeusia. Support Care Cancer. 2011;19(4):441-2.

355.

Boer CC, Correa MEP, Miranda ECM, de Souza CA. Taste disorders and
oral evaluation in patients undergoing allogenic hematopoietic SCT. Bone
Marrow Transplant. 2010;45:705-11.

356.

Overberg J, Hummel T, Krude H, Wiegand S. Differences in taste sensitivity
between obese and non-obese children and adolescents. Arch Dis Child.
2012;97(12):1048-52.

357.

Donaldson LF, Bennett L, Baic S, Melichar JK. Taste and weight: is there a
link? Am J Clin Nutr. 2009;90(3):800S-3S.

358.

Armstrong JE, Laing DG, Wilkes FJ, Kainer G. Smell and taste function in
children with chronic kidney disease. Pediatric Nephrology. 2010;25(8):1497504.

359.

Lai J-S, Cella D, Peterman A, Barocas J, Goldman S. Anorexia/cachexiarelated quality of life for children with cancer. Cancer. 2005;104(7):1531-9.

360.

Chang

VT,

Xia

Q,

Kasimis

B.

The

Functional

Assessment

of

Anorexia/Cachexia Therapy (FAACT) Appetite Scale in Veteran Cancer
Patients. J Support Oncol. 2005;3(5):377-82.
361.

Nicklaus S, Boggio V, Chabanet C, Issanchou S. A prospective study of food
preferences in childhood. Food Quality and Preference. 2004;15:805-18.

362.

Wardle J, Sanderson S, Leigh Gibson E, Rapoport L. Factor-analytic
structure of food preferences in four-year-old children in the UK. Appetite.
2001;37(3):217-23.
251

363.

Sheskin DJ. Handbook of parametric and nonparametric statistical
procedures. 5th ed. Florida: Boca Raton:Chapman and Hall/CRC; 2011.

364.

de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA.
Long-term quality of life of patients with head and neck cancer.
Laryngoscope. 2000;110(1):98-106.

365.

Landis BN, Scheibe M, Weber C, Berger R, Bramerson A, Bende M, et al.
Chemosensory interaction: acquired olfactory impairment is associated with
decreased taste function. J Neurol. 2010;257(8):1303-8.

366.

Lim SS, Norman RJ, Clifton PM, Noakes M. Hyperandrogenemia,
psychological distress, and food cravings in young women. Physiol Behav.
2009;98(3):276-80.

367.

Thompson FE, Subar AF, Coulston A, Boushey C. Dietary assessment
methodology. Nutr Prevent Treat Dis. 2008;2:3-39.

368.

Watson JF, Collins CE, Sibbritt DW, Dibley MJ, Garg ML. Reproducibility and
comparative validity of a food frequency questionnaire for Australian children
and adolescents. Int J Behav Nutr Phys Act. 2009;6:62

369.

Hodgson JM, Hsu‐Hage BHH, Wahlqvist ML. Food variety as a quantitative
descriptor of food intake. Ecol Food Nutr. 1994;32(3-4):137-48.

370.

Hill CW, Hansen GS. A longitudinal study of the cause and consequences of
changes in diversification in the US pharmaceutical industry 1977–1986.
Strat Manag J. 1991;12(3):187-99.

252

APPENDIX A – CHILD FEEDING QUESTIONNAIRE

253

254

255

256

257

APPENDIX B – 3 DAY FOOD DIARY

Parental Attitudes to Nutrition Study
3-day food diary
Instructions
1.
2.
3.
4.
5.
6.

Pick three days to keep your child’s food diary-one of these days should be 1 weekend and 2 weekdays
Do not change your child’s eating habits during this time
Record everything your child eats and drinks over those three days
Please be as accurate as possible including brands, amounts (weighed if possible) and how it was cooked.
Please indicate if the food is made at home or is bought at a store
Try and include individual ingredients i.e. a ham sandwich is 2 slices white bread & 2 slices of primo ham & 1 tsp margarine
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Example
Meal

Time

Breakfast
Breakfast
Recess
Recess

6.15am
6.15am
10.30am
10.30am

Lunch
Lunch
Lunch
Lunch
Afternoon Tea
Afternoon tea
Dinner
Dinner
Dinner
Dinner

12.10pm
12.10pm
12.10pm
12.10pm
3.30pm
3.30pm
6.30pm
6.30pm
6.30pm
6.30pm

Food Item
Rice bubbles
Shape milk
UncleTobys muesli bar
Orange
Juice-freshly
squeezed
White bread
Tomato
Cheese
Lettuce
Apple-Granny Smith
Chips-salt & vinegar
Lamb chop-grilled
Broccoli-boiled
Carrots-steamed
Chips-fried-McCain
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Serving Size
½ cup
½ cup
1 bar
200ml
2 slices
4 slices
1 Kraft cheese slice
1 leaf cos lettuce
1 small
25g packet
2 x 60g
3 rosettes (30g)
¼ cup
½ cup

Extras (salt, mayo etc
2 tsp sugar

2 tsp margarine

2 tsp tomato sauce

Name:_______________________________________
Date:________________
Meal

Time

Day

Food Item
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of

Week:__________________________________

Serving Size

Extras (salt, mayo etc

Name:_______________________________________
Date:________________
Meal

Time

Day

Food Item
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of

Week:__________________________________

Serving Size

Extras (salt, mayo etc

Name:_______________________________________
Date:________________
Meal

Time

Day

Food Item

262

of

Week:__________________________________

Serving Size

Extras (salt, mayo etc

Name:_______________________________________
Date:________________
Meal

Time

Day

Food Item
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of

Week:__________________________________

Serving Size

Extras (salt, mayo etc

Name:_______________________________________
Date:________________
Meal

Time

Day

Food Item

264

of

Week:__________________________________

Serving Size

Extras (salt, mayo etc

Name:_______________________________________
Date:________________
Meal

Time

Day

Food Item
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of

Week:__________________________________

Serving Size

Extras (salt, mayo etc

APPENDIX C – ETHICS APPROVAL LETTER (CHAPTER 3 & 4)
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APPENDIX D – SEARCH STRATEGY FOR COCHRANE CENTRAL REGISTER OF
CONTROLLED TRIALS (CENTRAL)
1. For Population the following text words were used:

(infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies
OR neonat* OR child OR child* OR schoolchild* OR schoolchild OR school child OR school
child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen* OR boy* OR girl*
OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar*
OR puberty OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR
pediatric* OR paediatric* OR peadiatric* OR schools OR nursery school* OR preschool* OR
pre school* OR primary school* OR secondary school* OR elementary school* OR
elementary school OR high school* OR highschool* OR school age OR schoolage OR
school age* OR schoolage* OR infancy OR young adult OR young adults OR young adult*)

AND (post treatment OR off treatment OR treatment complet* OR treatment termin* OR
follow up OR follow-up OR followup OR survivor OR survivors OR Long-Term Survivors OR
Long Term Survivors OR Long-Term survivor OR survivo* OR surviving)

2. For Nutrition the following text words were used:

patient education OR practice guideline OR practice guidelines OR dietary guideline OR
dietary guidelines OR practice guideline* OR dietary guideline* OR diet OR diets OR diet*
OR diets* OR dietetic OR dietetics OR diet therapy OR health diet OR healthy food OR
health promoting behaviour OR health promoting behaviour OR (diet* AND intervent*) OR
(diet* AND advic*) OR diet* AND counsel* OR (diet* AND therap*) OR (diet* AND
treatment*) OR (diet* AND educat*) OR (nutriti* AND intervent*) OR (nutriti* AND advice*)
OR (nutriti* AND counsel*) OR (nutriti* AND therap*) OR (nutriti* AND treatment*) OR
(nutriti* AND educat*) OR (nutriti* AND support) OR supportive therapy
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3. For Outcome the following text words were used:

food OR foods OR food* OR foods* OR food intake OR eating OR ingestion OR nutrition OR
nutrition* OR (health* AND diet*) OR (health* AND food*) OR energy intake OR caloric
intake OR kilojoule OR kilojoules OR calorie OR calori* OR caloric restriction OR vitamin OR
vitamins OR vitamin* OR minerals OR minerals* OR mineral OR mineral* OR micro-nutrient
OR micro-nutrients OR macro-nutrient OR macro-nutrients OR nutrient OR nutrients OR
calcium OR folate OR folic acid OR iron OR ferric OR ferrous OR protein OR proteins OR fat
intake OR fat reduced OR dietary fat restriction OR low fat OR low calorie OR low energy
OR reduced energy OR calorie controlled OR fatty foods OR high fat OR fruit OR fruits OR
vegetable

OR

vegetables

OR dietary composition OR carbohydrate

intake

OR

obesity OR obese OR adiposity OR body weight OR overweight OR body mass index OR
BMI OR body mass OR body fat distribution OR body composition OR “bioelectrical
impedance analysis” OR health behavior OR health behaviors OR health behaviour OR
health behaviours OR health behaviour* OR health behaviour* OR health promotion OR
behaviour change OR behavior change OR behaviour change* OR behavior change* OR
health behaviour change OR health behavior change OR helath behaviour change* OR
health behavior change* OR life style OR life style* OR weight gain OR weight gains OR
weight gain* OR body weight OR weight loss OR weight change OR weight changes OR
weight change* OR overnutrition OR overeating OR hyperphagia OR Metabolic syndrome
OR Waist hip ratio OR Waist height ratio OR Skinfold thickness OR Skinfold thicknesses OR
Skinfold thickness* OR DEXA OR Diabetes OR type 2 diabetes OR glucose metabolism OR
insulin metabolism OR insulin resistance OR hyperinsulinemia OR hyperinsulinaemia OR
cardiomyopathy OR myocardial Infarction OR fat metabolism OR cardiovascular risk factor
OR cardiovascular risk factors OR cardiovascular risk factor* OR cardiovascular disease OR
cardiovascular diseases OR blood pressure OR hypertension OR blood lipid OR blood lipids
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OR blood lipid* OR hyperlipidemia OR hyperlipidaemia OR dyslipidemia OR dyslipidaemia
OR cholesterol metabolism OR hypercholesterolemia OR osteoporosis OR bone mineral
density OR dual energy x-ray absorptiometry OR malnutrition OR undernutrition OR
Nutritional Deficiency OR Nutritional Deficiencies OR ideal body weight OR body image OR
eating disorder OR eating disorders OR eating disorder* OR disordered eating OR fussy
eating OR food refusal OR quality of life OR QoL

4. For Cancer the following text words were used:

cancer OR oncology OR oncolog* OR neoplasms OR neoplas* OR carcinoma OR carcinom*
OR tumor OR tumour OR tumor* OR tumour* OR cancer* OR malignan* OR
hematooncological OR hemato oncological OR hemato-oncological OR hematologic
neoplasms OR hematolo* OR bone marrow transplantation OR bone marrow transplant* OR
leukemia OR leukaemia OR lymphoma

The

search

was

performed

in

Final search 1 and 2 and 3 and 4

[* = zero to many characters]
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title,

abstract

or

keywords

APPENDIX E – SEARCH STRATEGY FOR MEDLINE (PUBMED)
1. For Population the following MeSH headings and text words were used:

(infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies
OR neonat* OR perinat* OR postnat* OR child OR child* OR schoolchild* OR schoolchild
OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles*
OR teen* OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil*
OR youth* OR kindergar* OR puberty OR puber* OR pubescen* OR prepubescen* OR
prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR
nursery school* OR preschool* OR pre school* OR primary school* OR secondary school*
OR elementary school* OR elementary school OR high school* OR highschool* OR school
age OR schoolage OR school age* OR schoolage* OR infancy OR schools, nursery OR
infant, newborn OR young adult[mh] OR adult[mh] OR young adult)

AND (post treatment OR off treatment OR treatment complet* OR treatment termin* OR
follow up OR follow-up OR followup OR survivor OR survivors OR Long-Term Survivors OR
Long Term Survivors OR Long-Term survivor OR Survivor, Long-Term OR Survivors, LongTerm OR survivo* OR surviving)

2. For Nutrition the following MeSH headings and text words were used:

patient education OR practice guideline OR practice guidelines OR dietary guideline OR
dietary guidelines OR practice guideline* OR dietary guideline* OR diet OR diets OR diet*
OR diets* OR dietetic OR dietetics OR diet therapy OR health diet OR healthy food OR
health promoting behaviour OR health promoting behaviour OR (diet* AND intervent*) OR
(diet* AND advic*) OR diet* AND counsel* OR (diet* AND therap*) OR (diet* AND
treatment*) OR (diet* AND educat*) OR (nutriti* AND intervent*) OR (nutriti* AND advice*)
OR (nutriti* AND counsel*) OR (nutriti* AND therap*) OR (nutriti* AND treatment*) OR
(nutriti* AND educat*) OR (nutriti* AND support) OR supportive therapy
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3. For Outcome the following MeSH headings and text words were used:

food OR foods OR food* OR foods* OR food intake OR eating OR ingestion OR nutrition OR
nutrition* OR (health* AND diet*) OR (health* AND food*) OR energy intake OR caloric
intake OR kilojoule OR kilojoules OR calorie OR calori* OR caloric restriction OR vitamin OR
vitamins OR vitamin* OR minerals OR minerals* OR mineral OR mineral* OR micro-nutrient
OR micro-nutrients OR macro-nutrient OR macro-nutrients OR nutrient OR nutrients OR
calcium OR folate OR folic acid OR iron OR ferric OR ferrous OR protein OR proteins OR fat
intake OR fat reduced OR dietary fat restriction OR low fat OR low calorie OR low energy
OR reduced energy OR calorie controlled OR fatty foods OR high fat OR fruit OR fruits OR
vegetable

OR

vegetables

OR dietary composition OR carbohydrate

intake

OR

obesity OR obese OR adiposity OR body weight OR overweight OR body mass index OR
BMI OR body mass OR body fat distribution OR body composition OR “bioelectrical
impedance analysis” OR health behavior OR health behaviors OR health behaviour OR
health behaviours OR health behaviour* OR health behaviour* OR health promotion OR
behaviour change OR behavior change OR behaviour change* OR behavior change* OR
health behaviour change OR health behavior change OR health behaviour change* OR
health behavior change* OR life style OR life style* OR weight gain OR weight gains OR
weight gain* OR body weight OR weight loss OR weight change OR weight changes OR
weight change* OR overnutrition OR overeating OR hyperphagia OR Metabolic syndrome
OR Waist hip ratio OR Waist height ratio OR Skinfold thickness OR Skinfold thicknesses OR
Skinfold thickness* OR DEXA OR Diabetes OR type 2 diabetes OR glucose metabolism OR
insulin metabolism OR insulin resistance OR hyperinsulinemia OR hyperinsulinaemia OR
cardiomyopathy OR myocardial Infarction OR fat metabolism OR cardiovascular risk factor
OR cardiovascular risk factors OR cardiovascular risk factor* OR cardiovascular disease OR
cardiovascular diseases OR blood pressure OR hypertension OR blood lipid OR blood lipids
OR blood lipid* OR hyperlipidemia OR hyperlipidaemia OR dyslipidemia OR dyslipidaemia
OR cholesterol metabolism OR hypercholesterolemia OR osteoporosis OR bone mineral
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density OR dual energy x-ray absorptiometry OR malnutrition OR undernutrition OR
Nutritional Deficiency OR Nutritional Deficiencies OR ideal body weight OR body image OR
eating disorder OR eating disorders OR eating disorder* OR disordered eating OR fussy
eating OR food refusal OR quality of life OR QoL

4. For Cancer the following MeSH headings and text words were used:

cancer OR oncology OR oncolog* OR neoplasms OR neoplas* OR carcinoma OR carcinom*
OR tumor OR tumour OR tumor* OR tumour* OR cancer* OR malignan* OR
hematooncological OR hemato oncological OR hemato-oncological OR hematologic
neoplasms OR hematolo* OR bone marrow transplantation OR bone marrow transplant* OR
leukemia OR leukaemia OR lymphoma

5. For RCTs and CCTs the following MeSH headings and text words were used:

(randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomized[tiab]) OR
(placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab]))
AND (humans[mh]

Final search 1 and 2 and 3 and 4 and 5

[pt = publication type; tiab = title, abstract; sh = subheading; mh = MeSH term; * = zero to
many characters; RCT = randomized controlled trial; CCT = controlled clinical trial]
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APPENDIX F – SEARCH STRATEGY FOR EMBASE (OVID)
1. For Popuation the following Emtree terms and text words were used:

1. infant/ or infancy/ or newborn/ or baby/ or child/ or preschool child/ or school child/
2. adolescent/ or juvenile/ or boy/ or girl/ or puberty/ or prepuberty/ or pediatrics/
3. primary school/ or high school/ or kindergarten/ or nursery school/ or school/
4. or/1-3
5. (infant$ or newborn$ or (new adj born$) or baby or baby$ or babies or neonate$ or
perinat$ or postnat$).mp.
6. (child$ or (school adj child$) or schoolchild$ or (school adj age$) or schoolage$ or (pre adj
school$) or preschool$).mp.
7. (kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$).mp.
8. (minors$ or (under adj ag$) or underage$ or juvenil$ or youth$ or young adult or young
adults or young adult$).mp.
9. (puber$ or pubescen$ or prepubescen$ or prepubert$).mp.
10. (pediatric$ or paediatric$ or peadiatric$).mp.
11. (school or schools or (high adj school$) or highschool$ or (primary adj school$) or
(nursery adj school$) or (elementary adj school) or (secondary adj school$) or
kindergar$).mp.
12. or/5-11
13. 4 or 12

AND

1. (survivor or survivors or (long adj term survivor) or (long adj term survivors) or
survivo$).mp.
2. survivor/ or cancer survivor/
3. survivi$.mp.
4. (post treatment or off treatment).mp.
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5. (treatment complet* or treatment termin*).mp.
6. (follow up or followup or follow-up).mp. or exp follow up/
7. or/1-6

2. For Nutrition the following Emtree terms and text words were used:

1. patient education.mp. or exp patient education/
2. (practice guideline or practice guidelines or practice guideline$).mp.
3. exp practice guideline/
4. (dietary guideline or dietary guidelines or dietary guideline$).mp.
5. exp DIET/ or diet.mp.
6. (diets or diet$ or diets$ or dietetic or dietetics).mp.
7. diet therapy.mp. or exp diet therapy/
8. (health diet or healthy food).mp. or exp health food/
9. exp health behavior/
10. (health promoting behaviour or health promoting behavior).mp.
11. (diet$ and intervent$).mp.
12. (diet$ and advic$).mp.
13. (diet$ and counsel$).mp.
14. (diet$ and therap$).mp.
15. (diet$ and treatment$).mp.
16. (diet$ and educat$).mp.
17. (nutriti$ and intervent$).mp.
18. (nutriti$ and advice$).mp.
19. (nutriti$ and counsel$).mp.
20. (nutriti$ and therap$).mp.
21. (nutriti$ and treatment$).mp.
22. (nutriti$ and educat$).mp.
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23. (nutriti$ and support).mp.
24. supportive therapy.mp.
25. or/1-24

3. For Outcome the following Emtree terms and text words were used:

1. (food or foods or food* or foods* or food intake).mp.
2. exp FOOD INTAKE/ or exp FOOD/
3. eating.mp. or exp EATING/
4. ingestion.mp. or exp INGESTION/
5. exp NUTRITION/
6. (nutrition or nutrition$).mp.
7. (health$ and diet$).mp.
8. (health$ and food$).mp.
9. (energy intake or carbohydrate intake or caloric intake).mp. or exp caloric intake/
10. (kilojoule or kilojoules or calorie or calori$ or caloric restriction).mp.
11. vitamin/
12. (vitamin or vitamins or vitamin$).mp.
13. exp MINERAL/
14. (minerals or minerals$ or mineral or mineral$).mp.
15. exp trace element/
16. (micro-nutrient or micro-nutrients).mp.
17. exp MACRONUTRIENT/
18. (macro-nutrient or macro-nutrients or nutrient or nutrients).mp.
19. (calcium or 7440-70-2).mp.
20. (folate or folic acid or 59-30-3).mp.
21. (iron or 7439-89-6 or ferric or ferrous).mp.
22. protein/
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23. (protein or proteins).mp.
24. exp low fat diet/
25. (fat reduced or dietary fat restriction or low fat or fat intake).mp.
26. (low calorie or low energy or reduced energy or calorie controlled).mp.
27. (fatty foods or high fat).mp.
28. (fruit or fruits or vegetable or vegetables).mp.
29. exp dietary intake/ or dietary composition.mp.
30. exp OBESITY/
31. (obesity or obese).mp.
32. adiposity.mp.
33. body weight.mp. or exp body weight/
34. overweight.mp.
35. exp body mass/
36. (body mass index or BMI or body mass).mp.
37. body fat distribution.mp. or exp body fat distribution/
38. bioelectrical impedance analysis.mp.
39. body composition.mp. or exp body composition/
40. exp health behavior/
41. (health behavior or health behaviors or health behaviour or health behaviours or health
behaviour$ or health behaviour$).mp.
42. health/
43. (health knowledge or health attitude$).mp.
44. health promotion.mp. or exp health promotion/
45. exp behavior change/
46. (behaviour change or behavior change or behaviour change$ or behavior change$ or
health behaviour change or health behavior change or health behaviour change$ or health
behavior change$).mp.
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47. exp lifestyle/
48. (life style or life style$ or lifestyle or lifestyle$).mp.
49. (weight gain or weight gains or weight gain$).mp.
50. exp weight gain/
51. exp weight reduction/
52. (weight loss or weight change or weight changes or weight change$).mp.
53. exp OVERNUTRITION/
54. exp HYPERPHAGIA/
55. (overnutrition or overeating or hyperphagia).mp.
56. Metabolic syndrome.mp. or metabolic syntrome X/
57. Waist hip ratio.mp. or exp waist hip ratio/
58. Waist height ratio.mp.
59. exp skinfold thickness/
60. (Skinfold thickness or Skinfold thicknesses or Skinfold thickness$).mp.
61. DEXA.mp. or exp dual energy X ray absorptiometry/
62. (Diabetes or type 2 diabetes).mp. or exp diabetes mellitus/
63. glucose metabolism.mp. or exp glucose metabolism/
64. insulin metabolism.mp. or exp insulin metabolism/
65. exp hyperinsulinemia/ or (hyperinsulinemia or hyperinsulinaemia).mp.
66. exp CARDIOMYOPATHY/ or cardiomyopathy.mp.
67. myocardial Infarction.mp. or exp heart infarction/
68. fat metabolism.mp. or exp lipid metabolism/
69. exp cardiovascular risk/
70. (cardiovascular risk factor or cardiovascular risk factors or cardiovascular risk
factor$).mp.
71. exp cardiovascular disease/ or (cardiovascular disease or cardiovascular diseases).mp.
72. blood pressure.mp. or exp blood pressure/
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73. exp hypertension/ or hypertension.mp.
74. exp lipid blood level/
75. (blood lipid or blood lipids or blood lipid$).mp.
76. cholesterol metabolism.mp. or exp cholesterol metabolism/
77. exp hypercholesterolemia/ or hypercholesterolemia.mp.
78. exp hyperlipidemia/ or (hyperlipidemia or hyperlipidaemia).mp.
79. exp dyslipidemia/ or (dyslipidemia or dyslipidaemia).mp.
80. osteoporosis/co, dt, rt, si, th [Complication, Drug Therapy, Radiotherapy, Side Effect,
Therapy]
81. Osteoporosis.mp.
82. bone mineral density.mp. or exp bone density/
83. malnutrition.mp. or exp MALNUTRITION/
84. undernutrition.mp.
85. exp nutritional deficiency/
86. (Nutritional Deficiency or Nutritional Deficiencies).mp.
87. ideal body weight.mp. or exp body weight/
88. body image.mp. or exp body image/
89. exp eating disorder/
90. (eating disorder or eating disorders or eating disorder$ or disordered eating or fussy
eating).mp.
91. exp food refusal/ or food refusal.mp.
92. exp "quality of life"/ or (quality of life or QoL).mp.
93. or/1-92

4. For Cancer the following Emtree terms and text words were used:

1. (cancer or cancers or cancer$).mp.
2. (oncology or oncolog$).mp. or exp oncology/
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3. (neoplasm or neoplasms or neoplasm$).mp. or exp neoplasm/
4. (carcinoma or carcinom$).mp. or exp carcinoma/
5. (tumor or tumour or tumor$ or tumour$ or tumors or tumours).mp. or exp tumor/
6. (malignan$ or malignant).mp.
7. (hematooncological or hemato oncological or hemato-oncological or hematologic
neoplasms or hematolo$).mp. or exp hematologic malignancy/
8. (leukemia or leukaemia).mp. or exp LEUKEMIA/
9. lymphoma.mp. or exp LYMPHOMA/
10. or/1-9

5. For RCTs and CCTs the following Emtree terms and text words were used:

1. Randomized Controlled Trial/
2. Controlled Clinical Trial/
3. randomized.ti,ab.
4. placebo.ti,ab.
5. randomly.ti,ab.
6. trial.ti,ab.
7. groups.ti,ab.
8. drug therapy.sh.
9. or/1-8
10. Human/
11. 9 and 10

Final search 1 AND 2 AND 3 AND 4 AND 5

[mp = title, abstract, subject headings, heading word, drug trade name, original title, device
manufacturer, drug manufacturer name; sh = subject heading; ti,ab = title or abstract; / =
Emtree term; $= zero to many characters; co = complication; dt = drug therapy; rt =
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radiotherapy; si = side effect; th = therapy; RCT = randomized controlled trial; CCT =
controlled clinical trial]
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APPENDIX G – ETHICS APPROVAL LETTER FOR CHAPTER 6
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APPENDIX H – ETHICS APPROVAL LETTER FOR CHAPTER 8
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APPENDIX I – FOOD LIKING QUESTIONNAIRE
FOOD PREFERENCE QUESTIONNAIRE
Please indicate how much you like each food by ticking in the appropriate box
IF YOU HAVE NEVER TRIED A FOOD, TICK THE 1ST BOX ONLY

Never
tried it

I hate
it

I don’t
like it

It’s
OK

I quite
like it

I love it

Beef

□

□

□

□

□

□

Beefburger, hamburger

□

□

□

□

□

□

Lamb

□

□

□

□

□

□

Pork

□

□

□

□

□

□

Chicken

□

□

□

□

□

□

Turkey

□

□

□

□

□

□

Veal

□

□

□

□

□

□

Ham

□

□

□

□

□

□

Sausages / Frankfurts

□

□

□

□

□

□

Liver

□

□

□

□

□

□

Pate

□

□

□

□

□

□

Liver sausage /Liverwurst

□

□

□

□

□

□

Bacon

□

□

□

□

□

□

Mortadella / Devon / Salami

□

□

□

□

□

□

Fish: fried in batter or breadcrumbs

□

□

□

□

□

□
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Never
tried it

I hate
it

I don’t
like it

It’s
OK

I quite
like it

I love
it

Fish: plain, white (Snapper, Bream, Flounder)

□

□

□

□

□

□

High fat fish (Mullet, Gemfish, Herring)

□

□

□

□

□

□

Tuna / Salmon - tinned

□

□

□

□

□

□

Baked beans

□

□

□

□

□

□

Lentils, chickpeas etc

□

□

□

□

□

□

Tofu

□

□

□

□

□

□

Soya meat eg Nutolene,

□

□

□

□

□

□

TVP (textured vegetable protein)

□

□

□

□

□

□

Vegeburger, Vegesausage eg Sanitarium

□

□

□

□

□

□

Nuts, eg peanuts, nut dishes

□

□

□

□

□

□

Eggs: boiled, poached

□

□

□

□

□

□

Eggs: scrambled

□

□

□

□

□

□

Eggs: fried

□

□

□

□

□

□

Lasagne

□

□

□

□

□

□
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Never
tried it

I hate
it

I
don’t
like it

It’s
OK

I quite
like it

I love
it

Spaghetti Bolognaise

□

□

□

□

□

□

Meat pies / Party Pies

□

□

□

□

□

□

Pizza

□

□

□

□

□

□

Quiche

□

□

□

□

□

□

Sausage rolls

□

□

□

□

□

□

Shepherd’s pie

□

□

□

□

□

□

Bread, Bread Rolls

□

□

□

□

□

□

Lavash / Lebanese bread / Pitta bread

□

□

□

□

□

□

Saos/ Water crackers

□

□

□

□

□

□

Ryvita / Vita Weats/ Salada etc

□

□

□

□

□

□

Savoury snacks eg Ritz / Jatz/ Shapes

□

□

□

□

□

□

Cheese (processed)

□

□

□

□

□

□

Cheese (hard), eg cheddar

□

□

□

□

□

□

Cheese (soft), eg cottage cheese, Ricotta

□

□

□

□

□

□

Cheese: (cream) eg Philadelphia

□

□

□

□

□

□
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Never
tried it

I hate
it

I
don’t
like it

It’s
OK

I
quite
like it

I love
it

Cheese (soft): eg Brie, camembert

□

□

□

□

□

□

Bran cereals: e.g. All Bran

□

□

□

□

□

□

Muesli:

□

□

□

□

□

□

Porridge

□

□

□

□

□

□

Rice or corn cereal, eg Cornflakes, Rice
Bubbles

□

□

□

□

□

□

Sugared cereal, eg Frosties,
Coco Pops, Froot Loops

□

□

□

□

□

□

Wheat cereal, eg Weetbix, Shredded Wheat

□

□

□

□

□

□

Potatoes: boiled, mashed or jacket

□

□

□

□

□

□

Potatoes: chips

□

□

□

□

□

□

Potatoes: roast, fried

□

□

□

□

□

□

Broccoli

□

□

□

□

□

□

Cabbage, Bok Choy

□

□

□

□

□

□

Carrots

□

□

□

□

□

□

Cauliflower

□

□

□

□

□

□

Egg Plant

□

□

□

□

□

□

Pumpkin

□

□

□

□

□

□
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Never
tried it

I hate
it

I don’t
like it

It’s
OK

I quite
like it

I love
it

Green beans

□

□

□

□

□

□

Leeks

□

□

□

□

□

□

Zucchini

□

□

□

□

□

□

Mushrooms

□

□

□

□

□

□

Onions

□

□

□

□

□

□

Parsnips

□

□

□

□

□

□

Peas

□

□

□

□

□

□

Salad greens, eg lettuce

□

□

□

□

□

□

Capsicum

□

□

□

□

□

□

Tomatoes

□

□

□

□

□

□

Brussel Sprouts

□

□

□

□

□

□

Cucumber

□

□

□

□

□

□

Olives

□

□

□

□

□

□

Celery

□

□

□

□

□

□

Spinach

□

□

□

□

□

□
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Yams

□

Never
tried it

□

□

I hate
it

I don’t
like it

□

It’s
OK

□

□

I quite
like it

I love
it

Pumpkin

□

□

□

□

□

□

Sweetcorn

□

□

□

□

□

□

Avocado

□

□

□

□

□

□

Apricots

□

□

□

□

□

□

Apples

□

□

□

□

□

□

Bananas

□

□

□

□

□

□

Oranges

□

□

□

□

□

□

Mandarins

□

□

□

□

□

□

Grapes

□

□

□

□

□

□

Melon – Honeydew / Cantaloupe Watermelon

□

□

□

□

□

□

Peaches, Nectarines

□

□

□

□

□

□

Pears

□

□

□

□

□

□

Plums

□

□

□

□

□

□

Kiwi Fruit

□

□

□

□

□

□

Dried fruit eg Sultana, Prune, Apricot

□

□

□

□

□

□

Cherrys

□

□

□

□

□

□
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Never
tried it

I hate
it

I don’t
like it

It’s
OK

I quite
like it

I love
it

Strawberries

□

□

□

□

□

□

Mango

□

□

□

□

□

□

Pineapple

□

□

□

□

□

□

Tinned fruit eg two fruits, fruit salad

□

□

□

□

□

□

Soup: vegetable or meat-based

□

□

□

□

□

□

Milk (skimmed)

□

□

□

□

□

□

Milk (semi-skimmed)

□

□

□

□

□

□

Milk (full fat)

□

□

□

□

□

□

Soft drinks eg Coca Cola, Fanta, Lemonade

□

□

□

□

□

□

Fruit juice:

□

□

□

□

□

□

Cordial

□

□

□

□

□

□

Butter

□

□

□

□

□

□

Margarine

□

□

□

□

□

□

Cream

□

□

□

□

□

□

Biscuits: plain, eg Morning Coffee, Milk
Arrowroot

□

□

□

□

□

□
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Never
tried it

I hate
it

I don’t
like it

□

□

□

Biscuits: chocolate

□

□

Cakes

□

Pavlova, Cheese cake

It’s
OK

I quite
like it

I love
it

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

Buns/pastries, eg scones, Danish pastries

□

□

□

□

□

□

Fruit pie / tarts / crumbles

□

□

□

□

□

□

Sponge pudding

□

□

□

□

□

□

Ice cream

□

□

□

□

□

□

Ice blocks

□

□

□

□

□

□

Custard

□

□

□

□

□

□

Blancmange

□

□

□

□

□

□

Dairy desserts, eg mousse

□

□

□

□

□

□

Yogurt, Fruche

□

□

□

□

□

□

Doughnuts , Krispy Creams

□

□

□

□

□

□

Packet chips / Twisties / Burger Rings

□

□

□

□

□

□

Jam / Honey

□

□

□

□

□

□

Biscuits sweet eg cream biscuits, Monte Carlo,
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Never
tried it

I hate
it

I don’t
like it

It’s
OK

I quite
like it

I love
it

Chocolate

□

□

□

□

□

□

Lollies eg boiled / jelly

□

□

□

□

□

□

Lollies eg mints

□

□

□

□

□

□

Lollies: toffee, fudge

□

□

□

□

□

□

Sauces: BBQ, Tomato, Soy, HP, Teryaki etc

□

□

□

□

□

□

Sauces: Salad Dressing, Mayonnaise

□

□

□

□

□

□

Sauces: warm, savoury eg gravy

□

□

□

□

□

□

Rice

□

□

□

□

□

□

Pasta

□

□

□

□

□

□

Peanut Butter

□

□

□

□

□

□

Vegemite

□

□

□

□

□

□

Dried peas, beans or lentils

□

□

□

□

□

□

Baked beans

□

□

□

□

□

□

Tinned spaghetti

□

□

□

□

□

□

Thank you very much for helping us with our research.
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APPENDIX J – THE FUNCTIONAL ASSESSMENT OF ANOREXIA/CACHEXIA
TREATMENT QOL SCALE (FAACT)
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